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Abstract 
 
The heparan sulfate (HS) component of heparan sulfate proteoglycans 
(HSPGs) has been implicated in the initiation of several viral infections, 
including vaccinia virus (VACV). A cell infected with VACV releases two 
different forms of VACV, namely the mature virus (MV) released following the 
death of infected cells and which infects neighbouring cells, and the enveloped 
virus (EV) ejected from infected cells for long-range dissemination. The relative 
role of HS in the infectivity of the different forms of VACV is unclear. 
Furthermore, there is little known about the fine specificity of the VACV-HS 
interactions. Therefore, in order to develop HS based molecules that could 
potentially have antiviral properties against HS-dependent viral infection, VACV 
was used as a prototype virus to understand the structural and functional 
consequences of the interaction between VACV and HS. 
 
ELISA studies described in Chapter 3 were used to evaluate the specificity of 
the MV form of VACV for heparin, differentially sulfated HS, chondroitin sulfate 
(CS) A-D and hyaluronic acid (HA). Lack of appropriate EV specific antibodies 
meant that similar ELISA studies could not be performed for the EV form of 
VACV. Nevertheless, the MV form of VACV bound to immobilized heparin and 
highly sulfated HS (HShi) with high avidity, compared to lowly sulfated HS 
(HSlow). The MV particles also bound to CS A-D, however, very weakly. 
Furthermore, the ability of the MV rich Western Reserve (WR) strain of VACV to 
form plaques in vitro was affected by soluble heparin, WR plaque numbers 
being reduced 5-fold with an incremental increase in plaque size. The formation 
of plaques by the EV rich International Health Department-J (IHD-J) strain was 
	 viii	
also affected in the presence of heparin, there being a 10-fold reduction in 
plaque numbers, an incremental increase in plaque size and the disappearance 
of the trademark ‘comet’ shaped plaques. These data suggest that HS 
recognition plays a significant role in both MV and EV infectivity, with this 
recognition being more important for EV infectivity. 
 
To better understand the interaction between heparin/HS and the two forms of 
VACV, green fluorescent protein (GFP) expressing recombinant strains of 
VACV were constructed, as described in Chapter 4. Subsequent inhibition of 
infectivity assays, performed using soluble glycosaminoglycans (GAGs), 
suggested that sulfated GAGs more easily inhibited EV infections than the MV 
infections, with heparin and HShi being highly potent inhibitors of infection. 
Furthermore, the ability of the EV form of VACV to establish an infection was 
significantly reduced in cells treated with the HS-degrading enzyme heparanase 
and in cells genetically deficient in HS production, compared to the MV form of 
VACV which appeared largely unaffected. These findings confirmed that 
recognition of cell surface HS is vital for EV infectivity but less important for the 
infectivity of the MV form of VACV. 
 
In Chapter 5, the ability of soluble heparin/HS molecules and HS mimetics to 
inhibit VACV infections was further investigated to identify structural features of 
these molecules that are responsible for their interaction with VACV particles. 
The study also aimed to determine whether HS-based molecules could be used 
as possible antivirals against VACV and potentially against other HS-dependent 
viral infections. It was observed that the 2-O-sulfate of uronic acid and the 6-O 
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and N-sulfate groups of glucosamine residues were important for VACV 
infectivity, with 6-O-sulfate being particularly crucial and EV infections being 
more dependent on these groups than MV infections. Furthermore, the length of 
heparin chains did not affect their ability to interact with and inhibit VACV 
infectivity. However, the linkages of different D-glucose-based HS mimetics had 
a profound effect on the ability of the sulfated molecule to inhibit VACV 
infections, with the order of potency being β(1g4) > α(1g6) > α(1g4) > 
β(1g3). Interestingly, however, a D-mannose-based sulfated oligosaccharide 
mixture (PI-88, Muparfostat) was identified as the only HS mimetic that was a 
more potent inhibitor of MV infections than of EV infections, in fact it was a 
stronger inhibitor of MV infections than unfractioned heparin (UFH). These data 
suggest that the EV and MV forms of VACV interact with different structural 
aspects of HS chains and that synthetic HS-based molecules could be 
designed with the ability to inhibit both EV and MV forms of VACV. 
 
In Chapter 6 studies are described that attempted to identify the proteins on the 
surface of the EV form of VACV that are responsible for the interaction of the 
VACV with cell surface HS. Thus, EV and MV outer membrane proteins were 
solubilised and identified by Western blotting using polyclonal anti-VACV 
antibodies. Four potential heparin-binding proteins were identified in the EV 
outer membrane extracts, being 150 kDa, 85 kDa, 60 kDa and 25 kDa proteins. 
The 150 kDa heparin binding protein was further analysed using 1D nanoLC 
ESI MS/MS and was found to be a poxvirus DNA directed RNA polymerase, 
with sequence similarity to the 65 kDa VACV F12 protein, a protein important in 
EV formation. Bioinformatic searches were also performed to determine 
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possible HS-binding motifs in VACV proteins and identified the 64 kDa VACV 
B4R protein and a 78 kDa RNA helicase as likely candidates. Overall, it was 
concluded that there are multiple HS binding proteins on the outer EV envelope 
and that it is likely that in many instances the heparin/HS binding site(s) of 
these EV proteins may not be composed of linear amino acid sequences. 
 
Since both MV and EV forms of VACV bind HS, in Chapter 7 experiments are 
described that examined the role of heparanase in VACV spread, it being 
predicted that heparanase may aid spread by releasing VACV from cell surface 
and extracellular matrix (ECM) HS. Wild type (WT) and heparanase deficient 
(HPSE -/-) mice were inoculated with the WR strain of VACV via intranasal (i.n.) 
and intramuscular (i.m.) routes to evaluate the spread of infection in the two 
groups of mice. The WR strain of VACV was inoculated via the i.n. route when 
there was a 24 hr delay in weight loss in the HPSE -/- mice compared to the WT 
mice. Furthermore, this delay in weight loss correlated with a delay in the onset 
of disease with there being a 24-48 hr delay in the spread of infection from the 
primary site of inoculation to distant organs like the ovaries. Similarly, when 
VACV was delivered by the i.m. route, there was a 24-48 hr delay in the 
infection of the ovaries, although there was a similar delay in infection of the 
spleen, despite there being no weight loss difference. Overall, the results 
suggest that VACV depends on host-derived heparanase to aid its spread. 
Since heparanase mediated degradation of HS aids the infiltration of leukocytes 
with antiviral activity into sites of infection, the results obtained from the current 
study are contrary to the prevailing immunological paradigm. 
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In conclusion, VACV like several other viruses interacts with cell surface HS 
prior to infecting cells. Furthermore, VACV relies on host-derived heparanase to 
degrade cell surface and ECM HS to aid its spread. Thus, synthetic HS-based 
molecules could be designed that could inhibit EV and MV forms of VACV from 
infecting cells and may simultaneously act as heparanase inhibitors and 
consequently prevent VACV spread. 
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1.1	Introduction	to	viral	infections	Infectious	diseases	pose	a	major	threat	to	public	health	around	the	world.	It	is	believed	that	over	10	million	deaths	occur	annually,	accounting	for	a	staggering	quarter	of	all	deaths	globally	(Aquino,	Lee,	&	Park,	2010).	Increasing	efforts	are	being	made	to	control	and	treat	infectious	diseases,	however,	the	problem	of	emerging	and	re-emerging	pathogens	is	still	a	major	concern	for	medical	and	public	health	in	the	21st	century	(Morens,	Folkers,	&	Fauci,	2004).	Viral	infections	are	of	particular	concern	as	the	advances	in	the	field	of	antiviral	drug	development	have	lagged	behind	those	of	bacteriocidal	drugs	and	antibiotics,	especially	in	the	case	of	emerging	viral	pathogens	where	the	development	of	antiviral	therapies	has	significantly	lagged	behind	the	time	of	initial	viral	emergence	by	years,	or	even	decades	(McFadden,	2005).	A	classic	example	of	this	situation	was	with	severe	acute	respiratory	syndrome	(SARS),	this	syndrome	being	induced	by	a	new	member	of	a	neglected	virus	family,	namely,	the	SARS	coronavirus,	that	successfully	crossed	into	humans	from	unsuspected	reservoirs,	necessitating	the	scientific	community	to	rush	into	first	understanding	virus-host	dynamics	before	any	thought	could	be	given	to	developing	strategies	to	treat	this	infection	(Finlay,	See,	&	Brunham,	2004).			Variola	virus,	a	member	of	the	poxvirus	family	and	the	causative	agent	of	the	now	eradicated	smallpox,	has	killed	more	members	of	the	human	population	over	the	span	of	recorded	history	than	all	of	the	other	infectious	diseases	combined	(McFadden,	2005).	In	1980,	thanks	to	a	worldwide	vaccination	campaign,	the	World	Health	Organization	(WHO)	was	able	to	declare	the	complete	eradication	of	smallpox	from	the	human	community,	however,	a	considerable	fear	still	remains	
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that	variola	virus,	or	other	pathogens	from	the	poxvirus	family	such	as	monkeypox,	could	re-emerge	and	cause	a	pandemic	in	the	human	population	before	effective	vaccination	strategies	could	be	put	in	place.	A	threat	of	smallpox	being	used	as	a	potential	weapon	of	bioterrorism	has	also	maintained	active	interest	in	mechanisms	of	infection	and	pathogenesis	of	variola	virus	(Hughes,	Irausquin,	&	Friedman,	2010).	A	key	lesson	learnt	from	past	pandemics	was	the	need	to	constantly	develop	techniques	to	understand	viral	tropism,	an	understanding	crucial	for	the	development	of	novel	antiviral	therapies	to	counter	new	infectious	diseases.			In	order	to	establish	an	infection,	viral	pathogens	adopt	various	strategies	to	survive	within	the	host,	in	particular,	the	overpowering	of	the	host	immune	response.	Detailed	studies	understanding	the	strategies	that	infecting	viral	pathogens	adopt	to	evade	the	immune	system,	particularly	viruses	with	a	large	genome	such	as	poxviruses,	revealed	that	viruses	are	often	packed	with	several	virulence	factors	which	are	deployed	to	invade	host	cells,	damage	host	tissue,	disseminate	the	virus	and	cause	secondary	viral	infections	(Aquino	et	al.,	2010).	Viruses	have	been	shown	to	exploit	a	wide	variety	of	attachment	molecules	on	the	surface	of	cells,	and	use	them	as	receptors	to	invade	cells	and	establish	an	infection	(Rostand	&	Esko,	1997).	Virus	entry,	spread	and	pathogenesis	can	be	better	understood	by	identifying	the	cell	surface	receptor(s)	a	particular	virus	targets	(Shukla	&	Spear,	2001).	Virus	entry	is	mainly	a	two-step	process,	with	the	first	step	being	attachment	of	the	virus	particle	to	a	primary	receptor,	often	ubiquitous	cell	surface-associated	carbohydrate	moieties,	followed	by	interaction	with	a	co-receptor	that	is	usually	a	cell	specific	transmembrane	protein	belonging	to	a	well	
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defined	receptor	superfamily	(Shukla	et	al.,	1999;	Summerford	&	Samulski,	1998).	Understanding	the	interaction	between	proteins	on	the	surface	of	virus	particles,	and	the	cell	surface	receptors	exploited	by	the	virus	particles	to	enter	cells,	are	essential	to	understand	viral	tropism,	which	further	helps	in	designing	effective	antiviral	therapies.	The	following	sections	of	this	review	will	provide	a	general	overview	of	the	polysaccharide,	heparan	sulfate	(HS),	a	key	component	of	the	extracellular	matrix	(ECM)	and	an	important	cell	attachment	receptor	for	many	viruses.			
1.2	Extracellular	matrix	(ECM)	The	ECM	is	a	dense	latticework	of	macromolecules	that	not	only	occupies	the	extracellular	space	in	tissue,	but	also	provides	a	molecular	scaffolding	for	cells	to	interact	within	different	organs	(Parish,	Freeman,	&	Hulett,	2001).	Basement	membranes	(BM),	a	specialized	class	of	ECM,	are	produced	as	thin	but	rigid	sheet-like	structures	by	endothelial,	epithelial	and	many	mesenchymal	cells	(Parish	et	al.,	2001;	Yurchenco	&	Schittny,	1990).	The	BM	plays	a	pivotal	role	in	providing	a	concrete	support	for	different	cell	layers	within	a	tissue	and,	thereby,	provide	a	surface	on	which	cells	can	migrate,	proliferate	and	differentiate	(Parish	et	al.,	2001;	Yurchenco	&	Schittny,	1990).	Due	to	their	dense	structure	BMs	can	also	act	as	a	molecular	sieve	that	hinders	cell	migration	and	even	the	diffusion	of	macromolecules	(Jalali-Heravi,	Asadollahi-Baboh,	&	Shahbazikhah,	2008;	Yurchenco	&	Schittny,	1990).	As	a	result,	there	are	specific	mechanisms	in	place	that	license	the	migration	of	certain	cell	types,	for	example	inflammatory	leukocytes	and	metastatic	tumor	cells,	by	focally	degrading	BMs	to	allow	cells	to	cross	the	barrier	(Parish,	2006;	Yurchenco	&	Schittny,	1990).		
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1.3	Heparan	sulfate	proteoglycan	(HSPG)	Extensive	research	has	shown	that	a	number	of	bacteria,	parasites	and	viruses	use	the	heparan	sulfate	(HS)	component	of	cell	surface	heparan	sulfate	proteoglycans	(HSPGs)	as	an	initial	receptor	to	attach	to	cells	(Liu	&	Thorp,	2002;	Rostand	&	Esko,	1997;	Wadstrom	&	Ljungh,	1999;	Zhu,	Li,	&	Liang,	2011).	HSPGs	are	also	one	of	the	most	abundant	constituents	of	BM,	along	with	type	IV	collagen	and	laminin	(Figure	1.1)	(Levy-Adam,	Ilan,	&	Vlodavsky,	2010;	Parish	et	al.,	2001;	Yurchenco	&	Schittny,	1990;	Zcharia	et	al.,	2009).			
1.3.1	HSPG	core	proteins	HSPGs	are	glyco-conjugated	macromolecules	composed	of	a	carbohydrate	polymers	(HS	component)	covalently	attached	to	protein	cores	(Li	&	Vlodavsky,	2009;	Sasisekharan	&	Venkataraman,	2000;	Sugahara	&	Kitagawa,	2002).	The	HS	chains	present	on	cell	surfaces	have	been	shown	to	be	attached	to	two	main	classes	of	core	proteins,	namely,	syndecans	and	glypicans	(Figure	1.1)	(Bernfield	et	al.,	1999;	Li	&	Vlodavsky,	2009).	These	two	types	of	core	proteins	not	only	allow	HS	chains	to	be	anchored	to	the	cell	surfaces,	but	also	determine	where,	when	and	to	what	extent	these	HS	chains	are	expressed	(Bernfield	et	al.,	1999).	The	syndecan	core	proteins	are	a	family	of	transmembrane	proteins	with	four	isoforms	that	carry	HS	chains	near	their	extracellular	tips	(Bernfield	et	al.,	1999).	They	have	also	been	shown	to	occasionally	carry	chondroitin	sulfate	(CS)	chains	linked	closely	to	the	cell	surface	(Li	&	Vlodavsky,	2009;	Rostand	&	Esko,	1997).	The	glypican	core	proteins,	on	the	other	hand,	exist	as	six	different	isoforms	that	carry	their	HS	chains	near	the	plasma	membrane,	with	occasional	HS	chains	being	expressed	near	the	tip	of	their	ectodomains	(Bernfield	et	al.,	1999;	Kjellen	&	Lindahl,	1991).	
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Figure	1.1:	Structure	and	location	of	heparan	sulfate	(HS)	within	the	blood	
vessel	wall.	In	vessel	walls,	HS	is	expressed	as	either	cell	surface	associated	heparan	sulfate	proteoglycan	(HSPG),	such	as	syndecan	or	glypican,	or	as	HSPGs	in	the	subendothelial	basement	membrane	(BM)	as	perlecan,	agrin	(not	shown)	and	type	XVIII	collagen	(not	shown),	associated	with	other	BM	components,	such	as	laminin,	type	IV	collagen	(not	shown)	and	entactin	(not	shown).	HS	side	chains	are	polysaccharides	composed	of	alternating	N-acetylglucosamine	and	D-glucuronic	acid/D-iduronic	acid	residues	that	are	sulfated	at	various	positions	along	the	length	of	the	chain	(Adapted	from	Parish,	2006).					 	
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A	feature	of	glypicans	is	that	they	do	not	penetrate	the	lipid	bilayer	of	plasma	membranes.	Instead,	they	are	linked	to	membranes	via	glycosylphosphatidyl	inositol	(GPI)	anchors	attached	to	their	protein	cores	(Fransson	et	al.,	2004;	Rostand	&	Esko,	1997).			The	HSPGs	present	in	the	ECM	are	covalently	attached	to	three	main	classes	of	core	proteins	–	agrin,	collagen	XVIII	and	perlecan	(Figure	1.1)	(Li	&	Vlodavsky,	2009).	Agrin	core	proteins	are	synthesised	by	motor	neurons	and	bind	to	specific	signalling	receptors	on	the	muscle	cell	surface	(Denzer,	Gesemann,	Schumacher,	&	Ruegg,	1995).	Collagen	XVIII	and	perlecan,	on	the	other	hand,	are	distributed	widely	in	tissue	ECMs	and	BMs	and	have	a	complex	modular	structure	that	allows	them	to	interact	with	a	wide	range	of	other	ECM	components	(Iozzo,	1998).	
	
1.3.2	Structure	of	HS	The	HS	glycosaminoglycan	(GAG)	of	HSPGs	is	composed	of	repeating	disaccharides	of	glucosamine	and	hexuronic	acid,	joined	in	alternating	sequences	by	1,4-glycosidic	linkages,	which	gives	these	carbohydrate	chains	their	flexibility	to	bind	to	different	proteins	(Figure	1.1	and	1.2)	(Li	&	Vlodavsky,	2009;	Lindahl,	1990;	Lindahl	et	al.,	1979).	The	hexuronic	acid	may	exist	in	two	forms,	namely,	as	β-D-glucuronic	acid	(GlcA)	or	α-L-iduronic	acid	(IdoA)	(Coombe	&	Kett,	2005).	The	monosaccharide	constituents	of	the	HS	chains	are	sequentially	modified	by	a	series	of	reactions	involving	N-	and	O-sulfation	and	epimerization	of	the	glucuronic	acid	residues	to	iduronic	acid	(Figure	1.2)	(Lindahl,	1990).	The	modification	reactions	during	HS	biosynthesis	are	highly	regulated,	resulting	in	heterogenous	sulfation	and	epimerization	patterns	that	could	be	tissue	and	cell-type	specific	
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Figure	1.2:	Flow	chart	depicting	the	monosaccharide	modifications	that	form	
different	combinations	of	HS	disaccharides.	The	HS	disaccharides	are	made	up	of	a	hexuronic	(HexA)	and	a	D-glucosamine	(GlcN)	joined	in	alternating	sequences	by	α1,4-glycosidic	linkages,	giving	the	polysaccharide	its	flexibility.	The	D-glucosamine	and	hexuronic	acid	residues	are	joined	by	β1,4-glycosidic	linkages	(not	shown).	Hexuronic	acids	can	exist	as	either	β-D-glucuronic	acid	(GlcA)	or	α-L-iduronic	acid	(IdoA),	both	of	which	can	exist	as	an	unsulfated,	or	as	a	2-O-sulfated	monosaccharide.	D-glucosamine,	however,	can	be	N-sulfated,	N-acetylated	or	exist	as	free	amine.	Furthermore,	glucosamine	residues	can	also	exist	as	unsulfated,	3-O-	or	6-O	sulfated	monosaccharides,	or	any	combination	of	N-	and/or	O-sulfated	monosaccharides.			 	
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(Esko	&	Lindahl,	2001;	Ledin	et	al.,	2004).	Furthermore,	the	sulfation	and	epimerization	of	HS	chains	is	not	evenly	distributed	along	the	HS	chains	but	occurs	in	‘hot	spots’	of	extensive	modification	linked	by	areas	of	relatively	little	modification	(Parish,	2006).			
1.3.3	Functional	role	of	the	HS	component	of	HSPGs	The	role	of	the	HS	component	of	HSPGs	is	not	just	restricted	to	the	formation	of	ECM	and	BM.	HS	has	also	been	shown	to	bind	a	myriad	of	proteins,	thereby	regulating	their	availability	and	hence	their	function	(Coombe	&	Kett,	2005;	Rapraeger,	1993).		As	described	previously,	the	linear	HS	chains	exhibit	phenomenal	structural	diversity,	which	is	made	possible	by	differential	patterns	of	sulfation	and	uronic	acid	epimerization.	These	structural	features	of	HS	are	responsible	for	promoting	high	affinity	binding	of	several	growth	factors	like	fibroblast	growth	factor	(FGF)	(Lin	&	Bissell,	1993),	transforming	growth	factor-β	(TGF-β)	(McCaffrey,	Falcone,	&	Du,	1992)	and	vascular	endothelial	growth	factor	(VEGF)	(Park,	Keller,	&	Ferrara,	1993),	as	well	as	other	HS	binding	proteins.	Growth	factors	can	also	bind	to	HS	via	accessory	proteins	(Taipale	&	Keski-Oja,	1997).	Chemokines	and	cytokines,	such	as	interlukin	(IL)-3	(Roberts	et	al.,	1988)	and	IL-4	(Jones,	Willlams,	Finlayjones,	&	Hart,	1995),	also	bind	to	HS	with	a	very	high	affinity.	Due	to	the	heterogeneous	nature	of	HS,	it	is	able	to	interact	with	different	types	of	chemokines	that	bind	to	subsets	of	HS	structures,	thereby	raising	the	possibility	that	HS	is	involved	in	determining	the	specificity	of	leukocyte	migration	and	recruitment	in	vivo	(Li	&	Vlodavsky,	2009).	Enzymes,	notably	lipoprotein	lipase	(LPL),	have	also	been	shown	to	bind	to	HS	(Wang	et	al.,	2010).	Such	interactions	provide	the	cell	with	highly	accessible	‘depots’	of	growth	factors,	
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cytokines,	chemokines	and	other	proteins,	hence	averting	the	need	to	synthesize	these	factors	de	novo	when	required.			An	increasing	number	of	studies	have	shown	that	HSPG	play	a	crucial	role	in	facilitating	the	interaction	of	cells	with	components	of	the	microenvironment	that	control	functions	such	as	cell	adhesion,	proliferation,	shape	and	differentiation	(Bernfield	et	al.,	1999;	David,	1993;	Wight,	Kinsella,	&	Qwarnstrom,	1992).	Furthermore,	the	trans-membrane	and	membrane	anchored	HSPG	may	also	act	as	co-receptors,	which	together	with	other	cell	surface	molecules,	form	receptor	complexes	that	bind	ligands	and	mediate	their	action	(Zcharia	et	al.,	2001).	In	addition	to	its	co-receptor	properties,	syndecan-4	has	also	been	shown	to	be	a	key	molecule	in	numerous	cellular	processes.	Several	studies	have	shown	that	clustering	of	syndecan-4	directly	initiates	a	signaling	cascade	that	activates	PKCα	and	Rac1,	which	are	essential	for	cell	adhesion	and	directional	cell	migration	(Levy-Adam	et	al.,	2010).			
1.4	Chondroitin	sulfates	(CS)	Like	HS,	the	chondroitin	sulfates	(CS)	are	another	family	of	GAGs	that	are	covalently	attached	to	proteoglycans	and	can	occasionally	play	a	similar	role	as	HS	in	being	a	cell	surface	receptor	for	viruses	(Hsiao,	Chung,	&	Chang,	1999).	The	CS	GAGs	consist	of	a	repeating	disaccharide	composed	of	N-acetylgalactosamine	(GalNAc)	and	either	glucuronic	acid	(GlcA)	or	iduronic	acid	(IdoA)	residues	(Roden,	1980;	Silbert	&	Sugumaran,	2002).	However,	unlike	HS,	the	residues	of	CS	are	sulfated	in	highly	predictive	and	uniform	positions	to	yield	the	four	types	of	CS	chains,	namely,	CS-A	[chondroitin	4-sulfate],	CS-B	[also	known	as	DS	(Dermatan	
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sulfate)	(Trowbridge	&	Gallo,	2002)],	CS-C	[chondroitin	6-sulfate]	and	CS-D	[chondroitin	2,6-sulfate	(Silbert	&	Sugumaran,	2002)].	In	the	case	of	CS-A,	the	GalNAc	residues	are	4-O-sulfated,	with	CS-C	being	6-O-sulfated	and	CS-D	being	2	and	6-O-sulfated.	DS	are	a	modified	form	of	CS	in	which	a	portion	of	D-glucuronic	acid	residues	are	epimerized	to	L-iduronic	acid	residues	(Silbert	&	Sugumaran,	2002).	Furthermore,	similar	to	HS,	the	CS	chains	are	attached	to	serine	residues	in	their	core	proteins	via	glycosidic	linkages.	In	vertebrates,	CS	proteoglycans	are	a	major	component	of	connective	tissue,	particularly	cartilages,	and	are	also	found	on	cell	surfaces	and	in	BMs	(Iozzo,	1998;	Kjellen	&	Lindahl,	1991).			
1.5	Heparin	Like	HS,	heparin	is	another	linear	GAG	that	is	expressed	in	the	form	of	a	proteoglycan	(Li	&	Vlodavsky,	2009;	Sasisekharan	&	Venkataraman,	2000).	Heparin	and	HS	share	a	great	deal	of	resemblance	in	terms	of	their	molecular	structure	(repeating	disaccharide	units	of	glucosamine	and	hexuronic	acids),	however,	heparin	contains	more	iduronic	acid	residues	and	is	more	evenly	and	extensively	sulfated	than	HS	(Figure	1.3)	(Feyzi,	Trybala,	Bergstrom,	Lindahl,	&	Spillmann,	1997;	Li	&	Vlodavsky,	2009).	Furthermore,	the	core	protein	of	heparin,	serglycin,	compared	to	those	of	HS,	shows	differential	expression	patterns	(Li	&	Vlodavsky,	2009).	Heparin	has	been	shown	to	exhibit	biological	functions	including	regulation	of	cellular	behaviour	and,	more	importantly,	anticoagulation	(Yurchenco	&	Schittny,	1990).	Connective	tissue	mast	cells	are	the	only	known	cell	type	that	produces	heparin	(Feyzi	et	al.,	1997).	Heparin	is	produced	as	a	serglycin	proteoglycan,	to	which	10-15	heparin	chains	can	be	attached	(Li	&	Vlodavsky,	2009),	with	each	nascent	heparin	chain	averaging	60-100	kDa	(Horner,	1971),	
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which	when	bound	to	the	core	protein,	results	in	a	proteoglycan	of	approximately	1000	kDa	(Li	&	Vlodavsky,	2009).	There	is	much	greater	glucuronic	acid	epimerization	and	sulfation	of	heparin	than	of	HS,	in	fact,	studies	have	shown	that	80-85%	of	glucosamine	residues	in	heparin	are	N-sulfated,	compared	to	40-60%	in	HS	(Rostand	&	Esko,	1997).	Naturally	occurring	heparin,	which	is	released	from	mast	cells	as	10-15	kDa	heparin	chains,	is	often	referred	to	as	unfractioned	heparin	(UFH).			The	anticoagulation	activity	of	heparin	can	be	attributed	to	a	unique	pentasaccharide	sequence	in	the	polymer	(Lindahl	et	al.,	1979).	Antithrombin	III,	a	protease	inhibitor,	binds	specifically	to	a	pentasaccharide	sequence	of	heparin,	an	interaction	that	enhances	the	ability	of	antithrombin	III	to	inhibit	the	coagulation	proteases	thrombin	and	Factors	IXa	and	Xa	(Li	&	Vlodavsky,	2009).		Mast	cell	derived	heparin	can	also	exhibit	anti-inflammatory	activity	by	interfering	with	the	recruitment	of	leukocytes	to	inflammatory	sites	by	interacting	with	members	of	the	selectin	family	of	adhesion	receptors,	namely,	E-,	P-	and	L-selectin	(Wang,	Brown,	Varki,	&	Esko,	2002).	Studies	have	also	shown	that	heparin	can	have	additional	effects	in	vivo	on	selectin	function,	such	as	causing	leukocytosis	(Sasaki,	1967)	and	inhibiting	tumour	metastasis	by	blocking	the	P-selectin	mediated	interaction	of	platelets	with	tumour	cells	(Borsig	et	al.,	2001).			In	addition	to	the	anticoagulant	properties	of	heparin,	there	are	several	pharmacokinetic	limitations	due	to	its	high	negative	charge	causing	unwanted	binding	to	several	plasma	proteins	(e.g.,	histidine-rich	glycoprotein,	vitronectin,		lipoproteins,	fibronectin	and	fibrinogen),	proteins	secreted	by	platelets	(e.g.,	
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Figure	1.3:	Biosynthesis	of	HS	and	heparin.	Both	HS	and	heparin	are	linear	polysaccharides	consisting	of	alternating	N-acetylglucosamine	(GlcNAc)	and	D-glucuronic	acid	(GlcA)	residues.	The	first	step	in	the	biosynthesis	of	HS	and	heparin	chains	is	the	formation	of	a	polysaccharide-protein	linkage	region,	involving	the	attachment	of	four	sugar	units	(glucuronyl-galactosyl-galactosyl-xylosyl)	to	a	serine	residue	of	the	core	protein.	The	tetrasaccharide	sequence	is	extended	by	addition	of	GlcNAc	and	GlcA	residues,	which	is	accompanied	by	modifications	including	N-deacetylaton/N-sulfation	of	the	GlcNAc,	C5-epimerization	of	GlcA	to	L-iduronic	acid	(IdoA),	O-sulfation	of	IdoA	at	C2,	and	C6	sulfation	of	GlcNS	residues.	The	GlcNS	can	also	be	O-sulfated	at	C3,	a	hallmark	modification	for	formation	of	the	antithrombin	III	(AT)-binding	pentasaccharide	sequence	(Adapted	from	Li	&	Vlodavsky,	2009).		 	
		 14	
platelet	factor	4	and	high-molecular-weight	von	Willebrand	factor)	and	endothelial	cells	(Hirsh,	1991;	Young,	Prins,	Levine,	&	Hirsh,	1992).		Furthermore,	similar	to	other	anticoagulants,	excessive	use	of	heparin	can	also	cause	complications	of	bleeding	and	induce	heparin-induced	thrombocytopenia	(HIT)	and	osteoporosis	(Hirsh,	1998).	These	limitations	prompted	the	development	of	a	new	class	of	heparin-derived	molecules	with	the	same	anticoagulant	properties	of	heparin,	but	with	generally	reduced	unwanted	side	effects.	
	
1.6	Low	molecular	weight	heparin	(LMWH)	Chemical	or	enzymatic	depolymerization	of	traditional	heparin	yields	small	molecules	approximately	one-third	the	size	of	heparin	(i.e.,	4-5	kDa).	These	small	molecules,	termed	low	molecular	weight	heparins	(LMWH),	are	more	homogeneous	anticoagulants	than	traditional	UFH.	Furthermore,	LMWHs	have	been	shown	to	have	a	smaller	risk	of	bleeding,	a	lower	binding	affinity	for	several	plasma	proteins,	a	lower	chance	of	HIT,	and	have	a	more	predictable	behavior,	all	of	which	makes	them	safer	drugs	compared	to	heparin	(Franze,	Gennari,	Minghetti,	&	Cilurzo,	2015;	Hirsh,	1998;	Ingle	&	Agarwal,	2014;	TenCate	et	al.,	1997).	This	is	why	LMWHs	started	to	replace	heparin	as	an	antithrombotic	drug	in	the	prevention	and	treatment	of	DVT	in	the	mid	1980s	(Franze	et	al.,	2015;	Mousa,	2002).	Despite	this	remarkable	reduction	in	side	effects,	the	anticoagulant	activity	of	both	heparin	and	LMWH	is	exerted	via	the	same	unique	pentasaccharide	sequence	(Weitz,	1997).		 	
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1.7	Heparanase	An	important	regulator	of	HS	function	is	the	HS	degrading	enzyme,	heparanase.	There	is	increasing	evidence	that	degradation	of	the	ECM	and	BM	is	a	prerequisite	for	metastatic	tumour	cells	and	leukocytes	to	invade	tissues	(Parish	et	al.,	2001).	Indeed	these	invading	cells	deploy	a	battery	of	degradative	enzymes,	which	enables	them	to	remodel	and	traverse	the	ECM	and	BM	barriers.	Proteases	belonging	to	the	serine,	matrix	metalloproteinase,	cysteine	and	aspartic	protease	families,	have	been	shown	to	disassemble	ECM	barriers	(Duffy,	1996).	Invading	cells	have	also	been	shown	to	express	another	ECM	degrading	enzyme,	heparanase,	which	attacks	HS	in	the	ECM	and	BMs.	Heparanase	is	an	endo-β-glucuronidase	that	was	first	reported	40	years	ago	(Höök,	Wasteson,	&	Oldberg,	1975).	It	plays	a	crucial	role	in	cell	invasion	by	cleaving	HS	side	chains	at	a	limited	number	of	sites,	and	hence	releasing	saccharide	products	of	4-7	kDa	(Levy-Adam	et	al.,	2010;	Parish	et	al.,	2001).	Indeed	several	separate	studies	have	demonstrated	the	increased	expression	of	heparanase	mRNA	in	metastatic	rat	and	human	breast	cancer	cell	lines,	as	opposed	to	the	low	or	lack	of	expression	in	non-metastatic	variants	(Hulett	et	al.,	1999;	Vlodavsky	et	al.,	2000).	Furthermore,	tumours	of	larger	size	have	been	shown	to	be	associated	with	heparanase	upregulation	in	head,	neck,	tongue,	breast,	hepatocellular	and	gastric	carcinomas,	indicating	that	the	role	of	heparanase	is	not	only	limited	to	tumour	metastasis	but	also	in	accelerated	growth	of	primary	tumours	(Doweck	et	al.,	2006;	El-Assal,	Yamanoi,	Ono,	Kohno,	&	Nagasue,	2001;	Levy-Adam	et	al.,	2010).	It	has	been	previously	reported	that	human	platelets	are	another	major	source	of	mammalian	heparanase,	which	could	be	released	by	activated	platelets	at	sites	of	tissue	injury,	inflammation	and	tumour	growth/metastasis.	It	should	be	noted,	however,	that	
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there	is	only	one	heparanase	encoding	gene	in	the	mammalian	genome,	making	heparanase	an	excellent	drug	target.	In	fact,	my	supervisor’s	laboratory	has	developed	PI-88	(Muparfostat),	a	heparanase	inhibitor	that	has	reached	a	Phase	III	clinical	trial	in	hepatocellular	carcinoma	patients.				Today	it	is	widely	accepted	that	heparanase	activity	can	be	correlated	with	cell	invasion	associated	with	metastatic	tumours	(Levy-Adam	et	al.,	2010;	Li	&	Vlodavsky,	2009).	Such	degradation	of	HS	in	the	ECM	by	heparanase	also	liberates	ECM	bound	factors,	such	as	HS-binding	growth	factors,	cytokines,	chemokines,	and	enzymes,	that	bind	to	HS	with	high	affinity	and	are	made	available	for	physiological	processes	like	angiogenesis	and	wound	healing	(Hulett	et	al.,	1999;	Parish	et	al.,	2001;	Szymczak,	Kuzniar,	&	Klinger,	2010).	Heparanase	has	also	been	shown	to	have	an	impact	on	smooth	muscle	proliferation.	Post	injury,	heparanase	degrades	inhibitory	HS	in	the	ECM	of	blood	vessel	walls,	and	this	permits	smooth	muscle	cell	proliferation	(Campbell,	Rennick,	Kalevitch,	&	Campbell,	1992).	Interestingly,	there	are	some	reports	suggesting	that	heparanase	activity	is	affected	by	the	physiological	status	of	the	local	environment	(Gilat	et	al.,	1995).	Changes	in	the	pH	of	the	local	environment,	for	example,	can	cause	heparanase	to	either	function	as	an	enzyme	or	as	an	adhesion	molecule	(Gilat	et	al.,	1995;	Levy-Adam	et	al.,	2010),	with	the	maximal	ECM	degrading	activity	of	heparanase	being	observed	to	be	at	pH	6.2-6.8	(Gilat	et	al.,	1995).	It	should	be	emphasized,	however,	that	although	heparanase	has	been	implicated	in	cell	invasion	by	numerous	studies,	the	enzyme	could	potentially	deplete	cells	of	cell	surface	HS	and	affect	cell	adhesion	and	the	ability	of	viruses	to	both	infect	and	escape	from	infected	cells,	as	
		 17	
demonstrated	in	a	recently	published	study	using	herpes	simplex	virus	1	(HSV-1)	(Hadigal	et	al.,	2015).		
1.8	Role	of	GAGs	in	virus	infections	GAGs	expressed	on	cell	surfaces	serve	as	low	affinity	receptors	that	facilitate	the	interaction	of	pathogens	with	their	respective	secondary	internalization	receptors	(Aquino	et	al.,	2010).	Since	HS	is	ubiquitously	expressed	on	the	surface	of	cells	in	both	vertebrate	and	invertebrate	species,	a	number	of	viruses	from	different	families	have	been	shown	to	have	HS	dependent	entry	mechanisms	including,	herpes	simplex	virus	(HSV)	(Wudunn	&	Spear,	1989),	human	papillomavirus	(HPV)	(Giroglou,	Florin,	Schafer,	Streeck,	&	Sapp,	2001),	hepatitis	B	virus	(HBV)	(Cooper,	Tal,	Lider,	&	Shaul,	2005),	respiratory	syncytial	virus	(RSV)	(Hallak,	Collins,	Knudson,	&	Peeples,	2000),	foot-and-mouth	disease	virus	(FMDV)	(Jackson	et	al.,	1996),	human	immunodeficiency	virus	type	1	(HIV-1)	(Roderiquez	et	al.,	1995)	and	dengue	virus	(Chen	et	al.,	1997).	Furthermore,	alphaviruses	like	sindbis	virus	(SINV)	(Zhu	et	al.,	2010),	Ross	River	virus	(RRV)	(Heil,	Albee,	Strauss,	&	Kuhn,	2001),	Venezuelan	equine	encephalitis	virus	(VEEV)	(Bernard,	Klimstra,	&	Johnston,	2000)	and	semliki	forest	virus	(SFV)	(Smit	et	al.,	2002)	have	also	been	found	to	use	cell	surface	HS	as	a	receptor.	Of	particular	relevance	to	this	thesis	are	the	poxviruses	that	have	also	been	shown	to	interact	with	cell	surface	HS	(Chung,	Hsiao,	Chang,	&	Chang,	1998;	Lin,	Chung,	Heine,	&	Chang,	2000;	Moss,	2006;	Schmidt,	Bleck,	&	Mercer,	2012).	An	overview	of	vaccinia	virus	(VACV),	the	poxvirus	investigated	in	this	thesis,	is	presented	below.				
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1.9	Vaccinia	Virus	(VACV)	Vaccinia	virus	(VACV),	a	large	double	stranded	DNA	virus,	is	a	member	of	the	
Orthopoxvirus	(OPV)	genus	of	the	Poxviridae	family	(Roberts	&	Smith,	2008).	Poxviruses	are	known	to	have	large,	ovoid	or	brick-shaped	virions	that	replicate	in	the	cytoplasm	of	the	host	cell	(Moss,	2006;	Sodeik	&	Krijnse-Locker,	2002).	VACV	is	often	used	as	a	laboratory	prototype	virus	to	study	poxviruses	(Condit,	Moussatche,	&	Traktman,	2006).	This	prototype	poxvirus	contains	over	100	polypeptides	and	a	genomic	DNA	molecule	that	encodes	more	than	200	genes	(Geada,	Galindo,	Lorenzo,	Perdiguero,	&	Blasco,	2001).			VACV	has	a	complex	morphogenesis	that	leads	to	the	formation	of	two	distinct	forms	of	infectious	virus	particles,	the	intracellular	mature	virus	(IMV)	and	the	extracellular	enveloped	virus	(EEV)	(Roberts	&	Smith,	2008).	The	IMV	form	of	VACV	was	renamed	as	mature	virus	(MV)	and	the	EEV	form	as	extracellular	virus	(EV)	(Moss,	2006).	The	two	forms	differ	by	the	number	of	membranes	that	surround	the	virus	(Figure	1.4).	MV	is	the	simplest	form	of	the	virus	surrounded	by	a	single	membrane	and,	as	the	name	suggests,	remains	inside	the	cell	until	cell	lysis	(Payne	&	Kristensson,	1985;	Sodeik	&	Krijnse-Locker,	2002).	MV	particles	contain	a	biconcave,	DNA-containing	core,	flanked	by	lateral	bodies	which	fill	the	concavity	of	the	core	(Condit	et	al.,	2006).	The	EV	form	of	VACV,	on	the	other	hand,	is	essentially	an	MV	wrapped	in	a	second	membrane	that	allows	the	virus	to	be	released	from	infected	cells	before	virus-induced	cell	death	(Condit	et	al.,	2006;	Roberts	&	Smith,	2008).	Although	the	MV	form	makes	up	the	bulk	of	the	infectious	virion	progeny,	they	are	not	able	to	mediate	cell-to-cell	spread	of	the	virus	(Carter	et	al.,	2003).	The	MV	form	of	VACV	is	the	cytopathic	version	of	VACV,	as	the	MV	
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Figure	1.4:	VACV	morphogenesis.	In	a	cell	infected	with	vaccinia	virus	(VACV),	the	naked	viral	core	is	moved	on	the	microtubule	network	to	the	virus	factories	where	the	core	uncoats	and	the	replication	process	initiates	to	produce	the	immature	virion	(IV).	The	culmination	of	a	replication	cycle	results	in	intracellular	mature	virus	(MV)	particles	that	further	move	on	the	microtubule	network	to	the	Golgi	apparatus	where	they	are	wrapped	by	membranes	derived	from	early	endosomal	or	trans-Golgi	cisterna	and	become	intracellular	enveloped	virus	(IEV)	particles.	Finally,	the	IEVs	move	to	the	plasma	membrane	of	the	cell	via	the	microtubule	network	where	the	outer	IEV	membrane	fuses	with	the	plasma	membrane	to	form	cell-associated	enveloped	virus	(CEV).	Actin	tail	formation	pushes	the	CEV	away	from	the	infected	cell,	this	VACV	now	being	the	extracellular	enveloped	virus	(EV)	particle	(Adapter	from	Roberts	and	Smith,	2008).	 	
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particles	are	only	released	upon	death	of	an	infected	cell.	The	EV	form	of	VACV,	on	the	other	hand,	is	released	from	a	live	cell.	The	EV	form	of	VACV	is	also	known	as	cell-associated	enveloped	virus	(CEV),	if	it	is	retained	on	the	cell	surface	(Condit	et	al.,	2006).	Both	CEV	and	EV	are	important	for	viral	dissemination.	EVs	have	been	shown	to	mediate	long-range	dissemination	in	vitro,	whereas	the	CEVs	are	known	to	infect	neighbouring	uninfected	cells.	Interestingly,	the	intracellular	and	extracellular	forms	of	VACV	contain	different	viral	proteins	which	are	found	within	either	outer	membranes,	which	makes	MV	and	EV	structurally,	functionally	and	antigenically	different	(Roberts	&	Smith,	2008).		
	
1.9.1	VACV	gene	expression	and	morphogenesis	VACV	particles	have	been	shown	to	be	composed	of	four	different	structural	elements,	namely,	the	core,	lateral	bodies,	outer	membrane	and	the	envelope	which	is	a	characteristic	feature	of	only	EV	(Sodeik	&	Krijnse-Locker,	2002).	The	proteinaceous	core	membrane	surrounds	the	core,	which	contains	the	viral	genome,	DNA	associated	proteins,	viral	structural	proteins,	and	other	necessary	transcriptional	enzymes	that	are	required	to	initiate	replication	(Condit	et	al.,	2006;	Roberts	&	Smith,	2008;	Sodeik	&	Krijnse-Locker,	2002).	Poxviruses	differ	from	other	classes	of	DNA	viruses	in	that	the	virus	remains	in	the	cytoplasm	of	the	cell	for	the	entire	infectious	cycle,	indicating	that	the	poxviruses	have	evolved	to	be	highly	independent	of	the	host	cell,	especially	for	the	processes	that	involve	DNA	replication	(Broyles,	2003).		To	initiate	infection,	the	single	membrane	of	MV	fuses	with	the	cell	membrane,	and	the	remainder	of	the	infectious	virion,	the	naked	core,	enters	the	cell	cytoplasm.	
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The	core	is	then	transported	deeper	within	the	cell	on	microtubules	to	the	perinuclear	region	where	viral	replication	takes	place	(Carter	et	al.,	2003).	It	has	been	shown	that	heparin	causes	rupture	of	the	outer	EV	envelope,	thereby	releasing	MV	encapsulated	within	the	outer	membrane	(Law,	Carter,	Roberts,	Hollinshead,	&	Smith,	2006).	The	first	step	in	viral	replication	is	the	transcription	of	the	viral	genome	into	early	mRNA	by	the	viral	associated	enzymes	packaged	within	the	genome	core.	The	proteins	translated	from	these	early	mRNAs	are	not	only	involved	in	replication	of	viral	DNA,	but	also	in	the	modification	of	the	host	cell	to	advantage	the	virus	by	aiding	its	escape	from	the	innate	immune	system	(Broyles,	2003;	Roberts	&	Smith,	2008).	As	the	DNA	replicates,	transcription	of	intermediate	genes	commences.	These	intermediate	genes	encode	a	number	of	regulatory	proteins	that	induce	transcription	of	the	late	genes.	The	transcriptional	products	of	the	late	genes	are	viral	proteins	that	make	up	new	virus	particles	and	other	enzymes,	which	are	packaged	into	virions	to	initiate	the	next	round	of	transcription	in	another	infected	cell	(Broyles,	2003;	Roberts	&	Smith,	2008).			The	cytoplasmic	sites	where	viral	replication	takes	place	are	known	as	viral/DNA	factories	(Figure	1.4).	These	sites	contain	few	if	any	cellular	organelles	(Carter	et	al.,	2003;	Condit	et	al.,	2006;	Roberts	&	Smith,	2008).	A	crescent-shaped	arrangement	is	the	first	visible	structure	that	appears	in	the	virus	factories.	It	contains	proteins	and	lipids,	and	grows	to	form	an	oval	structure.	This	structure	engulfs	the	virus	core	components	and	is	termed	an	immature	virion	(IV)	(Figure	1.4).	As	the	viral	genome	is	packaged	into	IV,	the	action	of	several	proteolytic	enzymes	modifies	the	core	proteins.	These	modifications	transform	the	virus	into	
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the	brick-shaped	intracellular	MV	particles	(Condit	et	al.,	2006;	Roberts	&	Smith,	2008).			A	few	of	these	newly	formed	MVs	are	transported	away	from	the	viral	factories	to	a	site	near	the	microtubule-organizing	centre	(MTOC)	where	they	become	enveloped	by	a	double	cellular	membrane	to	form	intracellular	enveloped	virus	(IEV)	particles	(Carter	et	al.,	2003;	Roberts	&	Smith,	2008).	The	double	membrane	is	derived	from	endosomal	or	trans-Golgi	cisternae	(Roberts	&	Smith,	2008).	The	IEV	are	then	transported	to	the	periphery	of	the	infected	cell,	where	the	outer	IEV	membranes	fuse	with	the	plasma	membrane	and	produce	cell-associated	enveloped	virus	(CEV)	on	the	cell	surface	(Figure	1.4).	In	order	to	infect	the	neighboring	cells,	CEVs	need	to	detach	from	the	infected	cells.	CEVs	induce	actin	polymerization	beneath	the	plasma	membrane	in	order	to	push	the	virions	away	from	the	cell.	Once	detached	from	cells,	these	CEVs	are	called	extracellular	enveloped	virus	(EV)	(Carter	et	al.,	2003).			CEV	and	EV	forms	of	VACV	are	easily	able	to	evade	host	antibody	and	complement	by	being	wrapped	in	a	host-derived	outer	membrane	(Roberts	&	Smith,	2008).	The	outer	membrane	of	the	MV	form	of	VACV	is	highly	resistant	to	breakage,	which	makes	it	an	ideal	viral	form	to	cause	inter-host	transmission	(Chahroudi	et	al.,	2005;	Sodeik	&	Krijnse-Locker,	2002).	EVs,	on	the	other	hand,	are	known	to	mediate	cell-to-cell	spread	of	the	virus	as	they	have	acquired	an	extra	membrane	from	the	trans-Golgi	network	(Chahroudi	et	al.,	2005;	Vanderplasschen,	Hollinshead,	&	Smith,	1998).	
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1.9.2	VACV	interacts	with	HS	Previous	studies	have	shown	that	there	are	at	least	three	GAG-binding	receptors	on	the	surface	of	MV	(Chung	et	al.,	1998;	Ho	et	al.,	2005;	Lin	et	al.,	2000).	To	cause	an	infection,	virions	attach	to	cell	surface	GAGs	and	fuse	with	the	plasma	membrane	to	enter	a	cell.	The	receptors	required	for	plasma	membrane	fusion	are	still	unknown.	Envelope	proteins	H3L	and	A27L	have	been	shown	to	bind	HS,	whereas	D8L	has	been	shown	to	interact	with	chondroitin	sulfate	(Ho	et	al.,	2005;	Lin	et	al.,	2000).	Previous	studies	have	also	shown	that	B5R	and	A34R	proteins	present	on	the	outer	envelope	of	the	EV	form	of	VACV,	when	in	contact	with	cell	surface	HS,	initiate	the	dissolution	of	the	outer	EV	envelope,	which	is	followed	by	the	fusion	of	inner	viral	membrane	with	the	plasma	membrane	of	cells	(Law	et	al.,	2006).		Envelope	protein	A27L	has	been	shown	to	bind	cell	surface	HS	moieties,	an	interaction	required	for	fusion	of	the	virus	with	the	target	cell	plasma	membrane	(Lin	et	al.,	2000).	Extensive	studies	performed	on	A27L	show	that	the	protein	can	be	divided	into	four	functional	domains,	namely,	a	signal	peptide	for	protein	processing	(Takahashi,	Oie,	&	Ichihashi,	1994),	a	cell	surface	GAG	binding	region	rich	in	lysine	and	arginine	residues	(Hsiao,	Chung,	&	Chang,	1998),	a	coiled-coil	domain	that	is	involved	in	self	assembly	(Ho	et	al.,	2005),	and	a	C-terminal	sequence	that	has	been	shown	to	interact	with	A17L,	another	vaccinia	viral	protein,	and	is	vital	for	Golgi	membrane	wrapping	of	the	MV	during	the	formation	of	the	intracellular	and	extracellular	enveloped	forms	of	the	virus	(Rodriguez,	Esteban,	&	Rodriguez,	1995).	Studies	performed	using	A27L	mutants	showed	a	
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phenotype	where	the	plaque	size	was	greatly	reduced	indicating	that	A27L	is	essential	for	viral	spread	(Rodriguez	&	Esteban,	1987).			The	H3L	gene	encodes	p35	protein,	a	HS	binding	molecule,	which	is	an	immunodominant	antigen	on	the	surface	of	MV.	Studies	have	shown	that	the	H3L	mutant	virus	is	not	only	structurally	different	to	wild	type	MV,	but	also	has	greatly	reduced	infectivity	compared	to	wild	type	MV	(Lin	et	al.,	2000).		
	
1.9.3	Strains	of	VACV	Intensive	disease	surveillance,	combined	with	a	comprehensive	vaccination	strategy	using	VACV,	was	required	to	successfully	eradicate	smallpox.	However,	there	is	little	historical	evidence	of	the	biological	origin	of	VACV,	the	relationship	between	different	strains	of	VACV	used	to	eradicate	smallpox,	or	how	they	have	evolved	from	a	common	ancestral	strain	(Qin,	Favis,	Famulski,	&	Evans,	2015).	Western	Reserve	(WR)	and	International	Health	Department-J	(IHD-J)	are	two	of	the	most	commonly	used	laboratory-passaged	strains	of	VACV	and	were	the	strains	of	VACV	used	in	the	assays	described	in	this	thesis.	These	two	strains	of	VACV	are	known	to	plaque	differently,	with	the	IHD-J	plaques	being	‘comet’	shaped	and	the	majority	of	WR	plaques,	on	the	other	hand,	being	round	with	only	a	few	plaques	being	comet-like	in	appearance	(Figure	3.5A).	Both	the	WR	and	IHD-J	strains	of	VACV	produce	similar	amounts	of	MV,	IEV	and	CEV,	however,	about	40%	more	EV	is	released	by	the	IHD-J	strain	(Blasco	&	Moss,	1992).	This	makes	the	IHD-J	strain	the	more	infectious	of	the	two	strains.	Since	more	EV	is	released	by	the	IHD-J	strain,	the	spread	of	virus	to	distant	cells	is	more	efficient.	This	results	in	the	majority	of	IHD-J	plaques	appearing	as	comets.	
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Most	of	the	previous	studies	performed	with	VACV	have	been	with	the	MV	form	of	VACV	as	this	form	is	easily	purified	to	high	concentrations	and	is	easy	to	work	with.	Most	purification	protocols	used	to	isolate	EV	particles	involve	high-speed	centrifugation,	which	inevitably	damages	the	outer-membranes	of	the	EV	particle	and,	therefore,	results	in	the	release	of	the	enclosed	MV	particle	(Figure	3.5E	and	F).	Since	the	MV	and	EV	forms	of	VACV	differ	markedly	in	the	make	up	of	their	outer	membranes,	the	role	of	cell	surface	HS	in	the	infectivity	of	the	two	forms	of	the	virus	may	differ	substantially.	
	
1.10	Research	question	A	steady	increase	in	the	numbers	of	drug	resistant	viruses	has	become	a	reason	for	concern	in	the	scientific	community.	This	has	resulted	in	increasing	efforts	to	develop	new	classes	of	antiviral	drugs	that	are	less	intrusive,	less	toxic	and	more	resistant	to	virus	evasion	strategies	compared	to	the	traditional	treatments.	One	approach	is	to	target	virus	entry	into	cells	by	developing	compounds	that	block	virus	particles	from	interacting	with	their	cell	surface	receptors	and,	thereby,	prevent	virus	particles	from	establishing	an	infection.	Since	it	is	known	that	many	viruses	and	other	pathogens	use	cell	surface	HS	as	an	initial	docking	site	prior	to	their	interaction	with	their	specific	cell	surface	receptors,	which	then	allows	them	to	enter	and	establish	an	infection,	a	detailed	understanding	of	the	interaction	between	viruses	and	cell	surface	HS	would	be	vital	for	the	development	of	novel	HS	based	antiviral	drugs.		 	
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Figure	1.5:	VACV	interacts	with	cell	surface	HS	prior	to	infecting	cells.	A	diagrammatic	representation	of	VACV	interacting	with	cell	surface	HS.	VACV	bound	to	cell	surface	HS	is	then	able	to	more	efficiently	interact	with	more	specific	cell	surface	receptors	(not	shown).		Using	VACV	as	a	prototype	virus,	the	underlying	hypothesis	is	that	VACV	uses	cell	
surface	HS	as	an	initial	docking	site	prior	to	interacting	with	its	cell	surface	
receptors	(Figure	1.5).	Heparanase	mediated	cleavage	of	cell	surface	HS,	or	the	
use	of	cells	genetically	deficient	in	cell	surface	HS	expression,	would	hamper	
the	ability	of	VACV	to	cause	an	infection.	Understanding	the	interaction	
between	VACV	and	cell	surface	HS	at	a	structural	level	in	3D	space	would	allow	
development	of	small	molecules	based	on	the	parent	HS	structure,	which	could	
interfere	and	inhibit	VACV	interacting	with	cell	surface	HS.			Based	on	the	hypothesis	outlined	above,	the	research	described	in	this	thesis	attempted	to	address	the	following	research	aims.		
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Aim	1:	Establish	heparin,	heparan	sulfate	and	chondroitin	sulfate	binding	specificities	of	VACV	mature	virus	and	determine	effects	of	heparin	on	the	Western	Reserve	and	the	International	Health	Department-J	strains	of	VACV.		
Aim	2:	Construct	green	fluorescent	protein	expressing	Western	Reserve	and	International	Health	Department-J	strains	of	VACV	to	determine	the	role	of	cell	surface	heparan	sulfate	in	VACV	infections	in	vitro.		
Aim	3:	Determine	the	structural	features	of	heparin	(and	heparan	sulfate)	that	are	required	for	the	molecule	to	interact	with	VACV.		
Aim	4:	Identify	protein(s)	on	the	surface	of	outer	envelope	of	the	extracellular	enveloped	virus	that	interact	with	heparan	sulfate.		
Aim	5:	Evaluate	the	role	of	heparanase	in	VACV	infections	in	vivo.		 	
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2.1	Mice	and	Reagents	
2.1.1	Mice	Pathogen	free	female	C57BL/6	and	heparanase	knockout	(HPSE-/-)	(5-8	weeks	old)	mice	were	obtained	from	the	Australian	Phenomics	Facility	at	ANU,	and	maintained	under	the	ANU	Animal	Experimentation	and	Ethics	Committee	(AEEC)	guidelines.			
2.1.2	Ethics	statement	The	mice	used	for	all	the	experiments	for	the	purpose	of	this	PhD	thesis,	were	maintained	in	accordance	with	AEEC	approved	guidelines,	protocol	number	A2011/018.	All	the	experiments	performed	were	in	accordance	with	the	Australian	National	Health	and	Medical	Research	Council	guidelines	within	the	Australian	Code	and	Practice	for	the	Care	and	Use	of	Animals	for	Scientific	Purposes.	For	every	mouse	used	in	every	experiment	performed,	a	health	score-sheet	was	maintained	over	the	course	of	the	experiment.	Mice	were	monitored	daily	post	infection	and	were	scored	for	signs	of	distress,	illness	and	weight	loss.	All	the	mice	were	ethically	sacrificed	by	the	method	of	cervical	dislocation	in	accordance	with	the	above	AEEC	approved	protocol.		
2.1.3	Cell	lines	Human	osteosarcoma	143B	cells	(obtained	from	ATCC)	were	grown	in	MEM	(GIBCO-Invitrogen,	Grand	Island,	NY)	supplemented	with	5%	heat	inactivated	foetal	bovine	serum	(FBS	-	GE	Healthcare,	Pittsburg,	PA),	50	μg/mL	penicillin,	50	μg/mL	streptomycin	and	50	μg/mL	neomycin	(all	provided	by	the	media	unit,	John	Curtin	School	of	Medical	Research	-	JCSMR).	
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Baby	hamster	kidney	BHK-21	cells	(obtained	from	ATCC),	Chinese	hamster	ovary	CHO-K1	cells	(provided	by	Hulett/Hogarth,	The	Austin	Research	Institute,	Melbourne,	Australia),	and	xylosyltransferase-I-deficient	Chinese	hamster	ovary	pgsA-745	cells	(provided	by	Dr.	Eva	Lee,	JCSMR,	Canberra,	Australia),	were	all	grown	in	RPMI-1640	(GIBCO-Invitrogen)	supplemented	with	5%	FBS.		All	the	cell	lines	were	incubated	at	37°C	in	a	Hepa-Filtered	IR	Incubator	(Forma	Scientific	Inc.,	Marietta,	OH)	in	humidified	atmosphere	containing	5%	CO2.	Cells	were	passaged	every	two	days,	or	when	100%	confluency	(~	1	x	106	cells/mL)	was	reached,	depending	on	the	rate	of	cell	growth.	Confluent	cells	were	subcultured	at	a	cell	concentration	of	2	x	105	cells/mL	and	allowed	to	grow	to	the	maximum	concentration	of	1	x	106	cells/mL.		
2.1.4	Viruses	Two	different	strains	of	VACV	were	used	for	the	purpose	of	this	thesis,	namely,	the	International	Health	Department	strain	(IHD-J)	obtained	with	thanks	from	Dr.	David	Tscharke	(RSB,	Australian	National	University,	Canberra,	Australia)	and	the	Western	Reserve	strain	(WR).	Recombinant	forms	of	both	strains	of	VACV	were	constructed	by	inserting	green	fluorescent	protein	–	blasticidin	resistance	(GFP-
Bsd)	genes	in	their	genomes.	The	blasticidin	resistance	gene	Bsd,	when	fused	with	GFP	gene,	has	previously	been	shown	to	be	an	ideal	bi-functional	selection	marker	for	engineering	recombinant	poxviruses,	due	to	its	small	size	and	the	ability	to	allow	drug	selection	and	visual	screening	(Wong,	Lin,	Melo-Silva,	Smith,	&	Tscharke,	2011).	The	GFP-Bsd	cassette	used	in	this	thesis	is	based	on	the	cassette	used	previously,	but	has	been	modified	by	Dr.	Ronald	Jackson,	JCSMR,	such	that	the	
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GFP	molecule	fluoresces	brighter	at	470	nm,	is	more	stable	at	37°C,	and	has	its	own	strong	promoter,	all	of	which	enhance	GFP	expression	compared	to	the	original	GFP-Bsd	sequence.		
2.1.4.1	Cloning	GFP-Bsd	in	a	MVA	vector	As	mentioned	above,	the	GFP-Bsd	cassette	used	in	this	thesis	is	a	modified	version	of	the	cassette	that	has	previously	been	published.	To	clone	the	GFP-Bsd	cassette	into	a	Modified	Vaccinia	Ankara	(MVA)	vector,	both	pUC57	(GFP-Bsd	carrier	vector:	Figure	2.1A)	and	pUC57-MVAF	DNA	vectors	were	first	digested	using	the	restriction	enzyme	FseI	(New	England	BioLabs,	Ipswich,	MA).	A	restriction	digest	mix	was	prepared	was	composed	of	1	μL	of	FseI	restriction	enzyme	(2	units),	1	μL	of	10X	NEBuffer	4	(supplied	with	FseI),	1	μL	of	100X	bovine	serum	albumin	(BSA)	(supplied	with	FseI)	and	6	μL	of	double	distilled	water	(ddH2O)	(Media	Unit,	JCSMR).	The	respective	vector	DNAs	(1	μL)	were	added	to	the	reaction	mixture	and	incubated	at	37°C	for	1	hr.	To	denature	the	restriction	enzyme	post	digestion,	the	mixture	was	heated	at	65°C	for	20	min.			The	second	step	in	cloning	the	GFP-Bsd	gene	cassette	into	the	MVAF	vector	was	the	dephosphorylation	of	5’	phosphate	of	the	digested	MVAF	vector.	Shrimp	alkaline	phosphatase	(SAP)	(Promega,	Madison,	WI)	was	used	to	catalyze	the	reaction.	Initially	10	μL	of	ddH2O	was	added	to	both	digested	DNA	vectors,	with	the	digested	pUC57	being	left	on	ice,	whereas,	the	pUC57-MVAF	DNA	vector	was	further	processed	prior	to	treatment	with	SAP.	A	mixture	containing	2	μL	of	3	M	sodium	acetate	(Sigma-Aldrich,	St.	Louis,	MO)	and	60	μL	of	absolute	ethanol	was	added	and	the	samples	incubated	at	-20°C	for	30	min.	The	pUC57-MVAF	DNA	vector	was	
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then	centrifuged	at	30,100	g	for	25	min	to	allow	the	precipitated	DNA	to	pellet.	The	supernatant	was	removed	and	the	DNA	containing	pellet	left	to	air	dry.	Once	dried,	16	μL	of	ddH2O,	2	μL	of	SAP	buffer	(supplied	with	SAP	enzyme)	and	2	μL	SAP	enzyme	(2	units)	added	and	the	mixture	incubated	at	37°C	for	15	min.	After	phosphatase	treatment,	SAP	was	denatured	by	incubating	the	tube	at	70°C	for	15	min.		Both	the	pUC57	GFP	carrier	and	MVAF	vectors	were	loaded	and	run	on	a	1%	agarose	gel	(Sigma-Aldrich)	containing	3	μL	of	SYBR	safe	DNA	gel	stain	(ThermoFisher	Scientific,	Marietta,	OH).	Both	DNA	samples	(10	μL)	were	mixed	with	10X	BlueJuice	gel	loading	buffer	(2	μL)	(ThermoFisher	Scientific),	loaded	onto	the	gel	along	with	1	kb+	DNA	ladder	(ThermoFisher	Scientific),	a	mixture	of	20	highly	purified	double-stranded	DNA	bands	ranging	from	100	bp	to	12,000	bp,	to	estimate	the	molecular	weight	of	digested	DNA	fragments,	and	run	at	80	V	for	45	min.	Figure	2.1B	shows	the	restriction	digest	products.	Lane	1	contains	the	3.9	kb	empty	MVAF	vector	and	lane	3	shows	the	1	kb+	DNA	ladder.	Lane	4	contains	two	bands,	a	smaller	1.1	kb	band	and	a	larger	2.7	kb	band.	The	1.1	kb	band	is	the	GFP-
Bsd	cassette	resulting	from	the	restriction	digest,	whereas,	the	2.7	kb	band	represents	the	remaining	vector	(Figure	2.1A).		Both	the	3.9	kb	band	in	lane	1	(empty	pUC57-MVAF	vector)	and	the	smaller	band	in	lane	4	(GFP-Bsd	cassette)	were	excised	and	put	in	the	same	tube	for	purification	using	the	MiniElute	gel	extraction	kit	(Qiagen,	Valencia,	CA).	To	perform	the	ligation	of	the	two	DNA	plasmids,	4	μL	of	T4	DNA	ligase	(Promega)	and	5	μL	of	10X	ligase	buffer	(provided	with	DNA	ligase)	were	added	to	10	μL	of	a	purified	plasmid	
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Figure	2.1:	Cloning	of	GFP-Bsd	cassette	into	pUC57-MVA	vector.	(A)	Diagrammatic	representation	of	pUC57	carrier	vector	which	contains	a	1.1	kb	GFP-
Bsd	construct.	(B)	Agarose	gel	(1%)	showing	restriction	digest	of	both	pUC57	(GFP-Bsd)	carrier	(lane	4)	and	empty	pUC57-MVAF	vectors	(lane	1).	Both	empty	pUC57-MVAF	and	carrier	pUC57	vectors	were	digested	using	the	restriction	enzyme	FseI.	Lane	2	was	left	empty	and	lane	3	contains	a	1	kb+	DNA	ladder.	(C)	pUC57-MVAF	gene	map	containing	the	GFP-Bsd	gene	fragment	in	correct	orientation.	(D)	Another	1%	agarose	gel	showing	restriction	digest	of	products	after	a	transformation	assay.	Four	different	colonies	were	treated	with	the	restriction	enzymes	EcoRI	and	BstEII.	Lane	1	contains	a	1	kb+	DNA	ladder.	Lanes	2,	3	and	5	show	two	bands,	a	3.5	kb	and	a	smaller	1.6	kb	fragments,	indicating	that	the	GFP-Bsd	cassette	is	inserted	in	the	correct	orientation.	Lane	4	also	has	two	bands,	a	4.2	kb	and	a	smaller	0.8	kb,	indicating	that	the	GFP-Bsd	cassette	is	inserted	in	the	incorrect	orientation.	(E)	WR-GFP	plaques	and	(F)	IHD-J-GFP	plaques	forming	on143B	monolayers.	Images	were	taken	using	an	Olympus	IX81	fluorescence	microscope	at	400X	magnification.		
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preparation	and	incubated	overnight	at	16	°C.	The	GFP-Bsd	cassette	can	ligate	with	the	empty	pUC57-MVAF	vector	in	two	different	orientations.	Figure	2.1C	shows	the	correct	orientation	of	ligation	in	the	direction	of	the	F7	region.	GFP-Bsd	ligation	towards	the	F8	region	would	be	the	incorrect,	and	would	require	the	cloning	process	to	be	repeated	from	the	beginning.		
2.1.4.2	Transfection	To	perform	transfections,	10	μL	of	plasmid	DNA	from	the	cloning	step	was	added	to	50	μL	of	DH5α	(endA1)	E.	coli	strain	(ThermoFisher	Scientific)	and	incubated	on	ice	for	20	min.	Heat	shock	treatment	of	the	transfection	mixture	was	performed	by	incubating	the	mixture	at	42°C	for	30	sec,	with	the	heat	shock	treatment	forming	small	holes	in	the	bacterial	membranes	allowing	plasmid	DNA	to	enter	the	bacteria.	The	mixture	was	put	on	ice	for	2	min	to	allow	the	bacterial	cell	membranes	to	reseal.	Liquid	broth	(500	μL)	(Media	Unit,	JCSMR)	added	and	the	bacteria	incubated	at	37°C	for	1	hr.	The	transfected	DH5α	bacteria	were	inoculated	on	a	liquid	broth	agar	plate	supplemented	with	50	μg/mL	ampicillin	and	grown	overnight.	Five	different	single	colonies	were	randomly	picked	from	the	agar	plate	using	a	sterile	toothpick,	inoculated	into	five	different	5	mL	liquid	broth	tubes	supplemented	with	50	μg/mL	of	ampicillin	and	incubated	overnight	in	a	37°C	shaking	incubator.	
	
2.1.4.3	Plasmid	DNA	purification	and	confirmation	of	GFP-Bsd	orientation	To	purify	amplified	plasmid	DNA,	the	PureYield	Plasmid	Miniprep	system	kit	(Promega)	was	used.	Purified	plasmid	DNA	from	all	4	colonies	was	digested	to	confirm	the	orientation	of	the	GFP-Bsd	cassette	in	the	pUC57-MVAF-GFP	vector.	
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Figure	2.1C	shows	the	pUC57-MVAF	vector	map	with	the	GFP-Bsd	sequence	inserted	in	the	correct	orientation,	between	the	F7	and	F8	region.	Restriction	enzymes	EcoRI	and	BstEII	(New	England	BioLabs)	were	used	to	digest	all	five	pUC57-MVAF-GFP	vectors.	A	50	μL	reaction	mixture	was	prepared	containing	5	μL	of	10X	NEBuffer	(supplied	with	both	restriction	enzymes),	2	μL	of	EcoRI,	2	μL	of	
BstEII,	5	μL	of	10X	BSA	(supplied	with	both	restriction	enzymes)	and	35	μL	of	ddH2O.	The	reaction	mixture	was	divided	into	4	tubes,	each	with	10	μL	of	the	reaction	mix,	followed	by	addition	of	2	μL	of	purified	plasmid	DNA	to	the	respective	tubes	with	the	tubes	being	incubated	at	37°C	for	1	hr	for	digestion.	Once	digested,	the	products	were	run	on	a	1%	agarose	gel	as	described	earlier	in	section	2.1.4.1.	Figure	2.1D	shows	the	digested	products	of	all	five	colonies	tested.	Lanes	2,	3	and	5	have	two	bands,	a	3.5	kb	and	a	smaller	1.6	kb	fragment,	showing	the	digestion	products	expected	from	the	insertion	of	the	GFP-Bsd	cassette	in	the	correct	orientation	in	pUC57-MVAF	vector	(Figure	2.1C).	Lane	4,	however,	has	a	4.2	kb	fragment	and	a	0.8	kb	fragment,	indicating	that	the	GFP-Bsd	cassette	is	inserted	in	the	incorrect	orientation	in	the	pUC57-MVAF-GFP	plasmid.		
2.1.4.4	Transfection	of	WR-VACV	and	IHD-J-VACV	to	express	GFP-Bsd			Lipofectamine	2000	transfection	reagent	(ThermoFisher	Scientific)	was	used	to	aid	DNA	uptake	and	recombination	between	the	WR-VACV/IHD-J-VACV	genomes	and	the	pUC57-MVAF-GFP	vectors,	which	if	successful,	would	result	in	insertion	of	the	GFP-Bsd	cassette	in	the	WR-VACV	and	IHD-J-VACV	genomes.	Lipofectamine	reagent	(40	μL)	was	added	to	serum	free	MEM	(1	mL)	and,	in	a	separate	tube,	pUC57-MVAF-GFP	plasmid	(40	μL)	added	to	serum	free	MEM	(1	mL),	with	both	
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tubes	being	incubated	for	20	min	at	room	temperature,	prior	to	being	mixed	together.			BHK-21	cell	monolayers	were	grown	in	two	T25	tissue	culture	flasks	until	80	%	confluent.	Medium	from	both	flasks	was	removed	gently,	washed	once	with	sterile	phosphate	buffer	saline	(PBS)	(Sigma-Aldrich)	and	replaced	by	0.5	mL	of	fresh	MEM	(serum	free).	Both	flasks	were	incubated	in	a	37°C	incubator	for	1	hr	prior	to	the	addition	of	a	further	4.5	mL	of	MEM	(serum	free)	to	both	flasks	along	with	1	mL	lipofectamine	-	MVAF-GFP	plasmid	mix	and	100	μL	of	102	PFU	of	either	WR	or	IHD-J	strains	of	VACV.	The	flasks	were	then	incubated	for	72	hr	in	a	37°C	incubator.		Cell	monolayers	from	the	flasks	infected	with	the	WR	and	IHD-J	strains	of	VACV,	along	with	the	lipofectamine-plasmid	mix	were	subsequently	released	by	scraping.	Cells	were	sonicated	to	release	VACV	particles	within	which	were	used	to	infect	fresh	flasks	of	80%	confluent	BHK-21	cells	under	blasticidin	(ThermoFisher	Scientific)	selection	(10	μg/mL)	for	72	hr	in	a	37°C	incubator.	After	blasticidin	selection,	cell	monolayers	were	released	by	scraping,	sonicated	to	release	virus	as	before	and,	serial	dilutions	(1:10)	of	released	WR-VACV	and	IHD-J-VACV	infected	monolayers	made,	which	were	then	used	to	infect	100%	confluent	BHK-21	cell	monolayers	cultured	in	6-well	plates	in	the	absence	of	any	blasticidin.	VACV	was	allowed	to	infect	cells	for	1	hr	at	37°C	and	then	replaced	with	2	mL	of	1%	warm	low-melting-point	(LMP)	agarose	(Thermo	Fisher	Scientific)	mixed	with	an	equal	volume	of	1X	DMEM	(Media	unit,	JCSMR)	and	incubated	for	48	hr	in	a	37°C	
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incubator.	Following	the	incubation,	green	plaques	were	visualized	under	an	Olympus	IX81	fluorescence	microscope	at	400X	magnification.		Green	plaques	from	both	WR-VACV	and	IHD-J-VACV	infected	wells,	which	potentially	were	derived	from	GFP	expressing	VACV,	were	scraped	using	sterile	toothpicks,	transferred	to	tubes	containing	100	μL	of	MEM	(serum	free)	and	freeze	thawed	once	to	release	VACV	particles.	The	released	GFP	expressing	WR-VACV	and	IHD-J-VACV	particles	were	put	through	a	second	round	of	blasticidin	selection.	Fresh	monolayers	of	100%	confluent	BHK-21	cells	were	infected	with	the	released	GFP	expressing	WR-VACV	and	VACV	IHD-J	in	separate	12-well	plates	(Thermo	Fisher	Scientific)	and	incubated	for	1	hr	in	a	37°C	incubator.	Unbound	VACV	particles	were	removed	from	the	cell	monolayers	and	replaced	with	fresh	RPMI	(supplemented	with	5%	FBS	and	10	μg/mL	blasticidin).	The	infected	monolayers	were	incubated	for	further	48	hr	in	a	37°C	incubator.	The	culture	medium	was	subsequently	removed	from	the	cell	monolayers,	replaced	with	100	μL	of	fresh	RPMI	(supplemented	with	5%	FBS)	and	a	syringe	plunger	used	to	scrape	the	infected	cells	off	the	bottom	of	each	wells.	The	infected	cells	were	then	freeze-thawed	once	to	release	VACV	particles	and	serial	dilutions	made	which	were	then	used	to	infect	confluent	monolayers	of	BHK-21	cells	grown	in	6-well	plates	in	the	absence	of	any	blasticidin	selection	under	1%	LMP	agarose	as	described	earlier.	This	process	was	repeated	twice	to	ensure	WR-VACV	and	IHD-J-VACV	genomes	had	undergone	successful	recombination	events	with	the	pUC57-MVAF-GFP	plasmid	and	were	expressing	the	GFP-Bsd	cassette	without	any	contaminating	wild	type	WR-VACV	and	IHD-J-VACV	in	the	respective	recombinant	cultures.	
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2.1.4.5	PCR	confirmation	of	the	purity	of	the	recombinant	GFP-Bsd	VACV	
strains			To	confirm	that	there	were	no	contaminating	wild	type	WR-VACV	and	IHD-J-VACV	in	the	recombinant	WR-VACV	and	recombinant	IHD-J-VACV	preparations	respectively,	polymerase	chain	reactions	(PCR)	was	performed	on	DNA	isolated	from	green	plaques	using	primers	to	amplify	any	MVAF	plasmid	containing	the	GFP-Bsd	cassette	and,	therefore,	identifying	presence	of	wild	type	WR-VACV	or	IHD-J-VACV	in	green	plaques.	InstaGene	Matrix	(Bio-Rad,	Hercules,	CA)	was	used	to	prepare	DNA	from	mammalian	cells	by	following	the	protocol	supplied	by	the	manufacturer.	HotStarTaq	(Qiagen)	master	mix	was	used	with	the	MVAF	forward	and	reverse	primers	(Table	2.1)	to	amplify	the	products.	For	every	template	to	be	amplified,	12.5	μL	of	mastermix,	1	μL	of	forward	primers,	1	μL	of	reverse	primers,	8.5	μL	of	ddH2O	and	2	μL	of	template	was	used	such	that	the	total	reaction	volume	for	each	template	tested	was	25	μL.	The	cycling	conditions	are	summarized	in	Figure	2.2A.	Following	the	amplification,	PCR	products	were	run	on	1%	agarose	gels	as	described	earlier	in	section	2.1.4.1.	A	400	bp	PCR	product	is	indicative	of	the	presence	of	intact	pUC57-MVAF-GFP	plasmid	along	side	wild	type	VACV	strains.	Amplified	PCR	products	from	cells	obtained	from	supposedly	recombinant	WR-VACV	and	IHD-J-VACV	plaques	are	shown	in	Figures	2.2B	and	2.2C	respectively.	Lane	1	in	both	gels	contains	a	1	kb	+	DNA	ladder,	PCR	products	from	pUC57-MVAF-GFP	DNA	plasmid	(positive	control)	in	lane	3	and	the	amplified	products	from	WR-VACV	and	IHD-J-VACV	plaques,	respectively,	in	lane	5.		
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Figure	2.2:	Confirmation	of	successful	recombination	events	using	PCR.	(A)	Standard	PCR	cycle	conditions	used	to	amplify	pUC57-MVAF-GFP	plasmid	DNA.	Samples	were	incubated	at	95°C	for	15	min,	and	then	35	cycles	of	94°C	for	1	min,	55°C	for	30	sec	and	72°C	for	1	min.	After	all	35	cycles,	samples	were	incubated	at	72°C	for	10	min	before	bringing	the	temperature	down	to	15°C.	Products	from	a	PCR	amplification	of	DNA	purified	from	WR-VACV	(B)	and	IHD-J-VACV	(C)	infected	cell	monolayers.	Lane	1	contains	the	1	kb+	DNA	ladder,	lane	3	has	pUC57-MVAF-GFP	(positive	control)	and	lane	4	contains	amplified	products	from	the	DNA	purified	from	a	single	plaque	from	WR-VACV	(B)	and	IHD-J	(C).			 	
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Since	there	are	no	products	formed	from	the	PCR	amplification	of	the	WR-VACV	and	IHD-J-VACV	plaques,	it	can	be	concluded	that	both	genomes	contain	the	GFP-
Bsd	cassette.	Figure	2.1E	and	2.1F	show	plaques	formed	on	143B	cell	monolayers	when	infected	with	recombinant	WR-VACV	and	recombinant	IHD-J-VACV,	respectively.	
	
	
Table	2.1:	Primer	sequences	used	for	confirmatory	PCR	reactions	
Oligo	name Length	(bp) Sequence	(5'-3') 
	 	 	 
MVAF	
Forward 25 GAGCAGCCTCGTCCACGTACACCGC 
	 	 	 
MVAF	
Reverse 31 GGTTCTTATAATTGTAACATCCTTCTCTTCC 
   	
2.1.4.6	Purification	of	the	MV	and	EV	forms	of	VACV	from	WR	and	IHD-J	
strains	respectively	To	obtain	purified	GFP	expressing	mature	virus	(MV-GFP)	stocks	from	recombinant	WR-VACV,	BHK-21	cell	monolayers	were	grown	in	6	T175	flasks	until	80%	confluent.	Cells	were	then	infected	with	recombinant	WR-VACV	at	a	multiplicity	of	infection	(MOI)	of	0.1	for	1	hr	at	37°C.	Cell	monolayers	were	washed	once	with	PBS,	25	mL	of	fresh	RPMI	medium	(serum	free)	added	and	the	monolayers	incubated	for	a	further	48	hr	at	37°C.	Infected	cell	monolayers	were	scraped	off	the	flask	surface	and	pelleted	by	centrifugation	at	1800xg	for	5	min.	The	supernatant	was	discarded	and	each	cell	pellet	resuspended	in	3	mL	of	10	mM	
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Tris-HCl	buffer,	pH	9.0	and	pooled	together	prior	to	homogenizing	with	40	strokes	of	a	glass	dounce	homogeniser.	The	cells	were	centrifuged	again	for	5	min	at	300xg	to	remove	nuclei	and	other	cell	debris,	the	supernatant	retrieved	and	split	in	3	mL	aliquots.	All	aliquots	were	sonicated	at	intensity	3	for	30	sec	in	an	ice-cold	cup	sonicater,	the	sonicated	preparations	were	pooled	again	and	layered	onto	a	17	mL	cushion	of	36%	(weight/volume	-	w/v)	sucrose	(Sigma-Aldrich)	in	a	clear	ultracentrifuge	tube	and	centrifuged	at	32,000xg	for	1	hr	at	4°C	in	a	SW	28	rotor	under	vacuum	to	pellet	MV-GFP	particles.	Supernatant	was	discarded,	the	MV-GFP	pellet	resuspended	in	500	μL	of	a	1	mM	Tris-HCl	buffer	at	pH	9,	with	the	purified	MV-GFP	being	stored	at	-80°C.	To	obtain	MV	rich	stocks	for	enzyme-linked	immunosorbent	assays	(ELISAs)	and	plaque	assays,	wild	type	WR	strain	was	used	instead	of	GFP	expressing	recombinant	WR	strain.	For	Western	blots,	detergent	treatment	of	MV-GFP	particles	was	performed	as	described	in	section	2.2.5.		To	obtain	a	purified	stock	of	GFP	expressing	enveloped	virus	(EV-GFP),	the	recombinant	IHD-J-VACV	was	used	to	infect	80%	confluent	monolayers	of	BHK-21	cells	in	T175	flasks.	Cell	monolayers	were	infected	at	a	MOI	of	0.1	for	1	hr	at	37°C,	washed	once	with	PBS	and	prior	to	adding	12	mL	of	fresh	RPMI	medium	(serum	free)	and	incubated	for	further	48	hr	at	37°C.	To	collect	EV-GFP	particles,	supernatants	from	the	infected	cells	were	removed	without	disturbing	the	cell	monolayers	and	centrifuged	at	230xg	for	10	min	to	remove	any	cell	debris.	The	supernatant	was	then	used	as	the	EV	rich	stock	to	perform	all	fluorescence-activated	cell	sorting	(FACS)	based	assays.	To	obtain	EV	rich	stocks	for	plaque	assays,	wild	type	IHD-J	strain	was	used	instead	of	GFP	expressing	recombinant	IHD-J	strain.	Low	speed	centrifugation	was	performed	to	prevent	any	damage	to	
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the	EV	outer	membrane	and,	hence,	avoid	any	MV	contamination	of	EV	preparations.	The	EV-GFP	preparations	were	stored	at	4°C	for	up	to	2	weeks.	To	obtain	EV	particles	for	Western	blots,	EV	containing	supernatants	were	further	centrifuged	at	18,000xg	for	1	hr	to	pellet	EV	particles,	which	were	resuspended	in	500	μL	of	a	1	mM	Tris-HCl	buffer	at	pH	9.	The	detergent	treatment	of	EV	particles	performed	as	described	in	section	2.2.5.			2.1.5	Virus	titrations	and	plaque	assays	For	the	purpose	of	VACV	titrations,	143B	cells	were	used.	Cells	were	seeded	into	6-well	plates	and	incubated	overnight	until	the	cells	reached	100%	confluency.	Serial	dilutions	(1:10)	of	virus	stocks	were	made	in	MEM	(supplemented	with	5%	FBS),	culture	medium	removed	from	the	143Bs	containing	wells	and	replaced	with	100	μL	of	each	dilution.	The	cells	were	then	incubated	at	37°C	for	up	to	1	hr	ensuring	cells	did	not	dry	out.		The	virus	dilutions	removed	from	the	cells	and	replaced	with	2	mL	of	MEM	(supplemented	with	5%	FBS).	Cells	were	then	incubated	for	a	further	48	hr	period.	Following	this	incubation	period,	the	culture	medium	was	removed	from	each	well	and	the	cells	stained	with	0.1%	crystal	violet	(Sigma-Aldrich)	in	20%	ethanol	to	visualize	plaques.	The	resulting	plaques	were	then	counted	to	determine	virus	titers.	Plaque	diameters	were	measured	using	ImageJ	particle	analysis	plugin	with	settings	(Size	pixel^.05-5;	Circularity	0.0-1.0)	under	Olympus	IX81	fluorescence	microscope.		
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2.2	In	vitro	techniques	
2.2.1	ELISA	assays	To	perform	ELISA	assays,	96	U-well	PVC	microtitre	plastic	plates	(Dynex	Technologies	Inc.,	Chantilly,	VA)	were	used.	Plate	wells	were	coated	with	BSA	(Sigma-Aldrich)	conjugated	with	heparin,	highly	sulfated	heparan	sulfate	(HShi)	or	lowly	sulfated	heparan	sulfate	(HSlow),	at	10	μg/mL	(25μL/well)	in	PBS	overnight	at	4°C.	Unbound	BSA	conjugate	was	removed	next	day	by	gently	flicking	the	plate.	Non-specific	binding	to	ELISA	wells	was	blocked	with	PBS/1%BSA	(200	μL/well)	for	2	hr	at	37°C.	Blocking	buffer	was	then	removed	by	gently	flicking	the	plate	and	the	wells	were	washed	three	times	(200	μL/well)	with	PBS/0.05%	Tween-20	(Sigma-Aldrich).	Purified	MV	particles	from	the	WR	strain	of	VACV	were	diluted	to	1	x	105	PFU/mL	in	PBS/1%BSA,	added	to	the	ELISA	wells	(50	μL/well)	and	incubated	for	2	hr	at	4°C.	Unbound	MV	particles	were	removed	by	flicking	the	plate.	Wells	were	washed	three	times	(200	μL/well)	with	PBS/0.05%	Tween-20.		A	biotin-conjugated	polyclonal	rabbit-anti-VACV	antibody	(Mybiosource,	San	Diego,	CA)	was	used	at	4.5	μg/mL	final	concentration	in	PBS/1%BSA	and	added	(50	μL/well)	for	2	hr	at	4°C.	Unbound	antibody	was	removed	by	flicking	and	the	wells	were	washed	three	times	as	described	earlier.	Detection	of	antibodies	bound	to	MV	particles	in	ELISA	wells	was	achieved	by	using	a	secondary	antibody,	streptavidin-conjugated	horseradish	peroxidase	(HRP)	(GE	Healthcare),	used	at	0.1%	final	concentration	in	PBS/1%BSA	and	added	(50	μL/well)	for	1	hr	at	4°C.	Unbound	antibody	was	removed	and	wells	washed	as	described	above.	Peroxidase	substrate,	2,2’-azido-bis(3-ethylbenzthiazoline-6-sulphonic	acid)	(ABTS)	(Kirkegaard	and	Perry	Laboratories	Inc.,	Gaithersburg,	MD),	was	used	as	a	
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colorimetric	substance	to	detect	peroxidase	conjugated	antibodies	bound	to	the	wells,	with	ABTS	being	added	(100	μL/well)	for	30	min	at	37°C.	The	absorbance	readings	of	the	enzymatic	product	formed	post	substrate	addition	was	read	at	405	nm	on	a	Tecan	Infinite®	M200Pro	microplate	reader.	Histogram	plots	from	analysed	data	were	constructed	using	GraphPad	Prism®	(version	5.0f).		
2.2.2	Heparanase	treatment	To	investigate	the	effect	of	heparan	sulfate	(HS)	removal	from	143B	cells	on	VACV	infections,	cell	surface	HS	on	143B	cells	was	digested	using	both	Flavobacterium	heparinases	(HPNSE)	(Sigma-Aldrich)	and	human	platelet	heparanase	(HPSE)	(gift	from	Dr.	Craig	Freeman,	John	Curtin	School	of	Medical	Research,	Canberra,	Australia).	There	are	three	different	HPNSEs	available,	each	targeting	different	HS	sequences.	For	the	purpose	of	the	assays	performed	in	this	thesis,	each	HPNSE	(HPNSE	I,	II	and	III)	was	used	either	individually,	or	as	a	cocktail	of	all	three	to	digest	cell	surface	HS	and	evaluate	the	role	of	cell	surface	HS	in	VACV	infection.		All	three	HPNSEs	were	prepared	in	50%	glycerol	(Sigma-Aldrich)	at	a	stock	concentration	of	0.25	units/μL.	143B	cells	were	grown	in	48-well	flat	bottom	plates	and	incubated	overnight	to	reach	100%	confluency.	Culture	medium	was	aspirated	off	the	confluent	143B	cells	monolayers	and	the	wells	washed	with	sterile	PBS.	Cells	were	then	treated	for	1	hr	at	37°C	with	each	HPNSE	either	individually,	or	as	a	cocktail	of	all	three	enzymes,	at	a	final	concentration	of	0.25	units/mL	(100	μL	/well)	in	pH	5.5	serum	free	MEM.	After	incubation,	the	HPNSEs	were	aspirated	from	each	well	and	the	cell	monolayers	were	washed	with	PBS	prior	to	VACV	infection.	
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HPSE	was	prepared	at	a	stock	concentration	of	4	μg/μL	and	confluent	monolayers	of	143B	cells	grown	in	48-well	plates	treated	with	platelet	heparanase	at	a	final	concentration	of	4	μg/mL	(100	μL/well)	in	pH	5.5	serum	free	MEM	for	1	hr	at	37°C.	After	the	incubation,	cell	monolayers	were	washed	with	sterile	PBS	and	treated	cells	either	detached	from	the	monolayer	and	stained	for	cell	surface	HS	expression	(see	2.2.3	below),	or	kept	as	monolayers	and	infected	with	VACV	to	evaluate	the	role	of	HS	in	VACV	infection.	
	
2.2.3	FACS	assays:	HS	staining	To	confirm	that	the	HPNSE	and	HPSE	treatments	removed	cell	surface	HS	from	143B	cell	monolayers,	treated	and	untreated	(control)	cells	were	stained	with	a	HS-specific	antibody	and	run	on	a	BD	LSR	bench	top	flow	cytometer.	The	untreated	and	treated	143B	cells	were	initially	released	from	monolayers	by	incubation	with	0.25%	trypsin-EDTA	(GIBCO-Invitrogen)	(100	μL/well)	for	5	min	at	37°C,	and	transferred	to	V-bottom	96-well	plates	(Thermo	Fisher	scientific).	The	cells	were	washed	once	with	FACS	buffer	(PBS	supplemented	with	0.1%	BSA)	and	potential	Fc	receptors	blocked	prior	to	HS	staining	by	incubation	with	Fc	block	(clone:	2.4G2;	BD	Pharmingen,	Franklin	Lakes,	NJ)	at	2.5	μg/mL	final	concentration	in	FACS	buffer	and	added	to	cells	(25	μL/well)	for	10	min	on	ice.	Cells	were	then	washed	twice	with	FACS	buffer	and	cell	surface	HS	detected	by	incubation	with	the	HS-specific	monoclonal	antibody	(mAB)	10E4	(Amsbio,	Cambridge,	MA)	at	a	concentration	of	4	μg/mL	in	FACS	buffer	(25	μL/well)	for	30	min	on	ice.	It	should	be	emphasized,	however,	that	the	10E4	HS-binding	mAb	interacts	with	a	HS	epitope	not	easily	removed	by	HPSE	or	HPNSE,	and	probably	binds	to	HS	stubs	remaining	after	digestions	(Prof.	C.	Parish,	personal	communication).	
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Mouse	IgM	κ-myeloma	(clone:	C48-6;	BD	Pharmingen)	at	20	μg/mL	in	FACS	buffer	(25	μL/well)	was	used	as	an	isotype	control	being	incubated	for	30	min	on	ice.	Also,	FACS	buffer	(25	μL	/well)	was	added	to	cells	not	exposed	to	antibodies,	which	served	as	negative	controls	for	HS	staining.	After	incubation	with	the	primary	10E4	antibody	or	an	isotype	control	antibody,	cells	were	washed	twice	with	FACS	buffer,	and	a	secondary	goat	F(ab’)2	anti-human	IgM-PE	(SouthernBiotech,	Birmingham,	AL)	was	added	to	detect	surface	bound	antibodies.	The	secondary	antibody	was	used	at	a	concentration	of	2.5	μg/mL	in	FACS	buffer,	added	to	cells	(25	μL/well)	and	incubated	for	30	min	on	ice.	The	secondary	antibody	was	not	added	to	control	cells	not	exposed	to	primary	antibodies,	and	instead	only	FACS	buffer	(25	μL/well)	being	added.	After	this	incubation,	cells	were	washed	twice	with	FACS	buffer	and	run	on	an	LSR	benchtop	flow	cytometer	to	detect	PE	binding	to	cells.		
2.2.4	FACS	assays:	VACV	infection	Purified	MV-GFP	(obtained	from	the	WR-GFP	strain)	and	EV-GFP	(obtained	from	the	IHD-J-GFP	strain)	were	used	for	FACS	based	assays	of	VACV	infection	based	on	GFP	fluorescence.	143B	cells	were	seeded	in	48-well	plates	and	incubated	overnight	until	the	cells	reached	100%	confluency.	Doubling	dilutions	of	heparin	and	HS	mimetics,	starting	from	100	μg/mL	down	to	0.09	μg/mL,	were	made	in	serum	free	MEM.	Each	dilution	(350	μL)	of	porcine	mucosa	heparin	(or	HS	mimetics)	was	incubated	with	virus	MOI	of	1	for	1	hr	at	4°C	prior	to	addition	(100	μL/well)	to	143B	cell	monolayers,	from	which	overnight	culture	medium	had	been	aspirated,	and	incubated	for	1	hr	at	37°C.	Virus	preparations	without	added	heparin/HS	mimetics	served	as	positive	controls,	whereas	wells	receiving	no	virus	
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served	as	negative	controls.	When	143B	cell	monolayers	were	treated	with	HPNSE	and	HPSE,	or	when	the	VACV	infection	used	CHO-K1	cells	and	xylosyltransferase	I	deficient	pgsA-745	cells,	both	purified	MV-GFP	and	purified	EV-GFP	were	used	for	infection	without	any	pre-incubation	with	heparin	(or	HS	mimetics).			Following	the	1	hr	incubation	at	37°C,	virus	mixtures	were	aspirated,	the	monolayers	washed	with	sterile	PBS,	fresh	MEM	(supplemented	with	5%	FBS)	added	(500	μL/well)	and	the	cells	incubated	for	another	5	hr	at	37°C.	All	culture	medium	was	then	aspirated,	0.25%	trypsin-EDTA	added	(100	μL/well)	and	wells	incubated	for	5	min	at	37°C	to	detach	cells	from	the	surface	of	wells.	Once	detached,	cells	were	fixed	in	0.5%	paraformaldehyde	(100	μL/well),	transferred	to	cluster	tubes	(Sigma-Aldrich),	and	run	on	a	BD	FACS	Calibur,	with	30,000	gated	events	being	collected.	Data	collection	and	analysis	were	performed	using	FLOWJO	software	and	GraphPad	Prism	was	used	to	plot	histograms	from	analyzed	data.		
2.2.5	VACV	membrane	protein	extraction	To	detect	proteins	on	the	surface	of	VACV	particles	that	interact	with	HS	on	cell	surfaces,	MV	(from	WR	strain)	and	EV	(from	IHD-J	strain)	were	purified	and	concentrated	as	described	in	section	2.1.4.6.	A	detergent	cocktail	containing	2%	Brij®-58	(Sigma-Aldrich),	50	mM	β-mercaptoethanol	(Sigma-Aldrich)	and	1%	final	concentration	of	complete	protease	inhibitor	(4-(2-Aminoethyl)	benzenesulfonyl	Fluoride	Hydrochloride)	(Roche,	Indianapolis,	IN),	was	prepared	in	50	mM	Tris-HCl	buffer	at	pH	7.5.	Equal	volumes	of	concentrated	VACVs	and	detergent	cocktails	were	mixed	and	incubated	at	room	temperature	for	30	min.	To	separate	membrane	proteins	from	VACV	cores,	the	complete	detergent-virus	mixture	was	
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loaded	onto	a	caesium	chloride	(CsCl)	(Sigma-Aldrich)	gradient	(in	PBS)	made	of	1.30	g/mL	(3	mL),	1.25	g/mL	(4	mL)	and	1.20	g/mL	(5	mL)	of	CsCl,	in	clear	ultracentrifuge	tubes.	Tubes	were	then	centrifuged	at	154,000xg	for	30	min	under	vacuum	and	without	any	brakes	in	a	Beckman-Coulter	LE-80K	ultracentrifuge.	The	cloudy	layer	of	separated	proteins,	formed	above	the	CsCl	gradient,	was	carefully	removed	using	a	29-gauge	needle	and	syringe,	by	making	a	hole	in	ultracentrifuge	tube	wall	from	outside.	The	protein	mixture	was	then	added	to	a	10	kDa	cutoff	Amicon	ultrafiltration	device	(Milipore,	Billerica,	MA)	to	filter	out	CsCl	from	the	protein	mixture	by	centrifuging	at	3200xg	in	a	Beckman-Coulter	Allegra	x-15r	bench-top	centrifuge	for	10	min,	with	the	concentrated	protein	mixture	being	resuspended	in	500	μL	of	PBS.		
	
2.2.6	Interaction	of	VACV	proteins	with	heparin	coupled	beads	The	membrane	protein	mixture	extracted	from	MV	and	EV	particles	were	incubated	with	heparin-Sepharose	6	fast	flow	beads	(GE	Healthcare)	to	separate	heparin-binding	proteins	from	other	VACV	membrane	proteins.	This	was	performed	by	placing	an	aliquot	(500	μL)	of	heparin	beads	in	a	1.5	mL	tube,	centrifuging	briefly	to	settle	the	beads	and	washing	the	beads	thrice	with	sterile	PBS.	Settled	beads	were	then	resuspended	in	membrane	proteins	mixture	(100	μL)	extracted	from	MVs	and	EVs,	and	incubated	overnight	on	a	small	tube	rotator	at	30	rpm	at	4°C.	Tubes	were	then	centrifuged	to	settle	the	Sepharose	beads	and	supernatants	containing	unbound	proteins	removed.	To	release	heparin-bead	bound	proteins,	settled	Sepharose	beads	were	resuspended	in	sodium	dodecyl	sulfate-polyacrylamide	gel	electrophoresis	(SDS-PAGE)	sample	buffer	(100	μL),	and	boiled	at	100°C	for	5	min,	the	process	releasing	proteins	bound	to	the	heparin-
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beads.	The	Sepharose	beads	were	then	settled	again	by	centrifugation	and	supernatant,	containing	heparin-binding	proteins	removed.		
2.2.7	SDS-PAGE	To	visualize	heparin-binding	VACV	membrane	proteins	and	other	VACV	membrane	proteins,	samples	from	2.2.6	were	first	run	on	SDS-PAGE.	Initially	all	samples	were	mixed	with	an	equal	volume	of	SDS-PAGE	sample	buffer	and	boiled	at	100°C	for	5	min.	Heparin-binding	VACV	membrane	proteins,	non-heparin	binding	VACV	membrane	proteins	and	the	complete	mixture	of	VACV	membrane	proteins,	were	then	loaded	onto	4-20%	Tris-HEPES	mini-gels	(NuSep,	Bogart,	GA)	and	run	at	80	V	for	up	to	1	hr.	Proteins	were	then	transferred	to	a	membrane	by	Western	blotting	(see	below)	for	specific	detection	using	anti-VACV	antibodies.		
	
2.2.8	Western	blotting	Western	blotting	was	performed	to	visualize	the	proteins	present	in	all	the	VACV	membrane	protein	preparations.	Proteins	were	transferred	from	SDS-PAGE	gels	to	Hybond-C-Super	nitrocellulose	membranes	(GE	Healthcare)	by	electroblotting	in	transfer	buffer	(25	mM	Tris,	192	mM	glycine	in	10%	methanol),	at	100	V	for	1	hr.	Membranes	were	then	blocked	with	5%	BSA	in	Tris-buffered	saline	(TBS,	25	mM	Tris,	137	mM	NaCl,	2.7	mM	KCl,	pH	7.4)	at	4°C	overnight	on	a	platform	rocker.	The	following	day	blocking	buffer	was	removed	and	the	membranes	were	washed	extensively	twice	for	10	min	with	TBS/0.1%	tween-20	(Sigma-Aldrich).	Membranes	were	then	incubated	with	either	a	biotin-conjugated	polyclonal	rabbit-anti-VACV	antibody	(Mybiosurces),	or	a	mouse-anti-VACV	A56	IgG1	mAb	(Immune	
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Technology	Corp.,	New	York,	NY),	diluted	in	TBS/0.1%	Tween-20,	at	4°C	overnight	on	a	platform	rocker.		The	membranes	were	then	washed	extensively	thrice	for	20	min	with	TBS/0.1%	Tween-20.	Membranes	incubated	with	biotin-conjugated	polyclonal	primary	antibodies	were	incubated	at	4°C	for	1	hr	on	a	platform	rocker	with	streptavidin-conjugated	HRP	as	the	secondary	detection	reagent,	diluted	in	TBS/0.1%	tween-20.	Conversely,	membranes	incubated	at	4°C	for	1	hr	on	a	platform	rocker	with	the	mouse	anti-VACV	A56	IgG1	mAb	were	incubated	with	a	HRP-conjugated	rabbit	anti-mouse	Ig	antibody	(Dako,	Carpinteria,	CA),	diluted	in	TBS/0.1%	Tween-20.	The	membranes	were	then	washed	extensively	thrice	for	10	min	with	TBS/0.1%	Tween-20.	Finally	membranes	were	developed	using	ECL	Western	blotting	reagents	(GE	Healthcare)	for	2	min,	membranes	being	imaged	using	an	ImageQuant	LAS	4000	imager	with	2	min	exposure	time.		
2.2.9	1D	NanoLC	ESI	MS/MS	analysis	for	protein	identification	The	protein	bands	on	the	SDS-PAGE	gel	were	excised	and	sent	to	Australian	Proteome	Analysis	Facility	(APAF)	at	Macquarie	University,	NSW,	for	identification.	A	team	of	scientists	led	by	Dr.	Xiaomin	Song	performed	1D	nano	liquid	chromatography	electrospray	ionization	tandem	mass	spectrometry	(1D	nanoLC	ESI	MS/MS),	on	the	protein	samples.	Briefly,	the	samples	were	digested	using	trypsin-EDTA	and	loaded	onto	a	Capillary	LC	system	that	is	coupled	to	an	MS/MS	instrument.	A	reversed	phase	C18	column	was	used	to	separate	peptides,	which	were	directly	eluted	into	the	MS.	The	ions	entering	MS	were	continuously	sampled	and	upon	detection	of	a	peptide,	there	was	an	automated	switching	from	
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MS	to	MS/MS	mode	and	the	peptides	were	fragmented.	Upon	the	completion	of	the	run,	computer	software	(e.g.,	Mascot)	interrogated	proteins,	DNA	or	EST	databases	to	identify	the	protein(s).	Blast	searching	and	de-novo	sequencing	was	performed	on	the	peptides	that	could	not	be	identified	from	the	initial	database	search.			
2.3	In	vivo	techniques	
2.3.1	VACV	inoculation	Prior	to	inoculation,	all	VACV	stocks	were	sonicated	(2	x	15	sec,	100	W,	Branson	Sonifier	B12)	and	diluted	in	sterile	PBS.		For	intranasal	(i.n.)	inoculation,	mice	were	lightly	anaesthetized	using	methoxyfluorane.	Once	under	anesthesia,	10	μL	of	virus	was	delivered	to	each	nostril	(20	μL	total)	using	a	pipette.		For	intramuscular	(i.m.)	inoculation,	mice	were	fully	anaesthetized	using	methoxyfluorane	and	50	μL	of	virus	was	injected	in	each	quadriceps	(100	μL	total)	using	a	29-gauge	needle	and	syringe.		
2.4.2	In	vivo	virus	spread	To	determine	the	spread	of	VACV	at	different	time	points	post	infection,	animals	were	euthanized	ethically,	and	organs	including	ovaries,	spleen,	quadriceps	muscles	and	lungs	were	removed.	All	the	organs	were	stored	at	-20°C.	Prior	to	organ	virus	titrations,	organs	were	thawed	on	ice	in	200	μL	of	MEM	(supplemented	with	5%	FBS).	All	the	organs	were	then	homogenized	(using	a	PRO200	Micro-homogeniser,	PRO	Scientific	Inc.,	Oxford,	CT),	and	the	total	volume	was	made	to	1	
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mL	with	MEM	(supplemented	with	5%	FBS).	The	homogenate	was	then	sonicated	(2	x	30	sec)	and	serial	dilutions	(1:10)	were	made,	which	were	then	plated	on	80%	confluent	143B	cells	as	described	in	section	2.1.6.		 	
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3.1	Abstract	Vaccinia	virus	(VACV)	has	previously	been	shown	to	interact	with	the	heparan	sulfate	(HS)	component	of	heparan	sulfate	proteoglycans	(HSPGs),	using	known	receptors	on	the	MV	form	of	VACV.	In	this	Chapter,	the	specificity	of	the	MV	form	of	VACV	for	heparin,	differentially	sulfated	HS,	chondroitin	sulfates	(CS)	A-D	and	hyaluronic	acid	(HA)	was	evaluated	using	an	enzyme-linked	immunosorbent	assay	(ELISA).	Overall,	the	MV	form	of	VACV	exhibited	a	high	binding	specificity	for	heparin	and	the	highly	sulfated	version	of	HS	(HShi),	but	only	weakly	reacted	with	lowly	sulfated	HS.	The	MV	form	of	VACV	also	bound	to	CS	A-D,	however,	with	much	lower	affinity.	Unfortunately,	an	ELISA	could	not	be	used	to	investigate	the	GAG	binding	specificity	of	the	EV	form	of	VACV	due	to	a	lack	of	appropriate	EV	specific	antibodies.	Nevertheless,	plaque	forming	assays	with	the	MV	rich	WR	and	EV	rich	IHD-J	strains	of	VACV	revealed	that	heparin	had	a	strain-specific	effect	on	plaque	formation.	Upon	co-incubation	with	heparin,	the	IHD-J	strain	of	VACV	lost	the	trademark	‘comet’	plaques.	Furthermore,	heparin	co-incubation	resulted	in	an	incremental	increase	in	WR	and	IHD-J	plaque	diameters	and	a	reduction	in	plaque	counts	by	5-	and	10-folds	respectively.	Collectively,	these	data	suggest	that	HS	recognition	plays	a	significant	role	in	the	infectivity	of	the	MV	and	EV	forms	of	VACV,	with	this	recognition	process	being	more	important	for	the	EV	form.		
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3.2	Introduction	and	rationale	Up	until	the	early	1990s	the	interaction	of	viruses	with	cell	surfaces	was	thought	to	be	a	simple	single	step	process,	virus	particles	attaching	to	a	single	cell	surface	molecule	by	a	single	virus	attachment	protein	(Haywood,	1994).	With	the	development	of	sophisticated	new	biochemical	and	genetic	techniques	it	became	evident,	however,	that	virus	entry	into	cells	involves	a	multi-step	process.	In	fact,	it	is	now	well	established	that	multiple	interactions	between	virus	attachment	proteins	and	cellular	co-receptors	is	required	for	viruses	to	successfully	enter	a	cell	(Schneider-Schaulies,	2000).			HSPGs	are	ubiquitously	expressed	on	cell	surfaces,	in	the	extracellular	matrix	(ECM)	and	in	basement	membranes	(BMs),	which	is	why	it	is	not	surprising	that	many	viruses,	including	herpes	simplex	virus	(Wudunn	&	Spear,	1989),		hepatitis	B	virus	(Cooper	et	al.,	2005),	human	papillomavirus	(Giroglou	et	al.,	2001),	dengue	virus	(Chen	et	al.,	1997)	and	hepatitis	C	virus	(Barth	et	al.,	2003)	use	the	HS	component	of	HSPG	as	an	initial	docking	site	for	infection	(Zhu	et	al.,	2011).	Despite	the	knowledge	that	a	large	number	of	viruses	use	HS	as	a	receptor	or	a	co-receptor	for	infection,	the	role	of	virus-HS	interactions	in	viral	pathogenicity	remains	rather	poorly	understood.	Therefore,	a	detailed	understanding	of	how	HS	plays	a	role	in	virus	attachment	could	give	vital	cues	on	the	molecular	mechanisms	of	virus	tropism	and,	therefore,	aid	in	the	development	of	novel	therapeutics	that	target	HS.		VACV	has	at	least	three	known	glycosaminoglycan	(GAG)	binding	proteins	on	the	surface	of	its	MV	form.	VACV	proteins	A27L	and	H3L	bind	HS	on	target	cells	(Chung	
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et	al.,	1998;	Lin	et	al.,	2000),	whereas	D8L	has	been	shown	to	interact	with	cell	surface	chondroitin	sulfate	(CS)	(Hsiao	et	al.,	1999).	These	studies	have	also	shown	that	soluble	heparin	could	inhibit	VACV	binding	to	cells	and	can	reduce	VACV	plaque	formation.			In	contrast	to	the	MV	form	of	VACV,	little	is	known	about	the	role	of	cell	surface	HS	in	the	infectivity	of	the	EV	form	of	VACV.	This	is	because	the	outer	envelope	of	the	EV	form	of	VACV	is	extremely	fragile,	making	it	incredibly	difficult	to	purify	intact	EV	particles	to	study.	Most	purification	systems	result	in	damaging	the	outer	EV	envelope,	resulting	in	contamination	with	the	enclosed	MV.	However,	there	are	at	least	two	proteins	on	the	outer	envelope	of	the	EV	form	of	VACV	that	have	been	shown	to	interact	with	HS,	namely	the	24-28	kDa	A34R	and	the	42	kDa	B5R	proteins	(Law	et	al.,	2006).	Since	EV	is	the	form	of	virus	required	for	long-range	dissemination	(Blasco,	Sisler,	&	Moss,	1993b;	Roberts	&	Smith,	2008),	it	would	be	important	to	understand	the	interaction	between	the	EV	form	of	VACV	and	cell	surface	HS	during	the	course	of	an	infection.	A	protocol	is	used	in	this	Chapter	that	was	developed	to	obtain	EV	rich	preparations	from	the	IHD-J	strain	of	VACV,	a	strain	of	virus	that	produces	large	amounts	of	the	EV	form.	Hence,	the	specific	aims	of	this	Chapter	were	to	establish,	based	on	ELISAs,	the	binding	specificity	of	the	MV	form	of	VACV	for	heparin,	HS	and	CS,	and	evaluate	the	specific	effects	of	heparin	on	the	ability	of	the	MV	rich	WR	strain	and	the	EV	rich	IHD-J	strain	of	VACV	to	form	plaques.		 	
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3.3	Results	
3.3.1	Analysis	of	the	interaction	of	the	MV	form	of	VACV	with	HS	VACV	A27L	is	a	MV	membrane	protein	that	interacts	with	cell	surface	HS	and	has	been	shown	to	be	crucial	for	fusion	of	virus-infected	cells	(Chung	et	al.,	1998;	Gong,	Lai,	&	Esteban,	1990;	Hsiao	et	al.,	1998;	Rodriguez,	Rodriguez,	&	Esteban,	1993).	A27L	has	also	been	shown	to	associate	and	form	a	stable	complex	with	A17L,	which	is	crucial	for	wrapping	of	MV	in	Golgi	derived	membranes	(Rodriguez	&	Smith,	1990;	Rodriguez,	Risco,	Carrascosa,	Esteban,	&	Rodriguez,	1997).	Deletion	of	A27L	results	in	a	small	plaque	phenotype	(Dallo,	Rodriguez,	&	Esteban,	1987;	Paez,	Dallo,	&	Esteban,	1987).	The	H3L	gene	product,	p35,	is	the	other	known	HS	binding	protein	present	on	the	surface	of	MV.	Deletion	of	H3L	was	shown	to	attenuate	VACV	virulence	in	vivo	and	in	vitro	compared	to	the	wild	type	(WT)	VACV	(Lin	et	al.,	2000).	These	findings	were	observed	using	plaque	assays	as	the	primary	method	of	detection.	The	research	described	in	this	thesis	focuses	on	studying	the	early	interaction	between	cell	surface	HS	and	the	two	forms	of	VACV,	with	the	ultimate	aim	of	finding	HS	mimetics	that	could	potentially	be	used	as	inhibitors	of	VACV	infection.	Thus,	initial	studies	presented	in	this	Chapter	used	ELISAs	to	validate	the	HS	binding	specificity	of	MV	particles.	Unfortunately,	the	HS	binding	specificity	of	the	EV	form	of	VACV	could	not	be	investigated	in	this	study	as	no	EV-specific	antibodies	were	available	that	were	suitable	for	ELISAs.		
3.3.1.1	Purified	MV	preferentially	interacts	with	highly	sulfated	HS	(HShi)	and	
heparin	The	WR	strain	of	VACV	was	used	to	infect	baby	hamster	kidney-21	(BHK-21)	cell	monolayers	to	obtain	MV	particles,	which	were	then	purified	on	a	sucrose	cushion	
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as	described	in	section	2.1.4.6	of	this	thesis.	ELISA	plates	were	coated	with	10	μg/mL	of	either	bovine	serum	albumin	(BSA)	conjugated	highly	sulfated	HS	(HShi)	or	BSA	conjugated	lowly	sulfated	HS	(HSlow)	overnight.	The	purified	MV	particles	were	then	incubated	in	HShi	or	HSlow	coated	ELISA	wells	in	the	presence	or	absence	of	soluble	heparin	at	varying	concentrations.	Bound	MV	particles	were	then	detected	using	a	sandwich	ELISAs	as	described	in	section	2.2.1	of	this	thesis.	The	results	obtained	demonstrated	that	MV	particles	bound	to	immobilised	HShi	more	efficiently	than	to	immobilised	HSlow	(Figure	3.1A	&	B).	Furthermore,	as	little	as	10	μg/mL	of	soluble	heparin	was	able	to	inhibit	MV	particles	from	binding	to	immobilised	HS	in	the	assay	wells	(p	<	0.001).	In	fact,	MV	binding	to	HShi	was	reduced	to	below	background	levels	when	incubated	in	the	presence	of	soluble	heparin	(Figure	3.1A).	Since	heparin,	like	HShi,	is	a	highly	sulfated	form	of	HS,	these	results	indicate	that	MV	particles	preferentially	interact	with	highly	sulfated	versions	of	HS.		Additional	ELISAs	were	performed	using	immobilised	heparin	(BSA-heparin)	to	confirm	the	previously	obtained	results,	using	HShi	or	HSlow	as	soluble	competitive	inhibitors	of	MV	binding	to	immobilised	heparin.	In	these	assays,	ELISA	wells	were	coated	with	BSA-heparin	overnight	prior	to	adding	purified	MV	particles	in	the	presence	or	absence	of	either	HShi	or	HSlow.	As	expected,	MV	particles	bound	to	immobilised	heparin	at	similar	levels	compared	to	immobilised	HShi	(compare	Figures	3.1A	and	3.2).	However,	as	much	as	50	μg/mL	of	soluble	HShi	was	required	to	significantly	inhibit	MV	particles	from	attaching	to	immobilised	heparin	(P	<	0.001)	(Figure	3.2A).	Conversely,	soluble	HSlow	could	not	inhibit	MV	attachment	to	immobilised	heparin	even	at	a	concentration	as	high	as	100	μg/mL		(Figure	3.2B).	
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Figure	3.1:	Interaction	of	the	MV	form	of	VACV	with	immobilised	HShi	and	
HSlow	in	the	absence	or	presence	of	soluble	heparin.	HShi	and	HSlow	were	immobilised	in	assay	wells	as	BSA	conjugates	and	MV	(106	PFU)	binding	to	the	wells	determined	by	ELISA	using	polyclonal	rabbit	anti-VACV	antibodies.	The	ability	of	soluble	heparin	(10-100	μg/mL)	to	inhibit	MV	binding	to	immobilised	HShi	(A)	and	HSlow	(B)	is	presented.	Dashed	lines	indicate	background	binding	of	MV	to	BSA	coated	wells.	Control	bars	represent	MV	binding	to	immobilised	HShi	and	HSlow	in	the	absence	of	soluble	heparin.	Data	presented	as	mean	±	SEM	(n=8)	and	representative	of	three	independent	experiments.	Statistical	analysis	was	performed	using one-way ANOVA with Dunnett’s multiple comparisons. *** - p < 
0.001.			 	
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Nevertheless,	results	obtained	from	these	assays	were	consistent	with	previous	findings	presented	in	Figure	3.1	suggesting	that	purified	MV	particles	interact	with	highly	sulfated	versions	of	HS	(heparin	and	HShi)	more	efficiently	compared	to	lowly	sulfated	versions	(HSlow).			Since	it	is	HS	that	is	present	in	the	ECM	and	BMs,	and	not	heparin,	the	subsequent	assays	were	designed	to	understand	the	interaction	between	MV	particles	and	soluble	forms	of	both	HShi	and	HSlow.	Purified	MV	particles	were	added	to	ELISA	wells	pre-coated	with	BSA-HShi	at	a	concentration	of	10	μg/mL,	in	the	presence	or	absence	of	soluble	HShi	or	HSlow.	Since	MV	particles	have	a	weaker	affinity	for	HS	compared	to	heparin,	the	highest	concentration	of	the	two	soluble	HS	molecules	used	as	competitive	inhibitors	was	increased	to	800	μg/mL.	Results	obtained	from	this	assay	indicate	that	soluble	HShi	was	able	to	significantly	inhibit	virus	attachment	to	immobilised	HShi	at	concentrations	of	200	μg/mL	and	above	(p	<	0.001)	(Figure	3.3A).	HSlow,	on	the	other	hand,	was	a	much	weaker	inhibitor	of	MV	attachment	compared	to	HShi,	as	a	statistically	significant	inhibition	(p	<	0.05)	of	MV	binding	to	ELISA	wells	was	only	observed	at	a	concentration	of	800	μg/mL	(Figure	3.3B).	Results	obtained	from	these	ELISAs	were	consistent	with	the	results	observed	in	Figures	3.1	and	3.2,	collectively	suggesting	that	MV	particles	have	a	high	affinity	for	highly	sulfated	versions	of	the	HS	molecule.		
3.3.2	Interaction	of	MV	form	of	VACV	with	chondroitin	sulfates	(CS)	The	MV	form	of	VACV	has	a	protein,	D8L,	on	its	outer	membrane	that	has	previously	been	shown	to	bind	to	cell	surface	CS	(Hsiao	et	al.,	1999).	Studies	using		
		 63	
	
	
	
Figure	3.2:	Interaction	of	the	MV	form	of	VACV	with	immobilised	heparin	in	
the	absence	or	presence	of	soluble	HShi	and	HSlow.	Soluble	heparin	was	immobilised	in	assay	wells	as	a	BSA	conjugate	and	MV	binding	(106	PFU)	to	wells	determined	by	ELISA	using	polyclonal	rabbit	anti-VACV	antibodies.	The	ability	of	soluble	HShi	(A)	and	HSlow	(B)	(10	μg/mL)	to	inhibit	MV	binding	to	immobilised	heparin	is	presented.	Dashed	lines	indicate	background	binding	of	MV	to	BSA	coated	wells.	Control	bars	represent	MV	binding	to	immobilised	heparin	in	the	absence	of	soluble	HShi	or	HSlow.		Data	presented	as	mean	±	SEM	(n=8)	and	representative	of	three	independent	experiments.	Statistical	analysis	was	performed	using one-way ANOVA with Dunnett’s multiple comparisons. *** - p < 
0.001; ns – not significant – p > 0.05. 	
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Figure	3.3:	Interaction	of	the	MV	form	of	VACV	with	immobilised	HShi	in	the	
absence	or	presence	of	soluble	HShi	and	HSlow.	HShi	was	immobilised	in	assay	wells	as	a	BSA	conjugate	and	MV	binding	(106	PFU)	to	wells	determined	by	ELISA	using	polyclonal	rabbit	anti-VACV	antibodies.	The	ability	of	soluble	HShi	(A)	and	HSlow	(B)	(10	μg/mL)	to	inhibit	MV	binding	to	immobilised	HShi	is	presented.	Dashed	lines	indicate	background	binding	of	MV	to	BSA	coated	wells.	Control	bars	represent	MV	binding	to	immobilised	HShi	in	the	absence	of	soluble	HShi	or	HSlow.		Data	presented	as	mean	±	SEM	(n=8)	and	representative	of	three	independent	experiments.	Statistical	analysis	was	performed	using one-way ANOVA with 
Dunnett’s multiple comparisons. * - p < 0.05; *** - p < 0.001; ns – not significant – p > 
0.05.	 
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mutant	viruses	lacking	either	A27L	or	D8L,	or	double	mutants	lacking	both	proteins,	indicate	the	importance	of	D8L	in	VACV	infectivity	(Hsiao	et	al.,	1999;	Lai,	Gong,	&	Esteban,	1991;	Maa,	Rodriguez,	&	Esteban,	1990).	These	studies	have	also	shown	that	soluble	CS,	but	not	heparin,	could	compete	with	the	soluble	VACV	D8L	protein	for	binding	to	cells,	suggesting	that	CS	on	the	surface	of	cells	could	acts	as	a	receptor	for	VACV	D8L.	Also,	lack	of	functional	D8L	was	shown	to	results	in	low	virus	titres	and	reduced	infectivity	(Hsiao	et	al.,	1999).	However,	these	studies	also	showed	that	soluble	CS	could	not	inhibit	MV	infectivity	(Chung	et	al.,	1998).	A	more	detailed	study	showed	that	soluble	CS-A,	CS-B	and	CS-C	had	no	effect	on	MV	infectivity	(Carter,	Law,	Hollinshead,	&	Smith,	2005).	Since	most	of	the	virus	infectivity	studies	in	vitro	focus	on	viral	plaque	assays,	the	final	outcome	of	an	infection,	the	early	interaction	of	virus	proteins	with	cell	surface	receptors	is	often	overlooked.	Therefore,	it	was	important	to	determine	if	soluble	CS	could	act	as	a	competitive	inhibitor	to	virus	binding	to	immobilised	HShi.	Since	the	current	experimental	approach	involves	using	an	ELISA,	this	study	would	provide	a	highly	sensitive	indication	of	whether	CS	can	inhibit	the	binding	of	MV	to	HS	and,	therefore,	provide	an	estimate	of	MV	affinity	for	CS	compared	to	HS.		There	are	four	types	of	CS	chains,	namely,	CS-A	[chondroitin	4-sulfate],	CS-B	[also	known	as	DS	(Dermatan	sulfate)	(Trowbridge	&	Gallo,	2002)],	CS-C	[chondroitin	6-sulfate]	and	CS-D	[chondroitin	2,6-sulfate	(Silbert	&	Sugumaran,	2002)].	Along	with	all	four	CS,	fucoidan	and	hyaluronic	acid	(HA)	were	also	used	in	this	study	as	positive	and	negative	controls	respectively.	Fucoidan	is	a	highly	sulfated,	heparin	like,	polysaccharide	that	is	derived	from	brown	seaweeds	(Hsu	et	al.,	2013).	Previously,	fucoidan	has	been	shown	to	be	a	potent	inhibitor	of	VACV	infectivity	
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Figure	3.4:	Interaction	of	the	MV	form	of	VACV	with	immobilised	HShi	in	the	
absence	or	presence	of	soluble	CS,	fucoidan	and	hyaluronic	acid.	HShi	was	immobilised	in	assay	wells	as	a	BSA	conjugate	and	MV	binding	(106	PFU)	to	wells	determined	by	ELISA	using	polyclonal	rabbit	anti-VACV	antibodies.	The	ability	of	soluble	CS-A	(A),	CS-B	(B),	CS-C	(C),	CS-D	(D),	fucoidan	(E)	and	hyaluronic	acid	(F)	to	inhibit	MV	binding	to	immobilised	HShi	is	presented.	Dashed	lines	indicate	background	binding	of	MV	to	BSA	coated	wells.	MV	control	bars	represent	background	binding	of	MV	to	immobilised	HShi	in	the	absence	of	any	inhibitory	compound.	Heparin	control	(Hep	control)	bars	represent	binding	of	MV	to	immobilised	HShi	in	the	presence	of	10	μg/mL	of	soluble	heparin.	Data	presented	as	mean	±	SEM	(n=8)	and	representative	of	three	independent	experiments.	Statistical	analysis	was	performed	using	one-way	ANOVA	with	Dunnett’s	multiple	comparisons.	*	-	p	<	0.05;	**	-	p	<	0.01;	***	-	p	<	0.001;	ns	–	not	significant	–	p	>	0.05.		
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(Baba,	Snoeck,	Pauwels,	&	Declercq,	1988).	HA	is	a	non-sulfated	GAG	that	is	upregulated	during	tissue	injury	and	wound	healing,	and	regulates	several	aspects	of	tissue	repair	including	activation	of	inflammatory	cells	to	enhance	immune	responses	(Papakonstantinou,	Roth,	&	Karakiulakis,	2012).	To	determine	the	interaction	of	MV	particles	with	different	CS	molecules,	BSA-HShi	(10	μg/mL)	was	immobilised	in	ELISA	wells	overnight.	Purified	MV	particles	were	added	to	the	wells	with	or	without	a	soluble	competitive	inhibitors.	Results	obtained	suggest	that	high	concentrations	(100μg/mL)	of	all	four	CS	could	partially	inhibit	MV	from	interacting	with	immobilised	HShi,	although	at	slightly	different	levels	(Figure	3.4).	Importantly,	high	concentrations	of	CS-A	(Figure	3.4A),	CS-B	(Figure	3.4B)	and	CS-C	(Figure	3.4C)	showed	statistically	significant	(p	<	0.001)	inhibition	of	MV	attachment	to	immobilised	HShi.	Out	of	the	four	CS	molecules	examined,	CS-D	appeared	to	be	the	weakest	inhibitor	of	MV	attachment	to	immobilised	HShi	(Figure	3.4D).	Interestingly,	the	CS	inhibitory	activity,	with	the	exception	of	CS-A,	tended	to	not	increase	with	increasing	concentrations	of	the	respective	CS,	suggesting	that	only	a	subset	of	HShi	binding	molecules	could	be	blocked	by	CS.	HA	did	not	inhibit	MV	particles	from	attaching	to	immobilised	HShi	(Figure	3.4F),	whereas	fucoidan	(Figure	3.4E)	was	just	as	effective	as	heparin.	Results	obtained	from	these	assays	further	confirm	that	the	MV	form	of	VACV	tends	to	interact	with	GAGs	that	have	a	high	sulfate	content.	
	
3.3.3	Soluble	heparin	interferes	with	VACV	plaque	formation	Viruses	lacking	certain	proteins	associated	with	their	dissemination	have	a	reduced	plaque	forming	ability.	For	example,	VACV	strains	lacking	the	GAG	binding	proteins	A27L,	H3L	or	D8L	have	been	shown	to	have	a	reduced	plaque	count,	as	
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well	as	a	reduced	plaque	size	(Chung	et	al.,	1998;	Hsiao	et	al.,	1999;	Lin	et	al.,	2000;	Roberts	et	al.,	2009).	Since	it	has	been	reported	previously	that	MV	surface	proteins	A27L	and	H3L	interact	with	cell	surface	HS,	the	effect	of	soluble	heparin	on	plaque	formation	by	the	MV	form	of	VACV	was	examined	next.	In	addition,	the	effect	of	soluble	heparin	on	EV	plaque	formation	was	investigated,	particularly	as	some	studies	have	suggested	that	heparin	affects	EV	entry	but	not	MV	entry	into	cells	(Bengali,	Satheshkumar,	&	Moss,	2012).			It	is	known	that	the	WR	and	IHD-J	strains	of	VACV	produce	similar	numbers	of	cell	associated	virus	(CEV)	(Figure	1.4),	however,	a	significantly	higher	proportion	of	the	EV	form	is	shed	from	cells	infected	with	the	IHD-J	strain	of	VACV	(Blasco	&	Moss,	1992),	thus	making	the	IHD-J	strain	the	more	infectious	of	the	two	strains.	As	more	EV	particles	are	released	by	the	IHD-J	strain	of	VACV,	the	infection	of	distal	cells	is	more	efficient,	resulting	in	‘comet’	shaped	plaques.	In	contrast,	the	majority	of	WR	plaques	are	round,	with	no	or	minimal	plaques	being	comet-like	in	appearance.	Since	plaque	morphology	of	a	particular	strain	of	VACV	is	dependent	on	the	number	of	EV	particles	released	from	an	infected	cell,	it	was	of	interest	to	determine	the	effects	of	soluble	heparin	in	the	culture	medium	on	the	release	of	EV	(and	MV)	from	infected	cells	and,	therefore,	the	effects	on	the	plaque	morphology	of	the	two	VACV	strains.		As	described	in	section	2.1.4.6	of	this	thesis,	the	IHD-J	strain	of	virus	was	used	to	infect	BHK-21	cell	monolayers	in	serum	free	conditions	to	obtain	an	EV	rich	virus	preparation.	During	this	process,	the	EV	particles	were	not	subjected	to	high-speed	centrifugation	in	order	to	prevent	any	damage	to	the	integrity	of	the	outer	EV	
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envelope.	The	MV	particles	used	in	plaque	assays	were	obtained	from	the	WR	strain	of	VACV.			Confluent	monolayers	of	143B	osteosarcoma	cells	were	infected	with	either	VACV	pre-incubated	with	heparin	(virus	+	heparin)	or	without	any	pre-incubation	(virus	alone).	The	cell	monolayers	were	then	washed	to	remove	any	traces	of	free	VACV	and	covered	with	fresh	culture	medium,	with	or	without	soluble	heparin,	such	that	the	monolayers	that	were	infected	with	the	virus	+	heparin	mixture	were	overlaid	by	culture	medium	containing	heparin.			Infected	monolayers	were	incubated	for	48	hr	at	37°C	prior	to	staining.	Overall,	data	obtained	from	the	plaque	assay	analysis	indicated	that	heparin	can	induce	a	significant	change	in	the	plaque	morphology	of	the	IHD-J	strain,	but	not	the	WR	strain	(Figure	3.5A).	The	‘comet’	shaped	plaques,	which	are	a	hallmark	of	the	IHD-J	strain	(EV	rich),	disappeared	when	soluble	heparin	was	added	to	the	culture	medium.	In	fact,	in	the	presence	of	heparin	there	was	>	90%	reduction	(Figure	3.5B)	in	the	number	of	IHD-J	strain	plaques	forming	comets	(p	<	0.0001,	n	=	275	plaques/treatment).	Since	comets	result	from	the	release	of	the	EV	form	of	VACV	into	the	culture	medium,	this	finding	suggests	that	EV	particles	interact	with	heparin	more	efficiently	than	MV	particles.	Furthermore,	a	detailed	analysis	of	the	plaque	morphology	revealed	that	the	addition	of	heparin	significantly	increased	the	diameter	of	both	WR-VACV	and	IHD-J-VACV	plaques	(p	<	0.0001,	n	=	30	plaques/treatment)	(Figure	3.5C).	This	is	a	rather	interesting	finding	since	any	interference	with	virus	infectivity	usually	causes	a	reduction	in	plaque	size.	Another	important	finding	from	this	study	was	that	there	was	a	ten-fold	reduction	
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(Figure	3.5D)	in	IHD-J-VACV	plaque	formation	upon	addition	of	heparin	(p	=	0.0024),	whereas	only	a	five-fold	reduction	in	WR-VACV	plaque	formation	was	observed	in	the	presence	of	heparin	(p	=	0.0218).	Photos	of	the	two	VACV	strains	used	in	this	study	were	taken	using	an	electron	microscope	(EM).	Cell	monolayers	infected	with	the	IHD-J	strain	of	VACV	(Figure	3.5E)	produced	a	high	proportion	of	EV	particles,	whereas	cells	infected	with	the	WR	strain	(Figure	3.5F)	produced	mostly	MV	particles.			 	
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Figure	3.5:	Effects	of	heparin	on	plaque	formation	by	the	IHD-J	(EV)	and	WR	
(MV)	strains	of	VACV.	Both	EV	(obtained	from	IHD-J-VACV)	and	MV	(obtained	from	WR-VACV)	were	pre-incubated	with	heparin	prior	to	infection.	Both	strains	of	VACV	were	then	added	to	a	confluent	monolayer	of	143B	osteosarcoma	cells	in	the	presence	(virus	+	heparin)	or	absence	(virus	alone)	of	heparin	(10	μg/mL).	(A)	Representative	plaque	assay	plates	depicting	the	effects	of	heparin	(10	μg/mL)	on	plaque	formation	by	the	IHD-J	and	WR	strains.	The	trademark	‘comet’	shaped	EV	plaques	disappeared	in	the	presence	of	heparin.	(B-D)	Quantification	of	effects	of	heparin	(10	μg/mL)	on	(B)	percentage	of	IHD-J	strain	plaques	developing	comets,	(C)	IHD-J	and	WR	plaque	diameters	and	(D)	plaque	numbers.	(E-F)	EM	photos	of	the	two	strains	of	viruses	used	in	this	study	(50,000X	magnification)	with	the	IHD-J	strain	(E)	having	many	more	virus	particles	with	an	outer	envelope	(red	arrows)	than	the	WR	strain	(F).	In	(B)	data	presented	as	mean	±	SEM	(n=6)	of	percentage	of	275	plaques	forming	comets	in	heparin	treated	and	untreated	cell	monolayers	infected	with	the	IHD-J	strain	of	VACV,	the	data	presented	being	from	one	representative	assay.	Plaque	diameters	in	(C)	obtained	for	30	plaques	for	each	treatment	and	plaque	numbers	(D)	from	6	replicates.	Data	presented	as	mean	±	SEM	with	a	Mann-Whitney	t-test	being	used	for	the	statistical	analysis.	Assays	measuring	number	of	comets	formed	by	IHD-J	(B),	plaque	diameters	(C)	and	plaque	numbers	(D)	were	repeated	thrice	with	plots	shown	in	this	figure	being	of	the	data	obtained	from	one	representative	experiment.		 	
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3.4	Discussion	This	study	aimed	to	investigate	the	dependence	of	VACV	infections	on	recognition	of	cell	surface	HS	and,	ultimately,	whether	HS	recognition	could	be	targeted	to	develop	antivirals.	Since	the	interaction	of	the	MV	form	of	VACV	with	cell	surface	HS	is	one	of	the	first	events	that	takes	place	in	VACV	infection	of	cells,	it	was	important	to	develop	assays	that	enabled	one	to	study	this	early	interaction.	Therefore,	an	ELISA	was	initially	used	to	evaluate	the	interaction	of	the	MV	form	of	VACV	with	differentially	sulfated	HS,	CS	and	heparin,	the	latter	being	a	heterogeneous	polysaccharide,	which	is	distinguished	from	HS	by	its	higher	extent	of	sulfation.			Immobilizing	either	HShi	or	HSlow	in	assay	wells	as	BSA	conjugates	and	inhibiting	MV	attachment	to	the	immobilised	HS	using	heparin	showed	that	the	MV	form	of	VACV	preferentially	interacts	with	heparin	(Figure	3.1A	and	3.1B).	In	fact,	a	heparin	concentration	as	low	as	10	μg/mL	was	able	to	significantly	inhibit	MV	attachment	to	both	immobilised	HShi	and	HSlow.	The	strong	affinity	of	MV	particles	for	highly	sulfated	polysaccharides	was	also	evident	when	comparing	the	attachment	of	MV	to	immobilised	HShi	and	HSlow	in	the	absence	of	heparin	(control	bars	in	Figures	3.1A	and	3.1B),	with	the	MV	form	of	VACV	binding	much	more	strongly	to	HShi	compared	to	HSlow.	These	results	were	consistent	with	the	previous	findings	suggesting	that	the	MV	form	of	VACV	has	strong	affinity	for	highly	sulfated	HS	molecules	(Chung	et	al.,	1998).			Furthermore,	similar	results	were	obtained	when	the	assay	setup	was	reversed,	i.e.,	heparin	was	immobilised	in	the	wells	(Figure	3.2A	and	3.2B).	It	was	clear	that	
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MV	bound	to	highly	sulfated	polysaccharides	with	much	higher	affinity	than	to	lesser-sulfated	polysaccharides.	Thus,	a	very	high	concentration	of	HShi	(100	μg/mL)	was	required	to	significantly	inhibit	MV	binding	to	immobilised	heparin	(Figure	3.2A),	whereas	HSlow	was	unable	to	inhibit	MV	attachment	to	immobilised	heparin	at	the	concentration	range	tested	(Figure	3.2B).	A	similar	conclusion	was	drawn	when	HShi	and	HSlow	were	examined	for	their	ability	to	inhibit	binding	of	MV	to	immobilised	HShi	(Figure	3.3).	Unfortunately,	such	comparative	ELISAs	could	not	be	performed	with	the	EV	form	of	VACV	due	to	the	unavailability	of	appropriate	EV	specific	antibodies.		Previous	studies	have	shown	that	the	D8L	protein	from	the	MV	form	of	VACV	binds	CS,	with	mutants	MV	particles	lacking	D8L	having	a	reduced	infectivity	(Hsiao	et	al.,	1999).	Consistent	with	this	observation	it	was	found	that	at	high	concentrations,	all	four	CS	types	could	partially	inhibit	MV	attachment	to	immobilised	HShi.	However,	this	inhibition	of	HShi	binding	could	be	purely	due	to	steric	hindrance.	Thus,	soluble	CS	bound	to	VACV	D8L	on	the	surface	of	MVs	could	be	indirectly	interfering	with	other	proteins	on	the	surface	of	MV	from	interacting	with	immobilised	HShi.	Since	MV	interacts	with	HS/heparin	and	CS	via	different	surface	proteins,	a	convincing	conclusion	could	not	be	drawn	from	these	assays.	Unfortunately,	none	of	the	four	CS	types	were	available	as	BSA	conjugates,	therefore,	inhibition	assays	involving	immobilised	CS	that	would	resolve	this	issue	could	not	be	performed.			Data	presented	in	this	Chapter	shows	by	ELISAs	that	MV	particles	can	bind	with	high	avidity	to	immobilised	heparin	and	HShi,	with	soluble	heparin	having	the	
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ability	to	inhibit	this	interaction.	Consistent	with	this	observation,	subsequent	studies	revealed	that	soluble	heparin	significantly	inhibited	MV	rich	WR	plaque	numbers	with	an	incremental	increase	in	plaque	size.	However,	the	effects	observed	with	soluble	heparin	were	more	dramatic	for	the	EV	rich	IHD-J	strain	of	VACV.	The	trademark	‘comets’	formed	by	the	IHD-J	strain	plaques	disappeared	in	the	presence	of	heparin	along	with	a	10-fold	reduction	in	plaque	numbers	and	again	there	being	an	incremental	increase	in	plaque	diameters.	A	possible	explanation	for	this	phenomenon	is	that	heparin	is	able	to	inhibit	freshly	released	EV	particles	from	infected	cells	and,	therefore,	rendering	them	unable	to	infect	distant	cells.	The	more	dramatic	effect	of	heparin	on	EV	rich	IHD-J	than	MV	rich	WR	strain	plaque	formation	is	consistent	with	previous	studies	that	have	shown	that	soluble	heparin	affects	EV	cellular	entry	more	than	MV	entry,	in	vitro	(Bengali	et	al.,	2012).		The	incremental	increase	in	plaque	size	in	the	presence	of	heparin	could	be	attributed	to	the	mechanisms	VACV	particles	use	to	infect	cells.	VACV	particles	use	two	major	mechanisms	to	spread	from	cell-to-cell.	Progeny	MV	particles	from	an	infected	cell	can	directly	be	pushed	into	neighboring	cells,	thereby	minimizing	the	events	associated	with	forming	EV	particles	(Marsh	&	Helenius,	2006).	MVs	can	also	be	transported	to	the	plasma	membrane	where	they	can	be	released	from	the	cell	as	EVs,	which	then	infect	neighboring	cells	(Doceul,	Hollinshead,	van	der	Linden,	&	Smith,	2010;	Marsh	&	Helenius,	2006).	It	is	likely	that	the	inability	of	freshly	released	EV	particles	to	infect	distal	cells	in	the	presence	of	heparin	promotes	the	punching	mechanism	as	the	predominant	process	used	to	infect	neighboring	cells.	This	could	explain	why	addition	of	heparin	results	in	plaques	
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with	increased	diameters.	Furthermore,	there	is	also	evidence	that	suggests	that	the	VACV	serine	proteinase	inhibitor	(K2)	contains	the	heparin-binding	site	of	antithrombin	III	(Brum,	Turner,	Devick,	Baquero,	&	Moyer,	2003;	Turner	&	Moyer,	2006). The K2	protein	forms	a	complex	with	VACV	A56,	also	known	as	VACV	haemagglutinin	(HA),	with	the	complex	being	expressed	on	the	surface	of	infected	cells	(DeHaven,	Gupta,	&	Isaacs,	2011;	Moss,	2006).	The	A56/K2	complex	has	been	shown	to	inhibit	syncytia	formation	(Moss,	2006).	Furthermore,	studies	have	also	shown	that	antibodies	blocking	K2	or	A56	promote	syncytia	formation	(DeHaven	et	al.,	2011).	Therefore,	it	is	also	likely	that	heparin,	like	antibodies	against	K2,	may	have	similar	effect	on	K2	function	and,	therefore,	promote	syncytia	formation.	This	possibility	would	again	explain	why	an	incremental	increase	in	plaque	size	was	observed	when	cells	were	infected	with	WR	or	IHD-J	strains	of	VACV	in	the	presence	of	heparin.		In	conclusion,	it	is	likely	that	at	an	individual	plaque	level,	heparin	may	assist	the	rate	at	which	a	primary	plaque	grows	in	size.	However,	an	overall	reduction	in	plaque	numbers	was	also	observed	for	both	strains	of	VACV	when	used	to	infect	cells	in	the	presence	of	heparin,	suggesting	that	heparin	interferes	with	both	EV	and	MV	uptake	by	cells.	It	is	likely	that	heparin	blocks	HS-binding	receptors	on	the	surface	of	the	MV	particles.	Since	the	addition	of	heparin	does	not	completely	inhibit	the	infectivity	of	MV	particles,	this	would	indicate	the	presence	of	alternative	mechanisms	of	MV	entry	into	cells.	In	contrast,	comet	formation	resulting	from	the	release	of	the	EV	form	of	VACV	appears	to	be	completely	dependent	on	HS	recognition.	Collectively,	these	data	suggest	that	both	EV	and	MV	
		 78	
forms	of	VACV	recognise	and	interact	with	HS/heparin,	with	this	recognition	process	being	more	important	for	the	EV	form.			 	
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															 		Use	of	GFP	expressing	VACV	to	probe	role	of	heparin/HS	recognition	in	VACV	infections	
Chapter	4:	
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4.1	Abstract		There	are	two	infectious	forms	of	VACV,	namely	the	MV	and	the	EV	form,	both	being	structurally,	chemically	and	antigenically	different.	To	better	understand	the	role	of	heparin	and	cell	surface	HS	in	both	forms	VACV	infection,	GFP	expressing	strains	of	VACV	were	constructed	by	inserting	a	GFP-Bsd	gene	sequence	in	the	genomes	of	both	WR	(MV	rich)	and	IHD-J	(EV	rich)	strains	of	VACV,	the	GFP	component	of	the	bi-functional	sequence	functioning	as	a	fluorescent	marker	for	infectivity.	Overall,	the	results	from	VACV	inhibition	assays	with	the	MV-GFP	and	EV-GFP	forms	indicate	that	heparin	and	HShi	inhibit	the	infectivity	of	both	the	MV	and	EV	forms	of	VACV,	with	the	EV	form	being	much	more	easily	inhibited.	Infection	assays	in	which	cells	were	pre-treated	with	enzymes	to	degrade	cell	surface	HS	and	in	cells	genetically	deficient	in	HS	production,	suggested	a	role	for	cell	surface	HS	as	a	co-receptor	for	infection,	especially	for	the	EV	form	of	VACV.	Therefore,	based	on	these	studies,	soluble	GAGs	have	potential	to	act	as	inhibitors	of	EV	infections.	 	
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4.2	Introduction	and	rationale		VACV,	like	many	other	viruses,	has	been	shown	to	interact	with	cell	surface	GAGs.	In	fact,	several	studies	have	established	that	sulfated	GAGs	play	an	important	role	in	VACV	infections	(Carter	et	al.,	2005).	The	MV	form	of	VACV	has	two	known	HS	binding	proteins	on	its	outer	membrane	(Chung	et	al.,	1998;	Lin	et	al.,	2000),	whereas	the	EV	form	of	VACV	has	two	proteins	on	its	outer	envelope,	which	upon	contact	with	cell	surface	HS,	initiate	dissolution	of	the	outer	EV	envelope	(Law	et	al.,	2006).	Indeed,	ELISA	assays	reported	in	Chapter	3	showed	that	purified	MV	particles	bind	to	highly	sulfated	immobilised	heparin	and	HS.	Also,	these	strong	interactions	translated	into	soluble	heparin	inhibiting	MV	infections	in	vitro,	WR	(MV	rich)	plaque	numbers	being	reduced	5-fold	and	the	diameter	of	plaques	being	increased	in	the	presence	of	heparin.	However,	heparin	had	an	even	greater	effect	on	IHD-J	(EV	rich)	plaques	reducing	their	number	10-fold,	increasing	their	diameters	and	totally	preventing	formation	of	the	characteristic	‘comet’	shaped	plaques.	ELISA	based	assays	on	the	EV	form	of	VACV,	however,	could	not	be	performed	due	to	the	unavailability	of	EV	specific	antibodies.			The	difference	in	the	effects	of	soluble	heparin	on	plaque	formation	by	the	two	strains	of	VACV	could	result	from	the	fact	that	the	EV	form	of	VACV	differs	from	the	MV	form	by	the	presence	of	at	least	one	extra	outer	membrane	(Ichihashi,	1996).	Due	to	the	extra	membrane(s),	EV	and	MV	particles,	however,	not	only	differ	structurally,	but	also	chemically	and	antigenically	(Condit	et	al.,	2006).	Therefore,	a	fundamental	understanding	of	the	mechanisms	by	which	MV	and	EV	forms	of	VACV	infect	cells	was	required	to	explain	the	plaque	assay	discrepancies.	A	deeper	
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understanding	of	VACV-heparin/HS	interactions	would	also	help	determine	whether	such	interactions	can	be	exploited	to	develop	novel	GAG-based	antivirals.		The	EV	form	of	VACV	has	to	interact	with	cellular	receptors	on	uninfected	cells	in	order	to	enter	and	cause	an	infection.	The	MV	form	of	VACV,	however,	can	enter	in	neighboring	cells	by	directly	‘punching’	through	the	plasma	membranes	(Mercer	et	al.,	2010;	Schmidt	et	al.,	2012).	Such	‘punching’	into	neighboring	cells	bypasses	the	need	for	the	infectious	VACV	particle	to	be	released	from	the	infected	cell	into	the	culture	medium	and	re-enter	an	uninfected	cell.	Therefore,	to	study	the	effects	of	heparin/HS	on	VACV	infections,	it	was	essential	to	target	the	early	stages	of	an	infection.	Hence	the	major	aim	of	this	Chapter	was	to	construct	green	fluorescent	protein	(GFP)	expressing	WR	and	IHD-J	strains	of	VACV	to	be	used	in	a	highly	sensitive	novel	assay	that	would	allow	virus	infections	to	be	monitored	by	flow	cytometry.	The	second	aim	of	this	chapter	was	to	establish	the	role	of	cell	surface	HS	in	VACV	infections	using	GFP	expressing	MV	and	EV	forms	of	VACV	to	quantify	infectivity.				 	
		 83	
4.3	Results	
4.3.1	Construction	of	recombinant	VACV	WR	and	VACV	IHD-	strains	
expressing	GFP.	ELISA	studies	described	in	Chapter	3	showed	that	the	MV	form	of	VACV	binds	to	immobilized	heparin	and	HShi.	Plaque	assays	on	the	other	hand,	have	shown	that	soluble	heparin	more	efficiently	interferes	with	the	plaquing,	in	vitro,	of	the	EV	rich	IHD-J,	than	the	MV	rich	WR	strain	of	VACV.	In	light	of	these	observations	and	along	with	prior	knowledge	that	many	viruses	have	heparin/HS	binding	proteins	on	their	surface,	studies	were	undertaken	to	understand	the	interaction	between	MV	and	EV	forms	of	VACV	with	heparin	and	other	HS	mimetics	and,	therefore,	establish	the	importance	of	cell	surface	HS	in	VACV	infections	and,	whether	heparin	(or	other	sulfated	HS	mimetics)	can	act	as	possible	antivirals.	Prior	to	understanding	the	effects	of	heparin/HS	mimetics	on	the	infectivity	of	the	two	forms	of	VACV,	it	was	important	to	develop	assays	that	could	be	used	to	study	early	stages	of	VACV	infection.	Kinetics	studies	of	VACV	infections	indicate	that	new	VACV	virions	start	forming	5	to	6	hr	after	initiation	of	an	infection	(Payne	&	Kristenson,	1979).	Therefore,	to	evaluate	the	role	of	highly	sulfated	HS/heparin	in	VACV	infectivity,	assays	were	needed	to	be	designed	that	would	enable	quantification	of	the	first	replication	cycle.	A	flow	cytometry	based	assay	was,	therefore,	developed	with	GFP,	under	the	control	of	an	early-late	VACV	promoter,	being	used	as	a	fluorescent	marker	to	evaluate	the	infectivity	of	VACV	in	vitro	in	the	presence	of	heparin/HS	mimetics.	In	order	to	perform	these	assays,	recombinant	VACV	WR	and	VACV	IHD-J	strains	expressing	GFP	were	first	engineered	as	described	in	section	2.1.4.	Briefly,	for	the	construction	of	recombinant	VACV,	the	GFP-Bsd	gene	was	initially	cloned	from	the	pUC57	vector	
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and	inserted	in	the	MVAF	vector	to	create	the	pUC57-MVAF	vector.	Dr.	Ron	Jackson	designed	the	GFP-Bsd	gene	used	in	this	thesis.	This	particular	GFP	molecule	fluoresces	brighter	at	470nm,	is	more	stable	at	37°C,	and	has	its	own	strong	promoter,	all	of	which	enhance	GFP	expression.	BHK-21	cells	were	infected	with	the	parental	strain	VACV	WR	and,	subsequently,	transfected	with	the	GFP-Bsd	containing	pUC57-MVAF	vector.	Recombinant	virus	particles	generated	were	selected	using	4	rounds	of	blasticidin	selection.	To	confirm	that	there	was	no	contamination	of	parental	VACV	particles	in	the	recombinant	VACV	preparations,	DNA	was	extracted	from	infected	cells	and	a	PCR	was	performed	using	MVAF	primers.	GFP	expressing	recombinant	VACV	IHD-J	was	also	constructed	using	the	same	protocol	as	for	recombinant	VACV	WR.		
4.3.2	Kinetics	of	VACV	replication	as	measured	by	GFP	expression	Previous	studies	on	the	kinetics	of	VACV	replication	have	reported	that	new	virions	form	5	to	6	hr	post	infection	(Payne	&	Kristenson,	1979).	In	order	to	develop	inhibition	assays	using	GFP	expressing	VACV	and	heparin/HS	mimetics,	optimal	infection	conditions	were	required	to	be	established.	A	time-course	assay	was	first	undertaken	to	establish	the	time	taken	by	the	GFP	expressing	VACV	strains	to	infect	cells	in	vitro	and	produce	new	progeny	virions,	as	measured	by	flow	cytometry	of	GFP	fluorescence.			Confluent	monolayers	of	143B	human	osteosarcoma	cells	were	infected	with	purified	MV-GFP	(obtained	from	the	WR-GFP	strain)	and	EV-GFP	(obtained	from	the	IHD-J-GFP	strain)	for	1	hr.	Cells	were	then	washed	to	remove	unbound	VACV,	covered	with	fresh	culture	medium	and	incubated	further.	The	infection	was	
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stopped	and	the	adherent	cells	released	by	trypsin	treatment	at	different	time	points	(2,	4,	6,	8	and	12	hr)	post	infection,	the	cells	fixed	using	0.5%	paraformaldehyde	and	GFP	expression	measured	by	flow	cytometry,	with	data	being	expressed	as	fluorescence	intensity	units	(FIU)	(Figure	4.1	and	4.2).	Since	an	early-late	promoter	drives	GFP	expression	in	VACV	infected	cells,	a	shift	in	the	population	of	cells	expressing	GFP	can	be	seen	as	early	as	2	hr	post	infection,	with	20%	of	the	cells	being	GFP	positive	in	MV-GFP	infected	wells	(Figure	4.1),	and	approximately	7%	being	GFP	positive	in	EV-GFP	infected	wells	(Figure	4.2).	The	proportion	of	GFP	positive	cells	at	6	hr	post	MV-GFP	infection	was	approximately	60%	and	40%	post	EV-GFP	infection,	6	hr	being	how	long	it	takes	for	the	first	progeny	virions	to	be	generated.	Over	90%	of	the	cells	were	infected	with	the	virus	by	12	hr	post	infection	regardless	of	the	form	of	VACV	used.	Since	a	substantial	proportion	of	cells	became	GFP	positive	within	6	hr	post	infection,	it	was	then	important	to	assess	the	effects	of	heparin	on	MV-GFP	and	EV-GFP	infections,	as	detected	by	GFP	expression,	at	this	early	time	point.		To	evaluate	the	effects	of	heparin	on	the	kinetics	of	virus	infectivity,	a	more	detailed	kinetic	assay	was	performed.	143B	cell	monolayers	were	infected	with	purified	forms	of	both	MV-GFP	(obtained	from	the	WR-GFP	strain)	and	EV-GFP	(obtained	from	the	IHD-J-GFP	strain)	in	the	absence	(virus	alone)	or	in	the	presence	of	heparin	(1,	10	and	100	μg/mL).	As	before,	the	infection	was	stopped	at	different	time	points	(2,	4,	6,	8,	12	and	24	hr)	post	infection,	and	the	adherent	cells	released	by	trypsin	treatment,	fixed	and	analyzed	for	GFP	expression	by	flow	cytometry	(Figure	4.3).			
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Figure	4.1:	GFP	expression	in	143B	cells	infected	with	MV-GFP.	143B	cells	were	infected	with	purified	MV-GFP	virus	at	MOI	of	1.	Adherent	cells	were	then	released	by	treatment	with	trypsin	at	different	time	points	post	infection	(0,	2,	4,	6	and	12	hr),	fixed	and	analyzed	using	flow	cytometry	for	GFP	expression	in	fluorescent	intensity	units	(FIU).	Representative	contour	plots	show	GFP	expression	within	cells	at	different	time	points.	Values	associated	with	the	GFP	gate	of	each	plot	represent	the	%	of	GFP	positive	cells.	 	
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Figure	4.2:	GFP	expression	in	143B	cells	infected	with	EV-GFP.	143B	cells	were	infected	with	purified	EV-GFP	virus	at	MOI	of	1.	Adherent	cells	were	then	released	by	treatment	with	trypsin	at	different	time	points	post	infection	(0,	2,	4,	6	and	12	hr),	fixed	and	analyzed	using	flow	cytometry	for	GFP	expression	in	fluorescent	intensity	units	(FIU).	Representative	contour	plots	show	GFP	expression	within	cells	at	different	time	points.	Values	associated	with	the	GFP	gate	of	each	plot	represent	the	%	of	GFP	positive	cells.	 	
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Overall	heparin	caused	a	significant	inhibition	of	both	EV-GFP	and	MV-GFP	virus	infections	of	adherent	143B	cell	monolayers.	In	fact,	all	the	three	concentrations	of	heparin	tested	(1,	10	and	100	μg/mL)	had	an	apparent	impact	on	VACV	infectivity.	A	direct	comparison	between	EV-GFP	and	MV-GFP	infectivity	of	143B	cell	monolayers	in	the	presence	of	heparin,	however,	indicated	that	heparin	is	more	effective	at	inhibiting	EV-GFP	infections	than	MV-GFP	infections.	This	is	clearly	evident	from	the	results	obtained	from	the	time-course	inhibition	assay	where	at	the	24	hr	time	point	as	little	as	1	μg/mL	of	heparin	could	significantly	inhibit	EV-GFP	infections,	whereas	the	highest	concentration	of	heparin	(100	μg/mL)	failed	to	significantly	inhibit	MV-GFP	infectivity.			At	6	hr	post	infection,	the	time	point	of	most	interest,	over	60%	of	cells	infected	with	MV-GFP	and	just	under	50%	of	cells	infected	with	EV-GFP,	became	positive	for	GFP	expression.	Heparin	caused	a	statistically	significant	inhibition	of	both	MV	and	EV	infections,	compared	to	the	respective	virus	alone	controls,	even	at	its	lowest	concentration	(1	μg/mL)	at	the	6	hr	time	point.	Therefore,	the	6	hr	time	point	was	used	for	all	inhibition	assays	performed	henceforth.	A	direct	comparison	between	the	MV-heparin	and	EV-heparin	interactions	indicate	that	on	average,	heparin	more	efficiently	inhibits	infection	by	the	EV	form	of	VACV,	suggesting	that	EV	has	a	higher	avidity	for	heparin	and/or	cell	surface	HS	plays	a	much	greater	role	in	EV	infections	than	MV	infections.	These	observations	are	consistent	with	the	plaque	assay	findings	(Figure	3.5A).			
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4.3.3	Enzymatic	treatment	of	cells	in	vitro	to	remove	cell	surface	HS	and	the	
effects	of	this	treatment	on	virus	infectivity	The	data	presented	in	earlier	section	4.3.2	of	this	Chapter	indicates	that	heparin	can	inhibit	the	infectivity	of	both	the	EV	and	MV	forms	of	VACV.	The	simplest	interpretation	of	these	findings	is	that	cell	surface	HS	represents	a	co-receptor	for	both	EV	and	MV.	To	directly	test	this	conclusions,	HS	degrading	enzymes	were	used	to	deplete	cell	surface	HS	from	target	cells.	There	are	two	types	of	HS	degrading	enzymes	available,	being	mammalian	and	bacterial	in	origin.	Since	it	has	been	established	that	EV	particles	interact	more	avidly	with	cell	surface	HS	than	MV	particles,	and	that	this	interaction	is	crucial	for	EV	infectivity,	we	hypothesized	that	the	treatment	of	cell	monolayers	with	HS	degrading	enzymes	in	vitro	to	remove	cell	surface	HS,	would	impact	on	the	infectivity	of	purified	EV-GFP,	and	possibly	of	MV-GFP.	Three	different	Flavobacterium	heparinases	(HPNSE	-	Sigma-Aldrich)	are	commercially	available,	all	capable	of	degrading	heparin	and	HS,	but	with	different	substrate	specificities.	All	three	HPNSEs	were	used	to	treat	cell	monolayers,	either	individually	(HPNSE	1,	HPNSE	2	or	HPNSE	3),	or	as	a	cocktail	of	all	three	enzymes	(HPNSE	1+2+3).	Human	platelet	heparanase	(HPSE	-	gift	from	Dr.	Craig	Freeman,	John	Curtin	School	of	Medical	Research,	Canberra,	Australia)	was	also	used	to	remove	cell	surface	HS	from	target	cells	in	vitro.	Adherent	143B	monolayers	were	treated	with	the	different	HPNSEs	and	HPSE	for	1	hr	and	the	presence	of	cell	surface	HS	determined	by	flow	cytometry	using	a	HS-specific	mAb	(10E4)	(Figure	4.4).	HPNSE	1	was	the	least	effective	of	the	three	commercially	available	HPNSE	enzymes,	resulting	in	only	a	small	(~30%	depletion)	but	significant	reduction	in	HS	expression	following	HPNSE	1	treatment.	The	other		
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Figure	4.3:	Effects	of	heparin	on	infectivity	of	MV-GFP	and	EV-GFP	in	vitro.	143B	cells	were	infected	with	either	purified	MV-GFP	or	purified	EV-GFP,	both	in	the	absence	(virus	alone)	or	presence	of	heparin	(1,	10	and	100	μg/mL)	at	MOI	of	1.	Adherent	cells	were	then	released	by	treatment	with	trypsin	at	different	time	points	post	infection,	fixed	and	analyzed	using	flow	cytometry	for	GFP	expression.	Data	presented	as	histograms	shows	mean	percentage	of	GFP	positive	cells	±	SEM	(n=3)	in	the	absence	or	presence	of	heparin	(1,	10	and	100	μg/mL).	For	both	viruses,	statistically	significant	differences	between	GFP	expression	at	different	time	points	in	cells	infected	with	virus	alone,	and	in	cells	infected	in	the	presence	of	heparin,	was	determined	using	two-way	ANOVA	with	Bonferroni	multiple	comparisons.	The	data	presented	are	representative	of	at	least	two	independent	experiments.	*	-	p	<	0.05;	**	-	p	<	0.01;	****	-	p	<	0.0001;	ns	–	not	significant	–	p	>	0.05.	 	
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two	HPNSEs	were	more	effective	at	removing	HS	(~60%	depletion),	although	combining	all	three	enzymes	resulted	in	no	improvement	in	HS	removal	(Figure	4.4	A	and	B).	However,	the	most	effective	removal	of	HS	was	observed	following	HPSE	treatment	(~80%	depletion).	One-way	ANOVA	analysis	of	the	results	confirmed	that	all	the	HPNSE	and	HPSE	tested	in	these	experiments	significantly	reduced	cell	surface	HS	expression.	HPSE,	however,	was	the	most	effective	at	cell	surface	HS	removal,	of	all	the	enzymes	studied.	It	is	worth	noting,	however,	that	the	10E4	HS-binding	mAb	interacts	with	a	HS	epitope	not	easily	removed	by	HPSE	or	HPNSE	treatments,	and	probably	binds	to	HS	stubs	remaining	after	enzymatic	digestions	(Prof.	C.	Parish,	personal	communication),	thus,	complete	removal	of	cell	surface	HS	was	not	seen	using	any	of	the	four	HS	degrading	enzymes.		Enzymatic	treatment	of	cells	in	vitro	using	HPNSE	and	HPSE	removes	cell	surface	HS.	Since	many	viruses,	including	both	MV	and	EV	forms	of	VACV,	probably	use	cell	surface	HS	as	an	initial	docking	ligand	to	infect	cells,	it	is	important	to	understand	the	role	of	HS	in	VACV	infections.	Cell	monolayers	treated	with	all	the	three	HPNSE	individually	or	as	a	cocktail	of	all	three,	along	with	the	monolayers	treated	with	HPSE,	were	infected	with	MV-GFP	and	EV-GFP	and	incubated	for	6	hr	as	previously.	Untreated	cell	monolayers	infected	with	the	respective	viruses	were	used	as	100%	positive	controls.	Treatment	of	the	cell	monolayers	with	all	four	enzymes	significantly	reduced	both	MV-GFP	and	EV-GFP	infectivity,	although	the	effects	were	generally	modest,	being	only	15-20%	for	MV-GFP	and	15-50%	for	EV-GFP.			
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As	expected,	among	the	enzymes	tested,	HPSE	treatment	of	cell	monolayers	had	the	greatest	effect	on	the	infectivity	of	both	MV-GFP	and	EV-GFP,	with	HPSE	treatment	of	cells	reducing	MV-GFP	infectivity	by	about	20%,	whereas	the	same	treatment	reducing	EV-GFP	infectivity	by	50%	(Figure	4.5).		These	results	are	consistent	with	the	previous	findings	and	build	on	the	knowledge	that	both	MV	and	EV	forms	of	VACV	interact	with	cell	surface	HS	which	contributes	to	their	infectivity,	with	the	EV	form	of	VACV	being	more	dependent	on	this	interaction	compared	to	the	MV	form	of	VACV.	Nevertheless,	these	studies	may	be	underestimating	the	role	of	HS	in	MV	and	EV	infectivity	as	the	different	enzymatic	treatments	may	have	only	partially	removed	HS	from	the	target	cells.	Therefore,	to	evaluate	the	role	of	HS	in	MV	and	EV	infections,	a	cell	line	deficient	in	cell	surface	HS	was	used	in	the	following	study.		
4.3.4	VACV	infection	of	CHO-K1	and	HS	deficient	mutant	CHO-K1	(pgsA-745)	
cell	lines	VACV	is	known	to	have	a	very	broad	host	range,	with	it	being	able	to	replicate	in	cell	lines	from	mammalian	to	avian	in	origin.	Chinese	hamster	ovary	(CHO)	cells,	however,	are	known	to	be	non-permissive	for	VACV	replication	(Drillien,	Spehner,	&	Kirn,	1978;	Franke,	Roseman,	&	Hruby,	1985).	Nonetheless,	a	cowpox	virus	(CPV)	gene	(CHO-hr)	encoding	a	77	kDa	proteins	(CP77),	when	engineered	into	the	VACV	genome	at	the	thymidine	kinase	(tk)	locus,	allows	VACV	replication	in	CHO	cells	(Ramseyewing	&	Moss,	1995;	Sphener,	Gillard,	Drillien,	&	Kirn,	1988).	Previous	studies	have	shown	CHO	hr	is	in	fact	disrupted	in	VACV	WR	(Kotwal	&	Moss,	1988).			
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Figure	4.4:	Removal	of	cell	surface	HS	by	enzymatic	treatment	of	target	cells.	Confluent	monolayers	of	143B	cells	were	treated	with	HPNSE	1,	HPNSE	2,	HPNSE	3,	a	mixture	of	HPNSE	1,	2	and	3,	or	HPSE,	at	pH	5.5	for	1	hr,	and	then	examined	for	cell	surface	expression	of	HS	by	immunofluorescent	flow	cytometry	using	a	HS-specific	mAb	(clone	10E4).	(A)	Representative	histograms	(n	=	6)	showing	cell	surface	HS	remaining	following	different	HPNSE	or	HPSE	treatments.	(B)	Histogram	(n	=	6)	summarizing	cell	surface	HS	removal	(staining	for	HS	expression)	following	different	HPNSE	or	HPSE	treatments,	data	being	presented	as	mean	fluorescence	intensity	(MFI).	One-way	ANOVA	(Dunnett’s	Multiple	Comparison)	was	used	to	determine	the	statistical	significance	(*	-	p	<	0.05;	***	-	p	<	0.001)	of	cell	surface	HS	remaining	following	enzymatic	treatment,	relative	to	HS	on	untreated	cells.	Data	presented	are	representative	of	3	independent	experiments.		
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Figure	4.5:	Effects	of	enzymatic	treatment	of	target	cells	on	MV-GFP	and	EV-
GFP	infections	in	vitro.	Confluent	monolayers	of	143B	cells	were	treated	with	HPNSE	1,	HPNSE	2,	HPNSE	3,	HPNSE	1+2+3	and	HPSE,	at	pH	5.5	for	1	hr.	Cells	were	then	infected	with	either	purified	MV-GFP	or	EV-GFP	at	a	MOI	of	1.	Adherent	cells	were	released	by	treatment	with	trypsin	at	6	hr	post	infection,	fixed	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	histograms	show	mean	percentage	of	GFP	positive	cells	±	SEM	(n=6)	relative	to	control	143B	cells	infected	with	the	respective	viruses	but	not	put	through	any	enzymatic	treated	(100%	positive	control).	One-way	ANOVA	(Dunnett’s	Multiple	Comparison)	was	used	to	determine	statistical	significance	(*	-	p	<	0.05;	**	-	p	<	0.01;	***	-	p	<	0.001)	of	the	effects	of	enzymatic	treatment	on	EV	and	MV	infections	relative	to	the	respective	‘untreated’	controls.	Data	presented	are	representative	of	3	independent	assays.		 	
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Nevertheless,	VACV	is	able	to	infect	CHO	cells	and	initiate	the	virus	replication	cycle,	but	the	cycle	is	aborted	at	the	intermediate	gene	expression	stage.	Expression	of	early	VACV	genes,	however,	remains	unperturbed	(Ramseyewing	&	Moss,	1995).	The	parent	CHO	cell	line	produces	high	levels	of	cell	surface	HS	and	chondroitin	sulfate	(CS).	However,	pgsA-745,	a	mutant	CHO	cell	line,	has	a	defect	in	its	xylosyltransferease,	the	first	sugar	transfer	reaction	in	GAG	formation	(Esko,	Stewart,	&	Taylor,	1985),	with	this	mutation	leading	to	the	disruption	of	the	synthesis	of	cell	surface	HS	and	CS	in	pgsA-745	cells.			Although	replication	of	VACV	is	abortive	in	CHO	cell	lines,	early	VACV	genes	are	still	translated.	Since	an	early-late	promoter	drives	transcription	of	the	GFP-bsd	cassette	in	both	recombinant	VACV	WR	and	VACV	IHD-J	constructs,	VACV	cell	entry	assays	can	potentially	be	performed	in	these	cell	lines.	Furthermore,	the	property	of	the	parent	cell	line	to	produce	high	levels	of	cell	surface	HS	and	CS,	and	a	mutation	in	the	same	cell	line	inhibiting	the	synthesis	of	cell	surface	GAGs,	provides	an	ideal	opportunity	to	test	the	dependence	of	the	MV	and	EV	forms	of	VACV	on	cell	surface	GAGs	to	infect	the	cells	in	vitro.			CHO	and	pgsA-745	cell	monolayers	were	infected	with	a	low	(1)	and	a	high	(10)	MOI	of	both	MV-GFP	(obtained	from	the	WR-GFP	strain)	and	EV-GFP	(obtained	from	the	IHD-J-GFP	strain).	As	before,	the	infection	was	stopped	and	the	adherent	cells	released	by	trypsin	treatment	at	6	hr	post	infection.	A	relatively	low	percentage	of	both	cell	types	were	infected	by	MV-GFP	(18%)	and	EV-GFP	(12%).	However,	the	GFP	expression	in	the	MV-GFP	infected	CHO	and	pgsA-745	cell	monolayers,	measured	as	the	mean	fluorescent	intensity,	is	almost	identical	at		
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Figure	4.6:	GFP	expression	in	wild	type	CHO-K1	and	HS	deficient	CHO-K1	
(pgsA-745)	cells	infected	with	MV-GFP	and	EV-GFP.	CHO-K1	and	pgsA-745	cell	lines	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	two	different	MOIs	(1	and	10).	Adherent	cells	were	then	released	by	treatment	with	trypsin	6	hr	post	infection,	fixed	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	histograms	of	GFP	expression	by	both	CHO-K1	and	pgsA-745	cells	based	on	the	mean	fluorescence	intensity	(MFI)	±	SEM	(n=3).	The	data	presented	are	representative	of	at	least	four	independent	experiments,	with	statistical	analysis	performed	using	an	unpaired	Student’s	t-test.		 	
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both	concentrations	of	VACV	used	(Figure	4.6).	This	indicates	that	MV	entry	into	cells	is	not	heavily	dependent	on	the	presence	of	cell	surface	GAGs.	However,	GFP	expression	in	EV-GFP	infected	pgsA-745	cell	monolayers,	compared	to	the	expression	in	CHO	cell	monolayers,	is	significantly	reduced.	These	results	highlight	the	importance	of	cell	surface	GAGs	for	EV	infection	of	cells.	The	MV	form	of	VACV,	however,	is	not	heavily	dependent	on	GAGs	to	infect	cells	and,	consequently,	must	have	alternative	mechanisms	of	cell	entry.			
4.3.5	Differences	in	the	infectivity	of	the	MV	and	EV	forms	of	VACV	in	the	
presence	of	heparin	are	not	due	to	VACV	strain	differences		Infectious	VACV	particles	exist	in	two	different	forms,	namely	the	EV	and	the	MV	forms.	The	EV	form	is	essentially	the	MV	form	wrapped	in	at	least	one	additional	membrane	(Figure	1.4).	The	presence	of	one	or	more	membranes	around	the	EV	makes	this	form	of	VACV	structurally,	chemically	and	antigenically	different	from	the	MV	form	of	VACV	(Condit	et	al.,	2006).	It	has	been	reported	that	the	VACV	IHD-J	strain	releases	40	times	more	EV	compare	to	the	VACV	WR	strain,	although	the	size	of	the	primary	plaques	are	similar	in	the	two	strains	(Law	et	al.,	2006;	Law,	Hollinshead,	&	Smith,	2002;	Smith,	Vanderplasschen,	&	Law,	2002).	Both	the	WR	and	IHD-J	strains	of	VACV	produce	equal	amounts	of	intracellular	enveloped	virus	(IEV)	and	cell-associated	enveloped	virus	(CEV)	particles.	A	single	codon	mutation	(Lys-151àGlu),	located	in	the	putative	carbohydrate	recognition	domain	of	the	A34R	protein,	has	been	identified	to	be	the	cause	of	more	EV	release	from	the	IHD-J	strain	compared	to	the	WR	strain.	At	the	nucleotide	level,	the	VACV	A34R	gene	sequence	of	the	VACV	WR	strain	differs	from	that	of	the	VACV	IHD-J	strain	at	six	different	positions,	four	of	which	are	silent	(Blasco,	Sisler,	&	Moss,	1993a).	There	
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Figure	4.7:	Effects	of	heparin	on	infectivity	of	MV-GFP	and	EV-GFP	obtained	
from	different	strains	of	VACV.	143B	cell	monolayers	were	infected,	at	MOI	of	1	and	in	the	presence	of	doubling	dilutions	of	heparin,	with	MV-GFP	or	EV-GFP	isolated	from	either	VACV	WR	or	VACV	IHD-J	strains.	Adherent	cells	were	released	by	treatment	with	trypsin	at	6	hr	post	infection,	fixed	and	analyzed	using	flow	cytometry	for	%	GFP	positive	cells	relative	to	control	cells	infected	with	respective	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	Representative	plots	showing	mean	percentage	of	GFP	positive	cells	relative	to	control	cells	±	SEM	(n=3).	The	data	presented	are	representative	of	at	least	three	independent	experiments.	 	
		 101	
have	been	no	other	reports	of	the	two	strains	of	VACV	behaving	differently	in	other	ways.		Since	the	VACV	WR	strain	produces	much	less	of	the	EV	form	of	the	virus	than	the	VACV	IHD-J	strain,	the	VACV	IHD-J	was	used	as	a	source	of	the	EV	form	of	VACV	for	all	the	studies	reported	in	this	thesis.	Initial	studies	already	described	in	this	thesis	suggest	that	the	EV	form	of	VACV	interacts	with	heparin	much	more	strongly	than	does	the	MV	form.	However,	since	the	MV	and	EV	forms	of	VACV	were	isolated	from	different	VACV	strains,	namely	the	VACV	WR	and	VACV	IHD-J	strains	respectively,	it	was	essential	to	rule	out	the	possibility	that	the	differences	seen	in	the	interactions	of	the	EV	and	MV	forms	of	VACV	with	heparin	is	due	to	strain	differences	rather	than	being	an	intrinsic	property	of	the	two	virus	forms.	Thus,	the	MV	and	EV	forms	of	VACV	were	isolated	from	cultures	of	GFP	expressing	recombinant	VACV	WR	and	VACV	IHD-J	strains.	Both	MV-GFP	and	EV-GFP	were	purified	using	protocols	described	earlier	in	this	thesis.	Adherent	143B	cells	were	then	infected	with	purified	MV-GFP	and	EV-GFP	forms	of	VACV	in	the	absence	or	presence	of	heparin.	A	wide	concentration	range	(0.09	μg/mL	to	100	μg/mL)	of	heparin	was	used	in	this	assay	to	determine	the	heparin	IC50	for	the	MV	and	EV	forms	of	VACV	isolated	from	the	two	different	strains.			Overall,	heparin	inhibited	the	infectivity	of	the	EV	form	of	VACV	much	more	effectively	than	the	MV	form,	regardless	of	the	VACV	strain	from	which	it	was	obtained	(Figure	4.7).	In	fact,	the	heparin	inhibition	curves	for	the	EV	form	of	VACV	obtained	from	both	strains	of	VACV	virtually	overlap	each	other.	Likewise,	the	heparin	inhibition	curves	for	the	MV	form	of	VACV	isolated	from	the	two	
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different	VACV	strains	also	overlap	each	other.	The	IC50	for	heparin	inhibition	of	the	EV	infections	was	0.19	μg/mL,	whereas	the	IC50	for	the	MV	infections	was	4.7	μg/mL,	which	translates	to	over	a	16-fold	difference	in	the	IC50	values	for	the	two	forms	of	VACV.	These	results	indicate	that	the	differences	seen	between	the	EV-heparin	and	MV-heparin	interactions	are	due	to	the	two	different	forms	of	VACV,	and	not	due	to	the	VACV	strain	differences.	Therefore,	for	all	subsequent	assays,	purified	EV-GFP	was	obtained	from	the	recombinant	VACV	IHD-J	strain	and	purified	MV-GFP	from	the	recombinant	VACV	WR	strain.	As	seen	in	this	study,	titration	curves	for	the	inhibition	of	MV-GFP	and	EV-GFP	infectivity	by	heparin	are	highly	reproducible,	regardless	of	the	strain	of	origin	of	the	two	virus	forms.	Therefore,	in	all	subsequent	inhibition	assays	of	VACV	infectivity	by	HS	mimetics,	heparin	was	used	as	a	reference	compound	to	evaluate	the	relative	potency	of	other	inhibitors.			
4.3.6	Analysis	of	the	interaction	of	MV-GFP	and	EV-GFP	with	differently	
sulfated	HS		ELISA	assays	described	in	Chapter	3	examining	the	interaction	of	the	MV	form	of	VACV	with	immobilized	heparin,	HShi	and	HSlow	revealed	that	the	interaction	between	HS	and	purified	MV	was	highly	dependent	on	the	level	of	sulfation	of	the	HS	chains.	Thus,	heparin,	a	highly	sulfated	form	of	HS,	showed	the	strongest	interaction	with	the	purified	MV	particles.	HSlow	on	the	other	hand,	which	was	the	least	sulfate	HS	tested,	showed	the	weakest	interaction	with	purified	MV	particles	(Figures	3.1,	3.2	and	3.3).	The	unavailability	of	EV	specific	antibodies	meant	a	similar	ELISA	could	not	be	performed	with	the	purified	EV	particles.			
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Figure	4.8:	Effects	of	differently	sulfated	HS	on	MV-GFP	and	EV-GFP	infections	
in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	(obtained	from	VACV	WR)	or	EV-GFP	(obtained	from	VACV	IHD-J),	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	HShi	or	HSlow	starting	from	100	μg/mL.	Adherent	cells	were	released	by	treatment	with	trypsin	at	6	hr	post	infection,	fixed	and	analyzed	using	flow	cytometry	for	%	GFP	positive	cells	relative	to	control	cells	infected	with	the	respective	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	Representative	plots	showing	mean	percentage	of	GFP	positive	cells	relative	to	control	cells	±	SEM	(n=3).	The	data	presented	are	representative	of	at	least	three	independent	experiments.	 	
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With	the	development	of	the	new	FACS	based	infection	assays	using	GFP	producing	VACV	described	in	section	4.3.2,	both	purified	MV-GFP	and	EV-GFP	particles	were	used	to	examine	the	effect	of	differently	sulfated	HS	on	their	infectivity.	Thus,	adherent	cells	were	infected	with	the	purified	forms	of	MV-GFP	and	EV-GFP	in	the	absence	or	presence	of	HShi	and	HSlow	(Figure	4.8).	As	mentioned	in	section	4.3.5,	a	wide	concentration	range	(0.09	μg/mL	to	100	μg/mL)	of	the	differently	sulfated	HS	preparations	were	used	in	this	assay	to	estimate	the	IC50	of	HShi	and	HSlow	for	the	MV	and	EV	infections.		The	results	obtained	from	this	study	were	as	expected,	the	interaction	of	EV	with	HShi	being	much	stronger	than	the	interactions	with	HSlow,	with	the	IC50	of	HShi	for	the	EV-GFP	infection	being	0.39	μg/mL	compared	with	12.5	μg/mL	for	HSlow,	a	32-fold	difference.	Likewise,	the	interaction	of	MV-GFP	with	HShi	was	much	stronger	than	with	HSlow,	with	the	IC50	being	12.5	μg/mL	compared	with	an	IC50	of	>100	μg/mL	for	HSlow.	A	comparison	of	these	findings	with	the	heparin	inhibition	data	reported	in	section	4.3.5	shows	that	the	EV-GFP	and	MV-GFP	interact	most	avidly	with	heparin,	with	HShi	being	a	2-fold	less	effective	inhibitor	based	on	IC50	values.	These	studies	with	HShi	and	HSlow	also	confirmed	that	EV-GFP	interacts	with	HS	with	a	much	greater	avidity	than	MV-GFP.	Thus,	highly	sulfated	GAGs,	such	as	heparin	and	HShi,	are	much	more	potent	inhibitors	of	EV	infections	than	MV	infections.		 	
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	4.4	Discussion	To	increase	the	sensitivity	of	infection	assays,	recombinant	variants	of	both	the	WR	and	IHD-J	strains	of	VACV	expressing	GFP	were	constructed	by	inserting	a	GFP-Bsd	sequence	driven	by	an	early-late	poxvirus	promoter	at	an	inter-genic	site.	Blasticidin,	first	discovered	over	50	years	ago,	is	produced	by	Streptomyces	
griseochromogenes	(Takeuchi,	Hirayama,	Ueda,	Sakai,	&	Yonehara,	1958).	An	aminoacylnucleoside	antibiotic,	blasticidin	acts	as	a	protein	synthesis	blocker	by	interfering	with	the	peptidyl	transferase	reaction	(Tamura,	Kimura,	&	Yamaguchi,	1995).	The	use	of	the	Bsd	gene	sequence	as	a	blasticidin	resistance	gene	has	been	demonstrated	to	be	a	more	powerful	selection	marker	than	neomycin/G418	resistance,	to	select	for	transfected	mammalian	cell	lines	(Kimura,	Kamakura,	Tao,	&	Yamaguchi,	1994;	Kimura,	Takatsuki,	&	Yamaguchi,	1994).	Along	with	blasticidin	being	a	better	selection	marker,	it	is	also	a	smaller	gene	and	allows	easy	visual	screening.	These	properties	make	the	Bsd	gene	an	ideal	selection	marker.	The	fusion	between	GFP-Bsd	not	only	enables	selection	of	recombinant	VACV	particles	expressing	GFP,	but	also	allows	us	to	study	very	accurately	early	stages	of	a	VACV	infection.			Kinetic	studies	on	VACV	replication	performed	using	time-course	electron	microscopy	and	plaque	assays	have	shown	that	the	first	round	of	progeny	virions	is	produced	by	5-6	hr	post	infection	(Doceul	et	al.,	2010;	Payne	&	Kristenson,	1979).	In	order	to	understand	the	early	events	of	virus	entry	into	cells,	it	was	important	to	study	early	time	points	during	an	infection.	Since	an	early-late	promoter	drives	the	expression	of	GFP	in	virus-infected	cells,	this	allowed	us	to	detect	virus	infections	at	an	early	stage.	A	time-course	assay	was	initially	
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performed	to	measure	GFP	expression	in	infected	cells	over	time.	This	allowed	us	to	select	a	time	point	where	approximately	50%	of	the	cells	would	be	expressing	GFP,	for	future	inhibition	assays.	Since	a	substantial	proportion	of	cells	infected	using	either	MV-GFP	or	EV-GFP,	were	infected	by	6	hr	post	infection,	and	the	knowledge	that	6	hr	is	about	the	time	it	takes	for	the	first	round	of	viral	replication	to	complete,	the	6	hr	time	point	was	used	for	subsequent	inhibition	assays	(Figure	4.1	and	4.2).	Selecting	an	optimum	time	point	for	such	inhibition	assays	is	especially	important	as	VACV	uses	multiple	mechanisms	of	cell	entry,	including	the	infection	of	cells	by	‘punching’	MV	particles	from	infected	cells	to	neighboring	uninfected	cells,	which	bypasses	the	need	for	VACV	particles	to	interact	with	HS	and	other	cellular	receptors	(Mercer	et	al.,	2010;	Schmidt	et	al.,	2012).	To	evaluate	the	role	of	cell	surface	components	in	virus	attachment	and	entry,	it	is	essential	to	develop	assay	conditions	that	would	eliminate	non-HS	dependent	virus	entry	mechanisms.			The	initial	ELISA	findings	revealed	that	purified	MV	particles	bound	strongly	to	the	highly	sulfated	GAGs,	heparin	and	HShi,	immobilized	on	assay	wells	(Figure	3.1,	3.2	and	3.3)	and	can	reduce	MV	plaquing	by	5-fold	(Figure	3.5D).	A	time-course	of	heparin	inhibition	of	the	MV-GFP	and	EV-GFP	infections	revealed	that	heparin	can	inhibit	the	infectivity	of	both	viruses	early	during	an	infection	(Figure	4.3).	Thus,	even	the	lowest	concentration	of	heparin	tested	(1	μg/mL)	had	a	significant	effect	on	MV-GFP	infectivity	at	12	hr	post	infection,	but	by	24	hr	even	the	highest	concentration	of	heparin	used	(100	μg/mL)	failed	to	have	any	effect	on	MV-GFP	infectivity.	This	finding	contrasts	with	the	EV-GFP	infectivity,	which	was	still	substantially	inhibited	by	heparin	24	hr	after	culture	initiation.	The	results	
		 107	
obtained	with	the	GFP	producing	VACV	strains	confirm	and	expand	upon	the	ELISA	and	plaque	assay	results,	with	both	forms	of	VACV	interacting	with	hepain	but	the	EV	form	of	VACV	interacting	much	more	strongly.	This	difference	was	seen	whether	the	MV	and	EV	forms	of	VACV	were	obtained	from	either	the	VACV	WR	or	VACV	IHD-J	strains	of	VACV	(Figure	4.6).		As	discussed	earlier,	this	difference	in	heparin	sensitivity	could	partially	be	explained,	at	least	at	the	later	time	points,	by	the	ability	of	MV	particles	to	enter	uninfected	neighboring	cells	by	punching	through	the	plasma	membrane	of	the	neighboring	cells,	without	having	the	need	to	be	released	into	the	culture	medium,	and	hence	bypassing	the	MV-heparin	interaction.	On	the	other	hand,	heparin	has	a	much	greater	effect	on	EV	infectivity	at	both	early	and	late	time	points.	Thus,	even	at	24	hr	post	infection,	1	μg/mL	of	heparin	was	able	to	inhibit	EV	infections	by	50%.	This	is	a	remarkable	finding	since	the	EV	form	only	differs	from	the	MV	form	of	VACV	by	the	presence	of	at	least	one	extra	outer	membrane	(Ichihashi,	1996;	Smith	et	al.,	2002).	Also,	the	effects	of	heparin	on	EV	infectivity	go	beyond	the	24	hr	post	infection,	as	seen	with	the	plaque	assay	results	where	the	trademark	‘comets’	did	not	form	even	by	48	hr	post	infection	(Figure	3.5A).	These	findings	highlight	that	heparin,	and	presumably	cell	surface	HS,	play	a	far	greater	role	in	EV	infectivity	than	in	MV	infectivity.				The	simplest	interpretation	of	the	heparin	inhibition	experiments	is	that	HS	is	a	co-receptor	for	VACV	infections,	with	soluble	heparin	simply	blocking	the	HS	binding	sites	on	VACV	particles.	It	is	likely	that	HS	binding	receptors	on	the	surface	of	MV	particles	bind	to	cell	surface	HS	with	a	lower	avidity	compared	to	cell	surface	
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receptors	on	EV	particles.	Two	approaches	were	used	to	directly	test	this	hypothesis,	namely	removal	of	cell	surface	HS	by	enzymatic	treatment	prior	to	infection,	or	to	try	and	infect	cells	that	are	genetically	HS	deficient.		Three	bacterial	enzymes	that	degrade	HS	(HPNSE	1,	2	and	3)	and	mammalian	heparanase	(HPSE)	were	used,	with	varying	success,	to	remove	cell	surface	HS.	However,	treatment	of	cell	monolayers	with	all	of	these	enzymes	caused	a	statistically	significant,	but	modest,	reduction	in	both	MV-GFP	and	EV-GFP	infectivity	(Figure	4.5),	although	these	experiments	could	be	underestimating	the	role	of	cell	surface	HS	in	VACV	infectivity	due	to	the	partial	removal	of	cell	surface	HS.	An	alternative	approach	to	understand	the	significance	of	cell	surface	HS	in	VACV	infections	was,	therefore,	embarked	upon	by	infecting	cells	genetically	deficient	in	producing	cell	surface	HS.	CHO-K1	cells	produce	normal	levels	of	cell	surface	HS,	whereas	the	pgsA-745,	mutant	CHO-K1	cells,	are	HS	deficient	(Esko	et	al.,	1985).	However,	the	lack	of	CHO-hr	gene	in	VACV	makes	these	adherent	cells	non-permissive	for	VACV	infections.	VACV	plaque	assays,	therefore,	cannot	be	performed	on	CHO-K1	and	pgsA-745	adherent	cells.	Fortunately,	since	an	early-late	promoter	drives	the	GFP-Bsd	gene	expression	in	recombinant	strains	of	both	VACV	WR	and	VACV	IHD-J,	a	flow	cytometry	based	infection	assay	to	detect	GFP	fluorescence	in	infected	cells,	could	still	be	undertaken.	The	results	obtained	from	this	assay	were	consistent	with	the	previous	findings	that	HS	is	a	more	important	co-receptor	for	the	EV	form	of	VACV	than	the	MV	form.		VACV	infection	of	143B	cells	identified	cell	populations	with	varying	GFP	expression,	especially	by	8-12	hr	post	infection.	Since	an	early-late	poxvirus	
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promoter	drives	the	transcription	of	the	GFP-bsd	reporter	gene	used	in	the	current	study,	this	allows	quantification	of	GFP	expression	in	infected	cells	soon	after	the	primary	infection,	even	before	the	first	set	of	progeny	virus	particles	are	produced.	In	fact,	kinetic	studies	on	VACV	have	reported	that	progeny	VACV	are	formed	by	5	to	6	hr	post	infection	(Payne	&	Kristenson,	1979)	whereas	GFP	expression	can	be	seen	within	2	hr	of	infection	in	both	MV-GFP	and	EV-GFP	infected	cells	(Figure	4.1	and	4.2),	indicating	that	only	primary	virus	infection	is	being	observed	at	this	time	point.	As	time	progresses	and	one	full	replication	cycle	of	VACV	is	completed,	newly	formed	virus	particles	are	able	to	infect	neighboring	cells	at	around	6	hr	post	initial	infection,	some	of	which	may	not	have	been	infected	by	the	initial	infection	at	0	hr.	It	is	likely	that	a	second	round	of	replication	may	also	start	in	the	primary	infected	cell	and,	therefore,	results	in	the	expression	of	even	higher	amounts	of	GFP,	whereas	the	neighbouring	cells	may	only	just	start	to	produce	GFP	as	a	result	of	a	delayed	infection.	Furthermore,	not	every	virus	particle	may	enter	cells	at	the	same	time.	These	discrepancies	in	the	timing	of	infection	result	in	populations	of	cells	that	are	infected	early	during	infection	and,	therefore,	are	highly	GFP	expressing	by	12	hr,	along	with	populations	of	cells	that	are	infected	by	the	newly	formed	virions	from	the	primary	infection	and,	thus,	are	low	GFP	expressing	at	8-12	hr.			Since	VACV	replication	in	CHO	and	pgsA-745	cells	is	abortive,	only	the	cells	infected	by	the	primary	infection	express	GFP.	Virus	particles	once	inside	the	primary	cell	would	undergo	early	gene	transcription	and,	thus,	express	GFP,	however,	since	no	progeny	virus	would	form	within	the	primary	cell,	no	secondary	infection	of	neighbouring	cells	would	take	place.	This	is	the	reason	why	only	a	very	
		 110	
small	proportion	of	CHO	and	pgsA-745	cells	could	be	infected	and,	therefore,	unlike	the	143B	cells,	high	and	low	GFP	expressing	cell	populations	could	not	be	observed.	This	prompted	the	use	of	mean	fluorescence	intensity	(MFI)	rather	than	%	GFP	positive	cells	as	a	measure	of	infection	in	these	non-permissive	cells.		A	previous	report	suggests	that	the	outer	membrane	of	EV	lyses	when	in	contact	with	sulfated	GAGs,	resulting	in	the	release	of	the	inner	MV	particle,	which	then	causes	the	infection	(Law	et	al.,	2006).	Furthermore,	results	obtained	from	the	enzymatic	removal	of	cell	surface	HS	using	HPNSE	and	HPSE,	along	with	infection	studies	in	cells	genetically	deficient	in	producing	cell	surface	HS	performed	in	this	thesis	confirm	the	previous	findings	that	cell	surface	HS	is	particularly	important	for	EV	infections.	However,	use	of	time	course	inhibition	assays	in	the	current	study	also	suggests	that	both	MV	and	EV	forms	of	VACV	have	quite	distinct	infection	profiles,	when	used	to	infect	cells	in	presence	of	heparin	and	other	sulfated	GAGs.	Our	work	also	suggests	that	this	disruption	of	the	outer	EV	envelope	must	be	extremely	slow	as	even	at	24	hr	post	infection,	the	EV-GFP	particles	incubated	with	heparin	are	unable	to	infect	cells	monolayers	efficiently.	In	fact,	this	heparin-EV	interaction	slows	down	the	VACV	infection,	consistent	with	heparin	blocking	a	HS	binding	sites	on	EV	that	recognizes	cell	surface	HS	and	aids	EV	entry	into	cells.	These	results,	in	conjunction	with	previously	published	work,	imply	that	cell	surface	HS	is	crucial	for	EV	infections,	however,	more	research	needs	to	be	undertaken	to	identify	all	the	HS	binding	proteins	on	the	surface	of	the	EV	form	of	VACV.			
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Heparin	and	HS	share	a	very	similar	molecular	structure	(Li	&	Vlodavsky,	2009).	Connective	tissue	mast	cells	are	the	only	known	cell	type	that	produce	heparin	(Li	&	Vlodavsky,	2009;	Yurchenco	&	Schittny,	1990).	However,	unlike	HS,	heparin	is	not	a	component	of	the	ECM.	Therefore,	it	was	essential	to	understand	the	interaction	of	purified	MV-GFP	and	EV-GFP	particles	with	HS,	measured	using	the	highly	sensitive	flow	cytometry	detection	of	GFP	fluorescence.	A	broad	concentration	range	of	differently	sulfated	HS	(HShi	and	HSlow)	was	used	to	inhibit	MV-GFP	and	EV-GFP	infections	in	vitro.	As	expected,	HShi	(IC50	=	0.39	μg/mL)	was	more	efficient	at	inhibiting	EV-GFP	infections	compared	to	HSlow	(IC50	=	12.5	μg/mL),	this	difference	translating	into	a	32-fold	difference	in	inhibitory	activity.	Similarly,	HSlow	was	much	less	effective	than	HShi	at	inhibiting	MV-GFP	infectivity,	although	the	fold	differences	based	on	comparison	of	IC50	values,	could	not	be	calculated	(Figure	4.8).	In	contrast,	HShi	was	almost	as	effective	as	heparin	at	inhibiting	both	MV-GFP	and	EV-GFP	infections,	there	only	being	a	2-3	fold	difference	based	on	IC50	values,	indicating	that	heparin	provides	a	good	representation	of	the	HS	motifs	recognized	by	the	MV	and	EV	forms	of	VACV.			In	conclusion,	we	have	successfully	constructed	GFP	GFP-Bsd	expressing	VACV	WR	and	VACV	IHD-J	strains	of	VACV	and	used	the	two	strains	to	demonstrate	that	both	the	MV	and	EV	forms	of	VACV	interact	strongly	with	heparin.	Degradation	of	cell	surface	HS	using	different	HPNSEs	and	HPSE	resulted	in	partial	inhibition	of	EV	and	MV	infectivity	of	cells.	This	was	probably	due	to	the	inability	of	HS	degrading	enzymes	to	completely	degrade	cell-surface	HS.	The	residual	infection	observed	in	treated	cells	could	be	attributed	to	the	small	number	of	HS	binding	sites	still	present	on	the	surface	of	cells.	Results	obtained	from	infection	of	cells	genetically	
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deficient	in	cell	surface	HS	confirm	the	interpretation	of	the	results	obtained	with	the	HS	degradation	assays.	Together,	results	from	both	these	assays	substantiate	the	finding	that	interaction	with	cell	surface	HS	is	very	important	for	EV	infections.	In	contrast,	the	MV	form	of	VACV	is	not	heavily	dependent	on	HS	interactions	for	infection.	Similarly,	recognition	of	HShi		but	not	HSlow	is	required	for	the	EV	form	of	VACV	to	infect	cells,	indicating	that	EV	infection	of	cells	is	dependent	on	the	degree	of	sulfation	of	cell	surface	GAGs.	These	findings	are	a	significant	first	step	towards	novel	drug	development	for	poxvirus	infections.	 	
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													 		Interaction	of	chemically	modified	heparin	and	HS	mimetics	with	EV	and	MV	forms	of	VACV	
Chapter	5:	
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5.1	Abstract	
	It	was	demonstrated	in	Chapter	4	of	this	thesis	that	cell	surface	HS	can	potentially	act	as	a	co-receptor	for	VACV	entry	into	cells.	It	was	also	demonstrated	that	heparin	is	able	to	inhibit	EV	infectivity	more	effectively	than	MV	infectivity.	To	take	these	findings	further	and	develop	effective	and	safe	HS/heparin-based	antivirals,	it	was	first	important	to	understand	the	structural	features	of	HS/heparin	that	are	required	for	its	interaction	with	the	EV	and	MV	forms	of	VACV.		In	this	Chapter	it	is	shown	that	the	2-O-sulfate	of	uronic	acid	and	the	6-O-	and	N-sulfation	of	glucosamine	residues	are	all	important	for	VACV	infectivity,	with	the	6-O-sulfate	of	glucosamine	being	the	most	crucial.	It	was	also	shown	that	the	size	of	the	heparin	chains	does	not	affect	the	ability	of	the	molecule	to	inhibit	VACV	infections.	In	fact,	heparin	chains	as	small	as	1.7	kDa	(i.e.,	a	pentasaccharide)	are	able	to	inhibit	VACV	infections	just	as	well	as	5-30	kDa	unfractioned	heparin.	These	findings	are	extremely	significant	as	they	highlight	the	structural	requirements	for	HS/heparin	chains	to	act	as	efficient	antivirals.	Subsequent	screening	of	various	sulfated	di-	and	oligo-saccharides	(HS	mimetics)	confirmed	that	sulfated	pentasaccharides	are	generally	the	most	effective	inhibitors	of	both	MV	and	EV	infections.	However,	the	linkages	of	different	D-glucose-based	sulfated	saccharides	has	a	profound	effect	on	the	ability	of	the	sulfated	saccharides	to	inhibit	VACV	infections,	with	the	order	of	potency	being	β(1g4)	>	α(1g6)	>	α(1g4)	>	β(1g3).	Furthermore,	although	none	of	the	sulfated	D-glucose-based	saccharides	tested	could	inhibit	VACV	infections	as	effectively	as	heparin,	the	D-mannose-based	sulfated	oligosaccharide	mixture	PI-88	(Muparfostat)	inhibited	MV	infections	more	effectively	than	heparin	but	was	a	weak	inhibitor	of	EV	infections.	Collectively,	these	data	suggest	that	the	MV	and	EV	forms	of	VACV	interact	with	distinct	but	structurally	related	HS	motifs	on	target	
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cells,	with	the	position	of	negatively	charged	sulfate	groups	in	3D	space	determining	the	specificity	of	the	interactions.	
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5.2	Introduction	and	rationale		Heparin	and	HS	are	linear	GAG	chains	that	are	synthesized	as	proteoglycans,	i.e.,	glyco-conjugated	macromolecules	composed	of	carbohydrate	polymers	covalently	attached	to	a	protein	core	(Li	&	Vlodavsky,	2009;	Sasisekharan	&	Venkataraman,	2000;	Sugahara	&	Kitagawa,	2002).	The	HS	and	heparin	chains	share	a	great	deal	of	structural	similarity,	however,	the	protein	cores	of	these	GAG	chains	show	distinct	expression	patterns,	the	heparin	bearing	proteoglycan,	for	example,	being	largely	restricted	to	mast	cells	(Li	&	Vlodavsky,	2009).	The	HS	and	heparin	chains	are	composed	of	repeating	disaccharides	of	glucosamine	and	hexuronic	acid,	joined	in	alternating	sequences	by	1,4-glycosidic	linkages,	which	gives	these	carbohydrate	chains	their	flexibility	to	bind	to	different	proteins	(Li	&	Vlodavsky,	2009;	Lindahl,	1990;	Lindahl	et	al.,	1979).	The	carbohydrate	chains	of	both	heparin	and	HS	are	sequentially	modified	by	a	series	of	reactions	involving	N-	and	O-sulfation	and	epimerization	of	the	glucuronic	residues	to	iduronic	acid	(Lindahl,	1990).	The	modification	reactions	during	HS	biosynthesis	are	highly	regulated,	resulting	in	heterogenous	sulfation	and	epimerization	patterns	that	could	be	tissue	and	cell-type	specific	(Esko	&	Lindahl,	2001;	Ledin	et	al.,	2004).	It	is	believed	that	the	selective	modifications	allow	regulated	interactions	between	HS	and	various	HS	binding	proteins	(Kreuger,	Spillmann,	Li,	&	Lindahl,	2006).	However,	the	modification	reactions	in	heparin	biosynthesis	are	more	extensive	resulting	in	a	relatively	homogenous	structure	(Esko	&	Lindahl,	2001).	The	size	of	nascent	heparin	chains	is	60-100	kDa,	whereas	heparin	prepared	from	animal	tissue	is	a	mixture	of	saccharide	fragments	of	5-30	kDa	(Horner,	1971).		
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Naturally	occurring	unfractioned	heparin	(UFH),	commonly	referred	to	as	just	‘heparin’,	has	several	pharmacokinetic	limitations	due	to	its	high	negative	charge,	which	causes	binding	to	several	plasma	proteins	(e.g.,	histidine-rich	glycoprotein,	vitronectin,	lipoproteins,	fibronectin	and	fibrinogen),	proteins	secreted	by	platelets	(e.g.,	platelet	factor	4	and	high-molecular-weight	von	Willebrand	factor)	and	endothelial	cells	(Hirsh,	1991;	Young	et	al.,	1992).	Along	with	pharmacokinetic	limitations,	UFH,	like	several	other	anticoagulants,	can	cause	complications	of	bleeding	and	produce	thrombocytopenia	and	osteoporosis	(Hirsh,	1998).			Chemical	or	enzymatic	depolymerization	of	traditional	heparin	yields	low	molecular	weight	heparins	(LMWH),	which	are	a	more	homogeneous	anticoagulant	than	heparin	and	approximately	one	third	the	size	of	heparin	(i.e.,	4-5	kDa).	LMWHs	have	been	widely	shown	to	have	the	ability	to	overcome	some	of	the	limitations	of	UFH,	and	to	be	more	effective	in	the	treatment	of	deep	vein	thrombosis	(DVT)	(Hirsh,	1998).			Results	shown	in	this	thesis	so	far	have	demonstrated	the	ability	of	highly	sulfated	HS	and	heparin	to	inhibit	VACV	infectivity,	with	the	two	molecules	being	more	effective	against	EV	than	MV	infections.	However,	in	order	to	develop	GAG	based	antivirals	with	minimal	off-target	effects,	it	was	essential	to	further	understand	the	specific	modifications/structures	of	the	GAG	chains	that	interact	with	the	two	forms	of	VACV	and,	therefore,	affect	their	infectivity.	Hence,	the	specific	aims	of	this	Chapter	were	to	understand,	based	on	FACS	assays,	the	key	structural	features	of	heparin	(and	HS)	required	to	efficiently	inhibit	VACV	infectivity.	In	order	to	determine	the	structural	requirements,	a	systematic	approach	of	using	LMWHs	as	
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possible	inhibitors	of	VACV	infectivity,	was	initially	undertaken.	This	was	followed	by	understanding	the	role	of	different	heparin	modifications	on	anti-VACV	activity	along	with	testing	several	synthetic	sulfated	oligosaccharides	(HS	mimetics)	as	possible	inhibitors	of	VACV	infectivity.		
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5.3	Results	
5.3.1	Differences	in	VACV	infectivity	in	the	presence	of	different	low	
molecular	weight	heparins	(LMWH)	LMWH	started	to	replace	heparin	as	an	antithrombotic	drug	in	the	prevention	and	treatment	of	DVT	in	the	mid-1980s	(Franze	et	al.,	2015;	Mousa,	2002).	The	adaptation	of	LMWH	was	due	to	their	reduced	side	effects,	such	as	smaller	risk	of	bleeding,	lower	binding	affinity	for	several	plasma	proteins,	lower	chance	of	heparin-induced	thrombocytopenia	(HIT)	and	more	predictable	behavior,	all	of	which	made	them	a	safer	drug	compared	to	heparin	(Franze	et	al.,	2015;	Hirsh,	1998;	Ingle	&	Agarwal,	2014;	TenCate	et	al.,	1997).	It	should	be	noted,	however,	that	both	heparin	and	LMWH	exert	their	anticoagulant	activity	by	the	same	unique	pentasaccharide	sequence	(Weitz,	1997).			Today,	most	LMWHs	available	on	the	market	are	derived	from	heparin	using	four	different	depolymerisation	strategies,	namely,	oxidative	cleavage,	deaminative	cleavage	and	chemical	or	enzymatic	β-elimination	(Franze	et	al.,	2015).	The	size	of	LMWHs,	their	molecular	weight	distribution	and	their	degree	of	sulfation	is	dependent	on	the	specific	cleavage	reactions	used	for	their	generation,	the	resultant	cleavage	points	along	the	length	of	the	UFH	chains	producing	LMWH	preparations	with	distinct	physical,	chemical	and	biological	properties	(Minghetti,	Cilurzo,	Franze,	Musazzi,	&	Itri,	2013).	Enoxaparin	is	one	such	LMWH,	derived	from	the	β-elimination	cleavage	of	UFH	chains.	Previous	studies	have	shown	enoxaparin	to	be	one	of	the	most	suitable	antithrombotic	agent	which	can	be	delivered	intra-dermally	(Franze	et	al.,	2015).			
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Fondaparinux,	a	new	class	of	antithrombotic	agent,	is	a	totally	synthetic	pentasaccharide	sequence	that	is	structurally	based	on	the	antithrombin	III	binding	site	of	heparin	(Bauer,	Eriksson,	Lassen,	&	Turpie,	2001;	Chang	et	al.,	2014).	Unlike	heparin,	which	interacts	with	several	plasma	proteins	involved	in	coagulation,	fondaparinux	exhibits	only	factor	Xa	inhibitory	activity	via	binding	to	antithrombin	III	and	consequently	inhibiting	thrombin	generation	(Bauer	et	al.,	2001;	Petitou	et	al.,	2002).	Furthermore,	fondaparinux	has	been	shown	to	be	safer,	and	have	superior	efficacy	and	pharmacological	properties	compared	to	heparin,	however,	the	drug	is	much	more	expensive	than	naturally	available	heparin	(Walenga	et	al.,	2002).	Nevertheless,	in	order	to	identify	safe	GAG	based	antivirals,	it	was	important	to	determine	the	ability	of	fondaparinux,	along	with	other	commercially	available	LMWHs,	to	inhibit	MV	and	EV	infections.	The	LMWHs	used	in	the	inhibition	assays	described	in	this	thesis	include	1.7	kDa	fondaparinux,	3	kDa	enoxaparin,	4-6	kDa	LMWH	(Fluka-Sigma	Aldrich),	and	a	5	kDa	LMWH,	all	of	which	were	gifts	from	Dr.	Craig	Freeman,	John	Curtin	School	of	Medical	Research.		All	LMWHs	tested	had	a	similar	inhibitory	effect	on	the	EV	and	MV	forms	of	VACV,	indicating	that	chain	length	is	not	a	factor	that	determines	the	inhibitory	capacity	of	different	heparin	chains	(Figure	5.1).	In	fact,	the	fondaparinux	pentasaccharide	appeared	to	be	the	most	potent	inhibitor	of	all	the	LMWH	examined,	particularly	with	MV	infections,	with	the	inhibition	curves	almost	overlapping	with	that	of	heparin	(dashed	lines)	for	the	respective	VACV	forms	(Figure	5.1A),	the	IC50	values	of	fondaparinux	for	MV	and	EV	infections	being,	respectively,	only	2-fold	and	3-fold	higher	than	that	of	heparin	(Table	5.1).	Enoxaparin,	a	3	kDa	LMWH,	was	also	able	to	inhibit	both	MV	and	EV	infectivity,	with	the	IC50	values	for	MV	and	EV	
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infectivity	being	4-fold	more	than	heparin	for	both	VACV	forms	(Figure	5.1B,	Table	5.1).	The	larger	LMWHs,	including	the	4-6	kDa	Fluka	LMWH	and	the	5	kDa	LMWH,	were	also	able	to	inhibit	VACV	infections	efficiently,	the	IC50	values	for	both	being	identical	(Figure	5.1C	and	D),	with	values	for	the	IC50	for	EV	infections	being	2-fold	and	for	MV	infections	being	5-fold	higher	than	that	of	heparin	(Table	5.1).		
5.3.2	Differences	in	VACV	infectivity	in	the	presence	of	chemically	modified	
heparins	Several	studies	have	demonstrated	that	heparin	can	act	as	an	inhibitor	of	heparanase	activity	in	vitro,	inhibiting	the	degradation	of	cell	surface	and	ECM	HS	and	consequently	inhibiting	tumour	metastasis	and	inflammatory	responses	(Barner	et	al.,	1987;	Irimura,	Nakajima,	&	Nicolson,	1986;	Parish,	Coombe,	Jakobsen,	Bennett,	&	Underwood,	1987).	Heparin,	however,	is	a	potent	anticoagulant	and	can	induce	hemorrhagic	complications	when	administrated	in	high	concentrations.	This	led	to	the	development	of	safer	chemically	modified	derivatives	of	heparin	with	low	anticoagulant	potency,	but	similar	heparanase	inhibitory	activity	as	heparin	(Barner	et	al.,	1987).	Chemically	modified	heparins	are	essentially	heparin	chains	that	have	been	modified	by	addition	or	removal	of	specific	groups,	such	as	sulfate,	acetyl	or	carboxyl	groups,	across	the	length	of	the	heparin	chains.	In	order	to	develop	antiviral	drugs	that	were	also	safe	to	be	administered	it	was,	therefore,	important	to	evaluate	the	effectiveness	of	chemically	modified	heparins	as	inhibitors	of	VACV	infections.	Use	of	such	molecules	would	also	help	determine	the	heparin	modifications	that	enable	or	inhibit	infectivity.	The	chemically	modified	heparins	used	in	this	Chapter	were	all	a	
		 122	
gift	from	Dr.	Craig	Freeman,	and	were	developed	and	tested	in	the	Parish	laboratory	at	the	John	Curtin	School	of	Medical	Research,	Canberra,	Australia.		Preliminary	results	from	ELISA	assays	described	in	Chapter	3	of	this	thesis,	using	HS	preparations	with	different	levels	of	sulfation	(i.e.,	HShi	and	HSlow),	revealed	that	sulfation	density	has	an	impact	on	the	ability	of	MV	to	interact	with	immobilized	HS.	Furthermore,	infection	assays	performed	using	the	differently	sulfated	HS	preparations	as	inhibitors	of	VACV	infections,	described	in	Chapter	4	of	this	thesis,	suggest	that	the	level	of	sulfation	also	plays	an	important	role	in	the	ability	of	HS	to	inhibit	EV	and	MV	infections.	Previously	published	studies	on	Herpes	simplex	viruses	(HSV)	using	chemically	modified	heparins	and	heparanase	treatment	of	target	cells	have	shown	that	glycoproteins	gB	and	gC	on	the	surface	of	the	HSV-1	and	HSV-2	strains	recognize	different	structural	features	of	cell	surface	HS,	which	provides	an	initial	docking	site	for	HSV	entry	into	cells	(Shukla	&	Spear,	2001).	The	presence	of	2,3-O-sulfate	and	6-O-sulfate	groups	on	heparin	has	been	shown	to	be	critical	for	the	ability	of	heparin	to	bind	to	HSV-1	gB/gC,	but	not	for	heparin-HSV-2	glycoprotein	interactions	(Feyzi	et	al.,	1997;	Trybala,	Liljeqvist,	Svennerholm,	&	Bergstrom,	2000).	Thus	the	interaction	of	viral	glycoproteins	with	cell	surface	HS	is	crucial	for	HSV-1	entry	in	cells,	however,	such	interactions	are	relatively	less	important	for	HSV-2	infections	(Herold,	Gerber,	Belval,	Siston,	&	Shulman,	1996;	Shukla	et	al.,	1999;	Shukla	&	Spear,	2001).	Therefore,	in	order	to	understand	the	interaction	of	VACV	with	cell	surface	HS	to	be	able	to	design	antivirals,	it	was	essential	to	first	understand	the	role	of	individual	sulfate	groups	of	heparin	on	the	ability	of	heparin	to	inhibit	VACV	infectivity,	similar	to	the	HSV	studies	previously	published.		 	
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Figure	5.1:	Effect	of	different	LMWHs	on	MV-GFP	and	EV-GFP	infections	in	
vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	LMWHs,	namely	fondaparinux	pentasaccharide	1.7	kDa	(A),	enoxaparin	3	kDa	(B),	LMWH	(Fluka)	4-6	kDa	(C)	LMWH	5	kDa*	(D),	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.	
	
	
	
	*The	5	kDa	LMWH	was	prepared	by	chemical	depolymerization	of	heparin	by	Dr.	Craig	Freeman		 	
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To	perform	these	assays,	chemically	de-sulfated	heparin	molecules	lacking	2-O-sulfate	(de2S),	6-O-sulfate	(de6S)	or	N-sulfate	(deNS)	groups	or	being	completely	desulfated	(deS),	were	used	to	inhibit	EV	and	MV	infections.	In	these	assays,	adherent	143B	cells	were	infected	with	purified	MV-GFP	and	EV-GFP	forms	of	VACV	in	the	absence	or	presence	of	the	different	chemically	modified	heparins.	A	wide	concentration	range	(0.09	μg/mL	to	100	μg/mL)	of	heparin	variants	was	used	in	this	assay	to	determine	the	IC50	of	each	variant	for	both	the	MV	and	EV	forms	of	VACV	(Figure	5.2).	For	comparison,	plots	of	heparin	inhibition	of	MV	and	EV	infectivity,	from	section	4.3.5,	are	displayed	as	dashed	lines	in	each	Figure	depicted	in	Figure	5.2.	A	diagrammatic	representation	of	each	chemically	modified	heparin,	showing	the	sulfate	groups	lacking	from	the	heparin	chains,	is	presented	next	to	the	respective	line	plots.				Overall,	the	chemically	modified	heparins	tested	had	a	greater	inhibitory	effect	on	the	EV	form	of	VACV,	than	the	MV	form,	indicating	that	EV	interacts	with	the	sulfate	groups	of	heparin	(or	HS)	with	a	higher	avidity	than	MV.	Some	sulfate	groups,	however,	are	not	crucial	for	inhibition	of	MV	or	EV	infectivity,	with	the	2-O	sulfate	of	the	iduronic/glucuronic	acid	residues	being	the	least	important	(Figure	5.2A).	Thus	heparin	molecules	deficient	in	the	2-O-sulfate	group	were	still	quite	effective	inhibitors	of	VACV	infections,	exhibiting	IC50	values	for	EV	and	MV	infections	3-fold	and	5-fold	higher	than	heparins,	respectively	(Table	5.1).	In	contrast,	the	6-O-sulfate	and	N-sulfate	groups	were	crucial	for	inhibition	of	VACV	infectivity,	removing	either	of	these	two	sulfate	groups	having	a	very	significant	impact	on	the	ability	of	heparin	to	inhibit	EV	and	MV	infections.		
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Table	5.1:	Comparison	of	IC50	values	for	various	LMWHs	and	chemically	
modified	heparins	for	EV	and	MV	infections	in	vitro.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 		†	LMWH:	low	molecular	weight	heparin;	de2S:	de-2-O-sulfate;	de6S:	de-6-O-sulfate;	deNS:	de-N-sulfate;	deS:	de-sulfate;	deCarboxyl:	de-carboxylate;	reNAc:	re-N-acetyl;	reNS:	re-N-sulfate.		§	Fold	change	ratios	calculated	by	dividing	IC50	values	of	each	heparin	species	for	each	virus	form	by	the	IC50	value	of	heparin	for	each	virus	form.			 	
Heparin	Species†	 IC50	(μg/mL)			[Fold	change]§	
EV	 MV	Heparin	 0.19	 4.68	Fondaparinux	-	1.7	kDa	 0.58	[3x]	 9.36	[2x]	Enoxaparin	-	3	kDa	 0.78	[4x]	 18.75	[4x]	LMWH	(Fluka)	-	4-6	kDa	 0.39	[2x]	 25	[5x]	LMWH	-	5	kDa	 0.39	[2x]	 25	[5x]	de2S	 0.58	[3x]		 25	[5x]	de6S	 12.5	[65x]	 >	100	[>	21x]	deNS	 18.75	[98x]	 >	100	[>	21x]	deS	 >	100	[>	500x]	 >	100	[>	21x]	deCarboxyl	 0.29	[1.5x]	 12.5	[3x]	deNS,	reNAc	 0.39	[2x]	 18.75	[4x]	de2S,	deNS/reNAc	 1.17	[6x]	 50	[11x]	deS,	reNS	 37.5	[198x]	 >	100	[>	21x]	
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Figure	5.2:	Effect	of	different	chemically	modified	heparins	on	MV-GFP	and	
EV-GFP	infections	in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	chemically	modified	heparins,	namely	de-2-O-sulfate	(de2S)	(A),	de-6-O-sulfate	(de6S)	(B),	de-N-sulfate	(deNS)	(C)	and	de-sulfated	(deS)	(D)	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Diagrammatic	representation	of	different	chemically	modified	heparins	is	shown	next	to	line	plots	for	respective	modified	heparins*.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.								*For	simplicity,	iduronic	acid	is	depicted	as	the	hexuronic	acid	in	the	heparin	disaccharide,	but	it	equally	could	be	glucuronic	acid.		
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Thus	for	EV	infections,	the	IC50	value	for	heparin	lacking	6-O-sulfate	groups	on	glucosamine	residues	was	65-fold	higher	than	that	of	untreated	heparin	(Figure	5.2B,	Table	5.1).	Similarly,	heparin	molecules	lacking	N-sulfate	groups	on	their	glucosamine	residues	were	98-fold	less	effective	than	heparin	at	inhibiting	EV	infections	(Figure	5.2C,	Table	5.1).	Furthermore,	heparin	lacking	either	6-O-sulfate	or	N-sulfate	groups	was	much	less	effective	at	inhibiting	MV	infections,	although	IC50	values	could	not	be	obtained	as	they	were	not	reached	at	the	highest	modified	heparin	concentration	tested	As	expected,	removing	all	sulfate	groups	from	heparin	chains	completely	abolished	the	ability	of	heparin	to	have	any	inhibitory	effect	on	VACV	infectivity	(Figure	5.2D).	The	finding	that	6-O	and	N-sulfate	groups	along	the	length	of	the	heparin	chain	are	more	important	for	inhibiting	VACV	infections,	than	2-O	sulfate	groups,	lays	the	ground	work	for	determining	the	features	of	cell	surface	HS	important	for	both	EV	and	MV	infectivity.		The	next	investigation	examined	the	role	of	non-sulfate	groups	of	heparin	on	the	ability	of	the	molecule	to	inhibit	VACV	infections.	Therefore,	the	next	set	of	chemically	modified	heparins	examined	the	role	of	the	carboxyl	group	of	the	iduronic/glucuronic	acid	residues	(deCarboxyl)	and	the	effect	of	N-acetylation	of	glucosamine	residues	on	the	ability	of	heparin	to	inhibit	VACV	infections.	As	described	earlier,	adherent	143B	cells	were	infected	with	purified	MV-GFP	and	EV-GFP	forms	of	VACV	in	the	absence	or	presence	of	different	modified	heparins.	A	wide	concentration	range	(0.09	μg/mL	to	100	μg/mL)	of	modified	heparins	was	used	in	this	assay	to	determine	the	IC50	values	for	all	heparin	variants	for	both	the	MV	and	EV	forms	of	VACV	(Figure	5.3).	Removal	of	the	carboxyl	group	from	the	iduronic/glucuronic	acid	residues	of	heparin	had	a	minimal	effect	on	the	ability	of	
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heparin	to	inhibit	both	MV	and	EV	infections	(Figure	5.3A),	with	the	IC50	values	for	EV	and	MV	infections	being,	respectively,	only	1.5-fold	and	3-fold	higher	than	for	unmodified	heparin.	As	seen	previously	in	Figure	5.2C,	removal	of	the	N-sulfate	group	from	glucosamine	residues	dramatically	reduced	the	ability	of	heparin	to	inhibit	VACV	infections,	compared	to	the	removal	of	the	2-O-sulfate	group,	which	had	little	effect	on	inhibitory	activity,	suggesting	that	N-sulfate	groups	play	an	important	role	in	the	interactions	of	VACV	with	heparin/HS,	whereas	the	2-O-sulfate	groups	play	only	a	minor	role	in	this	interaction.	However,	the	generation	of	a	modified	heparin	with	N-acetyl	groups	substituting	for	N-sulfate	groups	on	glucosamine	residues,	almost	completely	restored	the	ability	of	N-desulfated	heparin	to	inhibit	MV	and	EV	infections	(Figure	5.3B),	with	the	IC50	values	for	EV	and	MV	infections	being,	respectively,	2-fold	and	4-fold	higher	than	that	for	untreated	heparin	(Table	5.1).	However,	if	the	2-O-sulfate	group	of	N-desulfated/N-reacetylated	heparin	is	also	deleted,	the	ability	of	heparin	to	inhibit	MV	and	EV	infections	is	further	hampered	(Figure	5.3C).	This	suggests	that	the	interaction	of	VACV	with	the	2-O-sulfate	groups	of	iduronic/glucuronic	acid	may	not	be	crucial	for	heparin/HS	binding,	however,	it	is	an	important	structural	component	of	the	heparin	molecule,	important	for	the	inhibitory	activity	of	heparin	as	a	whole.	Thus,	the	presence	of	N-acetyl	groups	on	the	glucosamine	residues	of	heparin	are	unable	to	compensate	for	the	loss	of	2-O-sulfate	groups	from	the	heparin	molecule.	As	a	result	the	IC50	values	for	de2S,	deNS/reNAc	heparin	are	6-fold	and	11-fold	higher	than	for	heparin	for	EV	and	MV	infections,	respectively.			 	
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Figure	5.3:	Effect	of	additional	chemically	modified	heparins	on	MV-GFP	and	
EV-GFP	infections	in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	chemically	modified	heparins,	namely	de-carboxylated	(deCarboxyl)	(A),	de-N-sulfate,	re-N-acetylated	(deNS,	reNAc)	(B),	de-2-O-sulfate,	de-N-sulfate	and	re-N-acetylated	(de2S,	deNS/reNAc)	(C)	and	de-sulfate,	re-N-acetylated	(deS,	reNS)	(D),	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Diagrammatic	representation	of	different	chemically	modified	heparins	is	shown	next	to	line	plots	for	respective	modified	heparins*.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.									*For	simplicity,	iduronic	acid	is	depicted	as	the	hexuronic	acid	in	the	heparin	disaccharide,	but	it	equally	could	be	glucuronic	acid.	 	
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Finally,	although	chemical	treatment	of	heparin	to	remove	all	3	types	of	sulfate	groups	from	the	polysaccharide	chain	resulted	in	the	total	loss	of	inhibitory	activity	(Figure	5.2D),	re-N-sulfation	of	desulfated	heparin	resulted	in	only	a	slight	restoration	of	inhibitory	activity,	based	on	IC50	values,	deS,	reNS	heparins	being	200-fold	less	effective	than	heparin	at	inhibiting	EV	infections	(Table	5.1).	Furthermore,	re-N-sulfation	had	no	detectable	effect	on	the	inability	of	desulfated	heparin	to	inhibit	MV	infections	(Figure	5.3D).	Collectively,	these	data	suggest	that	the	6-O-sulfates	on	glucosamine	residues	are	the	most	important	negatively	charged	groups	on	heparin	chains	that	interact	with	VACV.		
5.3.3	Differences	in	VACV	infectivity	in	the	presence	of	synthetic	sulfated	
oligosaccharides	(HS	mimetics)	Heparin	and	HS	have	been	studied	extensively	and	have	been	shown	to	interact	with	a	wide	range	of	structurally	diverse	proteins,	such	as	growth	factors,	proteases,	lipases,	cell	adhesion	molecules	and	cytokines	(Bernfield	et	al.,	1999;	Capila	&	Linhardt,	2002;	Esko	&	Selleck,	2002;	Gallagher,	2001;	Perrimon	&	Bernfield,	2000;	Turnbull,	Powell,	&	Guimond,	2001).	This	plethora	of	interactions,	as	discussed	previously,	results	in	structurally	diverse	heparin	having	many	undesirable	side	effects	in	vivo.	There	is	enough	evidence,	however,	to	suggest	that	heparin/HS	binding	proteins	interact	with	unique	saccharide	sequences	in	heparin/HS	(Esko	&	Selleck,	2002;	Gallagher,	2001;	Turnbull	et	al.,	2001).	In	fact,	several	HS	mimetics	have	been	developed	which	have	anti-angiogenic	and	anti-inflammatory	activity	like	heparin,	but	lack	the	undesirable	interactions	of	heparin	with	other	HS	binding	proteins	(Freeman	et	al.,	2005).	The	most	important	finding	from	these	HS	mimetic	studies	was	that	the	interaction	of	many	proteins	with	
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heparin/HS	is	critically	dependent	on	the	relative	position	of	negatively	charged	sulfate	groups	in	heparin/HS	molecules	(Freeman	et	al.,	2005).			Many	viruses	have	been	shown	to	use	HS	as	a	co-receptor	for	infecting	cells	(Zhu	et	al.,	2011).	In	fact,	studies	have	shown	that	HS	is	the	second	largest	group	of	carbohydrate-based	receptors	for	many	human	viruses	(Olofsson	&	Bergstrom,	2005).	As	a	result,	a	number	of	small	soluble	polysulfated	compounds	mimicking	cell	surface	HS	and,	thus,	having	a	broad	spectrum	of	antiviral	activity,	have	been	developed.	Most	of	these	compounds	were	first	reported	many	years	ago,	however,	the	mechanisms	underlying	their	antiviral	activity	are	still	unclear	(Baba	et	al.,	1988;	Ito	et	al.,	1987).			In	order	to	identify	synthetic	heparins	that	could	be	used	as	antivirals	for	VACV	infections,	sulfated	di-	and	oligo-saccharides	that	are	easy	to	synthesise,	and	have	been	shown	previously	to	have	certain	biological	activities	including	anti-tumour	(Kuda,	Yano,	Matsuda,	&	Nishizawa,	2005),	anti-apoptotic	(Kim,	Kim,	Kim,	Lee,	&	Lee,	2006),	anti-inflammatory	(Neyrinck,	Mouson,	&	Delzenne,	2007;	Nishimura	et	al.,	2010)	and	anti-coagulant	(Miao,	Ishaimichaeli,	Peretz,	&	Vlodavsky,	1995)	activities,	were	examined	for	their	effects	on	VACV	infections	in	vitro.	In	fact,	four	D-glucose-based	saccharides	were	used	with	differing	linkages	(i.e.,	α(1g4),	α(1g6),	β(1g4)	and	β(1g3)),	which	are	depicted	in	Table	5.2.		Previous	studies	have	shown	that	sulfated	maltotetraose	(an	oligosaccharide	based	on	maltose),	but	not	sulfate	maltose,	to	be	a	potent	inhibitor	of	angiogenesis	(Parish,	Freeman,	Brown,	Francis,	&	Cowden,	1999).	Isomaltose	is	another	D-
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glucose-based	disaccharide	similar	to	maltose,	however,	it	has	an	α(1g6)-linkage	instead	of	an	α(1g4)-linkage	(Table	5.2)	(Gaenzle	&	Follador,	2012).	Sulfated	forms	of	both	disaccharides,	and	other	longer	chain	sulfated	oligosaccharides	based	on	maltose	and	isomaltose	molecules,	were	used	as	inhibitors	of	VACV	to	determine	if	these	simple	sulfated	sugars	can	act	as	antivirals.	Among	the	sulfated	malto-saccharides	tested,	maltopentaose	appeared	to	be	the	most	potent	inhibitor	of	EV	infectivity	with	an	IC50	value	only	4-fold	higher	than	that	of	heparin	(Figure	5.4D,	Table	5.3).	Maltotriose	sulfate	was	not	as	potent	inhibitor	of	EV	infection	as	maltopentaose	sulfate,	but	was	more	effective	than	maltose	and	maltotetraose	sulfate	(Figure	5.4A,	B,	C	and	D,	Table	5.3),	maltotriose	sulfate	being	16-fold	and	maltose	and	maltotetraose	sulfate	being	50-fold	less	effective	than	heparin	at	inhibiting	EV	infections	(Table	5.3).	None	of	the	sulfated	malto-saccharides	achieved	IC50	values	for	MV	infections,	although	the	three	sulfated	malto-oligosaccharides	were	partially	inhibitory,	with	sulfated	maltopentaose	being	the	most	active	(Figure	5.4).				Among	the	three	sulfated	isomalto-oligosaccharides	available	for	use	as	inhibitors	of	VACV	infection,	isomaltopentaose	sulfate	appeared	to	be	the	most	effective	inhibitor	of	EV	and	MV	infections,	with	the	IC50	values	for	EV	and	MV	infections	being,	respectively,	8-fold	and	5-fold	higher	than	for	heparin	(Figure	5.5B).	Both	the	other	two	sulfated	isomalto-oligosaccharides	used,	sulfated	isomaltotetraose	and	isomaltohexaose,	were	much	less	effective	inhibitors	of	EV	infections	(Figure	5.5A	and	C),	being	49-fold	less	active	than	heparin	(Table	5.3).	Similarly,	isomaltotetraose	and	isomaltohexaose	sulfate	were	weak	inhibitors	of	MV	infections,	barely	achieving	IC50	values	(Figure	5.5	A	and	C,	Table	5.3).	Overall,		
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Table	5.2:	Structure	of	different	D-glucose	based	sulfated	saccharides	(HS	
mimetics)	used	in	this	study.		 	
Sulfated	
Saccharide	
Series	
Linkages	 Chemical	Structure	
Maltose	 α(1g4)	
	
	
Isomaltose	 α(1g6)	
	
							 	
Cellobiose	 β(1g4)	
	
		 	
Laminaribiose	 β(1g3)	
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Figure	5.4:	Effect	of	sulfated	malto-saccharides	on	MV-GFP	and	EV-GFP	
infections	in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	sulfated	malto-saccharides,	namely	maltose	(1155	kDa)	(A),	maltotriose	(1625	kDa)	(B),	maltotetraose	(2090	kDa)	(C),	and	maltopentaose	(2562	kDa)	(D),	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.			 	
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none	of	the	sulfated	malto-	and	isomalto-oligosaccharides	tested	could	inhibit	VACV	infections	as	effectively	as	some	of	the	LMWHs	and	chemically	modified	heparins	described	in	sections	5.3.1	and	5.3.2	of	this	thesis.		Cellobiose,	derived	from	cellulose,	is	another	D-glucose	based	saccharide	with,	in	this	case,	a	β(1g4)	linkage	(Table	5.2).	Sulfated	cello-oligosaccharides	have	been	extensively	tested	for	their	anticoagulant	activity,	with	sulfated	cellotetraose	being	the	shortest	sulfated	cello-oligosaccharide	exhibiting	significant	anticoagulant	activity	(Wall,	Douglas,	Ferro,	Cowden,	&	Parish,	2001).	The	three	sulfated	oligosaccharides	derived	from	cellulose	available	for	testing,	namely	cellotetraose,	cellopentaose	and	cellohexaose	sulfate	(Figure	5.5D,	E	and	F),	overall	appeared	to	be	better	inhibitors	of	VACV	infections	compared	to	the	sulfated	malto-	and	isomalto-oligosaccharides	used	previously	in	this	Chapter.	In	fact,	all	three	cello-oligosaccharides	exhibited	comparable	antiviral	activity	against	both	the	EV	and	MV	infections,	being	~8-16-fold	less	effective	than	heparin	(Table	5.3).			The	last	set	of	oligosaccharides	tested	for	their	ability	to	inhibit	VACV	infections	were	the	laminari-saccharides,	derived	from	the	storage	polysaccharide	laminarin	present	in	brown	algae.	Sulfated	laminari-saccharides	are	β(1g3)	linked	glucose	molecules	(Table	5.2),	which	have	previously	been	shown	to	exhibit	low	anticoagulant	activity	compared	to	sulfated	malto-,	isomalto-	and	cello-saccharides	(Wall	et	al.,	2001).	Four	sulfated	laminari-saccharides	including,	laminaribiose,	laminaritriose,	laminaritetraose	and	laminaripentaose,	were	tested	for	their	ability	to	inhibit	VACV	infections	in	vitro	(Figure	5.6).	All	four	sulfated	laminari-saccharides	had	little	or	no	effect	on	VACV	infectivity,	being	100-500-fold	less		
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Table	5.3:	Comparison	of	IC50	values	of	various	sulfated	saccharides	(HS	
mimetics)	for	EV	and	MV	infections	in	vitro.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 	§	Fold	change	ratios	calculated	by	dividing	IC50	values	of	each	sulfated	saccharide	for	each	virus	form	by	the	IC50	value	of	heparin	for	each	virus	form.				
Sulfated	saccharide	
IC50	(μg/mL)			
[Fold	change]§	
EV	 MV	Heparin	 0.19	 4.68	Maltose	 50	[263x]	 >	100	[>	21x]	Maltotriose	 3.125	[16x]	 >	100	[>	21x]	Maltotetraose	 50	[263x]	 >	100	[>	21x]	Maltopentaose	 0.78	[4x]	 >	100	[>	21x]	Isomaltotetraose	 9.38	[49x]		 >	100	[>	21x]	Isomaltopentaose	 1.56	[8x]	 25	[5x]	Isomaltohexaose	 9.38	[49x]	 100	[21x]	Cellotetraose	 1.56	[8x]	 50	[11x]	Cellopentaose	 1.56	[8x]	 37.5	[8x]	Cellohexaose	 3.125	[16x]	 50	[11x]	Laminaribiose	 75	[395x]	 >	100	[>	21x]	Laminaritriose	 100	[526x]	 >	100	[>	21x]	Laminaritetraose	 25	[132x]	 >	100	[>	21x]	Laminaripentaose	 75	[395x]	 >	100	[>	21x]	PI-88	(Muparfostat)	 3.125	[16x]	 1.17	[0.25x]	
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effective	than	heparin	against	EV	and	exhibiting	no	detectable	inhibitory	activity	against	MV	(Figure	5.6,	Table	5.3).		
5.3.4	Differences	in	VACV	infectivity	in	the	presence	of	the	anti-cancer	drug	
PI-88	(Muparfostat)	PI-88	is	a	highly	sulfated	synthetic	oligosaccharide	composed	of	predominantly	penta-	and	tetra-	saccharides	derived	from	the	extracellular	phosphomannan	produced	by	the	yeast	Pichia	holstii	(Khachigian	&	Parish,	2004;	McKenzie,	2007).	Mild	acid-catalyzed	hydrolysis	of	the	phosphomannan	liberates	a	number	of	oligosaccharides	which,	upon	exhaustive	sulfation,	result	in	a	highly	sulfated	mixture	of	oligosaccharides,	referred	to	as	PI-88	or	Muparfostat		(Khachigian	&	Parish,	2004).	These	sulfated	oligosaccharides	are	structurally	and	functionally	different	from	small	heparin-like-polyaromatic	anionic-type	compounds	and	other	synthetic	HS	mimetics	(Benezra	et	al.,	1994;	Parish	et	al.,	1999).	Furthermore,	PI-88	is	a	multi-component	mixture,	composed	predominantly	of	phosphomannopentaose	and	phosphomannotetraose	sulfates	(Figure	5.7A	and	B),	which	accounts	for	over	90%	of	the	mixture	(Yu	et	al.,	2002).	However,	small	quantities	of	the	di-,	tri-,	and	hexa-phosphomannosulfates	and	a	phosphotetrasaccharylamine	sulfate	are	also	present	in	the	PI-88	mixture	(Ferro,	Fewings,	Palermo,	&	Li,	2001).			PI-88	is	an	effective	inhibitor	of	the	HS	degrading	endoglycosidase	HPSE	and	is	the	only	HPSE	inhibitor	to	date	that	has	reached	advanced	clinical	trials	testing,	currently	being	in	a	Phase	III	clinical	trial	as	a	monotherapy	in	post-resection	hepatocellular	carcinoma	patients	(McKenzie,	2007).	Apart	from	preventing	
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Figure	5.5:	Effect	of	isomalto-	and	cello-oligosaccharides	on	MV-GFP	and	EV-
GFP	infections	in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	isomaltose	and	cellobiose	based	sulfated	oligosaccharides,	namely	isomaltitetraose	(2090	kDa)	(A),	isomaltopentaose	(2562	kDa)	(B),	isomaltohexaose	(3020	kDa)	(C),	cellotetraose	(2090	kDa)	(D),	cellopentaose	(2562	kDa)	(E),	and	cellohexaose	(3020	kDa)	(F),	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.	 	
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Figure	5.6:	Effect	of	sulfated	laminari-oligosaccharides	on	MV-GFP	and	EV-
GFP	infections	in	vitro.	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	different	laminar-oligosaccharides,	namely	laminaribiose	(1125	kDa)	(A),	laminaritriose	(1626	kDa)	(B),	laminaritetraose	(2090	kDa)	(C)	and	laminaripentaose	(2562	kDa)	(D),	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.		 	
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Figure	5.7:	Chemical	structure	of	the	anti-cancer	drug	PI-88	(Muparfostat)	
and	the	effect	of	PI-88	on	MV-GFP	and	EV-GFP	infections	in	vitro.	Diagrammatic	representation	of	the	chemical	structure	of	PI-88,	adapted	from	Khachigian	&	Parish	(2004).	PI-88	is	a	mixture	predominantly	(~90%)	composed	of	(A)	phosphomannopentaose	and	(B)	phosphomannotetraose	sulfates,	with	the	pentasaccharide	to	tetrasaccharide	ratios	ranging	from	approximately	2:1	to	3:2.	The	remaining	10%	of	the	PI-88	mixture	is	composed	of	di-,	tri-,	and	hexa-phosphomannosulfates,	and	a	phosphotetrasaccharyl	amine.	(C)	143B	cells	were	infected	with	purified	MV-GFP	or	EV-GFP	viruses	at	a	MOI	of	1,	in	the	presence	of	doubling	dilutions	of	PI-88	at	concentrations	ranging	from	0.09	μg/mL	to	100	μg/mL.	Adherent	143B	cells	were	released	with	trypsin	at	6	hr	post	infection,	fixed,	and	analyzed	using	flow	cytometry	for	GFP	expression.	Representative	line	plots	show	mean	(±	SEM;	n=3)	percentage	of	GFP	positive	cells	relative	to	control	cells	infected	with	the	viruses	in	the	absence	of	inhibitors	(100%	positive	control).	The	ability	of	unmodified	heparin	to	inhibit	MV-GFP	and	EV-GFP	infections	(dashed	lines)	is	included	in	each	graph	for	comparison	(see	Figure	4.7).	The	data	presented	are	representative	of	three	independent	experiments.					 	
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metastasis	of	tumours	by	inhibiting	HPSE,	PI-88	also	reduces	tumour	growth	by	inhibiting	angiogenesis	via	blocking	the	action	of	several	HS-binding	grown	factors	(Khachigian	&	Parish,	2004).	It	also	has	some	anticoagulant	activity	as	it	is	able	to	enhance	heparin	cofactor	II	inhibition	of	thrombin	(Wall	et	al.,	2001).	Moreover,	additional	studies	have	demonstrated	that	PI-88	can	act	as	an	inhibitor	of	arterial	restenosis	following	balloon	angioplasty	(Francis	et	al.,	2003).		Since	PI-88	is	a	well-characterized	sulfated	oligosaccharide	mixture	that	has	been	used	extensively	
in	vivo,	we	examined	the	effect	of	this	compound	on	VACV	infections.	Adherent	143B	cells	were	infected	with	purified	MV-GFP	and	EV-GFP	forms	of	VACV	in	the	absence	or	presence	of	PI-88	as	described	earlier	for	other	sulfated	oligosaccharides.	The	inhibition	curves	generated	from	the	assay	were	rather	unexpected	(Figure	5.7C).	PI-88	was	found	to	be	the	only	sulfated	oligosaccharide	identified	so	far	that	is	able	to	inhibit	MV	infections	more	efficiently	than	EV	infections,	with	IC50	values	for	MV	infections	being	1.17	μg/mL	compared	to	3.125	μg/mL	for	EV	infections.		Moreover,	PI-88	was	a	4-fold	better	inhibitor	of	MV	infections	than	heparin.	On	the	other	hand,	with	EV	infections,	heparin	was	a	better	inhibitor	(i.e.,	16-fold)	than	PI-88	(Figure	5.7C).		
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5.4	Discussion	The	HS	chains	of	HSPGs	are	extraordinarily	diverse	structures,	with	differences	in	positions	of	the	sulfate	groups	along	the	length	of	the	chain,	and	the	epimerization	of	glucoronic	acid	residues	to	iduronic	acid,	giving	rise	to	over	45	different	disaccharides	combinations	that	could	potentially	occur	in	any	given	HS	chain	(Parish,	2006).	There	is	also	much	evidence	to	support	the	view	that	unique	structural	motifs	in	HS,	mainly	composed	of	negatively	charged	carboxyl	and	sulfate	groups,	interact	and	bind	to	different	HS-binding	proteins	(Esko	&	Selleck,	2002;	Gallagher,	2001;	Lindahl	&	Kjellen,	2013;	Turnbull	et	al.,	2001).		In	fact,	HS	polysaccharides	are	capable	of	binding	a	large	number	of	proteins	and	can,	therefore,	act	as	regulators	of	a	variety	of	biological	processes	(Casu	&	Lindahl,	2001).	One	of	the	very	well	characterized	protein	binding	sites	in	HS	chains	is	the	antithrombin	III	binding	pentasaccharide	sequence	of	heparin	(Bauer	et	al.,	2001).	The	antithrombin	binding	pentasaccharide	contains	four	sulfate	groups,	all	of	which	are	essential	for	antithrombin	III	binding,	thereby	resulting	in	blood	anticoagulation	activity	(Casu	&	Lindahl,	2001).			However,	there	are	several	limitations	on	the	clinical	use	of	heparin	based	on	its	pharmacokinetic,	biophysical	and	anticoagulant	properties	(Hirsh,	1995,	1998).	One	of	the	major	limitations	of	heparin	is	its	ability	to	bind	to	several	proteins	and	cells	non-specifically	due	to	its	high	negative	charge	(Barzu,	Molho,	Tobelem,	Petitou,	&	Caen,	1985;	Hirsh,	1991).	Heparin	is	also	unable	to	inactivate	surface-bound	thrombin-factor	Xa	complexes	and,	therefore,	has	limited	efficacy	in	unstable	angina,	high-risk	coronary	angioplasty,	and	coronary	thrombolysis	(Hirsh,	1995).	Apart	from	these	pharmacokinetic	and	biophysical	limitations,	there	
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are	other	biological	limitations	associated	with	the	use	of	heparin.	Platelet	activation	due	to	heparin	binding	has	been	shown	to	stimulate	the	formation	of	antibodies	against	heparin-platelet	factor	4	complexes	that	cause	heparin-induced	thrombocytopenia	(Kelton	et	al.,	1994).	Moreover,	long-term	heparin	treatment	has	also	been	associated	with	osteoporosis	(Barbour	et	al.,	1994;	Monreal,	Lafoz,	Olive,	Delrio,	&	Vedia,	1994).			These	limitations	prompted	the	development	of	a	new	class	of	anticoagulants,	called	the	low-molecular-weight	heparins	(LMWHs)	that	are	usually	derived	from	naturally	occurring	unfractionated	heparin.	LMWHs	are	much	smaller	than	heparin	chains,	which	reduces	their	affinity	for	many	plasma	proteins	and,	therefore,	produces	more	predictable	results	when	they	are	administered	to	patients	compared	to	heparin.	Use	of	LMWH,	therefore,	reduces	the	side	effects	associated	with	the	long-term	use	of	heparin-based	antithrombotic	drugs,	which	is	why	LMWHs	started	to	replace	heparin	for	the	prevention	of	DVT	in	the	mid-1980s	(Franze	et	al.,	2015;	Mousa,	2002).		In	Chapters	3	and	4	of	this	thesis,	it	was	established	that	cell	surface	HS	can	act	as	a	potential	co-receptor	for	MV	and	EV	entry	into	cells	in	vitro.	It	has	been	demonstrated	in	the	current	study	that	heparin	can	inhibit	both	MV	and	EV	infections,	however,	with	different	efficiencies	(Figure	4.7).	Despite	the	inhibitory	effects	of	heparin	on	VACV	infectivity,	previously	published	studies	summarized	above	have	reported	the	unwanted	side	effects	associated	with	prolonged	heparin	administration	in	patients.	However,	the	fact	that	several	attempts	have	been	made	in	the	field	of	glycobiology	to	develop	safe	carbohydrate-based	drugs,	and	
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the	knowledge	that	VACV,	like	many	other	viruses,	interacts	with	cell	surface	GAGs	(Zhu	et	al.,	2011),	resulted	in	studies	reported	in	this	thesis	to	determine	whether	LMWHs,	chemically	modified	heparins	and	other	biologically	active	HS	mimetics	with	superior	safety	profiles	to	heparin,	can	inhibit	VACV	infections	by	interfering	with	the	VACV-HS	interaction.	Thus,	a	highly	systematic	approach	was	undertaken	to	identify	potentially	new	and	safe-carbohydrate-based	antivirals.			Initially,	commonly	used	LMWHs	were	used	in	VACV	inhibition	assays,	as	performed	previously	in	section	4.3.6.	Fondaparinux,	a	synthetic	pentasaccharide	sequence	structurally	based	on	the	heparin	antithrombin	III	binding	domain,	was	the	most	effective	of	all	the	LMWHs	used	as	possible	inhibitors	of	VACV	infections.	In	fact,	fondaparinux	was	able	to	inhibit	MV	and	EV	infections	almost	as	efficiently	as	untreated	heparin.	Furthermore,	enoxaparin	and	two	other	LMWHs	(4-6	kDa	Fluka	and	5	kDa	LMWH)	were	also	able	to	inhibit	both	MV	and	EV	infections	efficiently,	although	not	as	well	as	heparin	or	fondaparinux.	This	finding	suggests	that	the	length	of	the	GAG	chain	is	irrelevant	when	considering	inhibition	of	the	VACV-HS	interaction,	as	the	1.7	kDa	fondaparinux	pentasaccharide	is	able	to	effectively	inhibit	VACV	infections	in	vitro.	This	finding	is	very	encouraging	as	it	clearly	indicates	that	the	VACV-HS	interaction	is	highly	specific	and	not	dependent	on	weak	multivalent	binding	by	a	long	chain,	negatively	charged	HS	molecule.	In	fact,	the	strong	inhibitory	activity	of	fondaparinux	for	both	forms	of	VACV	strongly	suggests	that	both	MV	and	EV	forms	of	VACV	recognize	and	interact	with	a	small	pentasaccharide	sequence	in	HS/heparin.	Furthermore,	since	fondaparinux	is	based	on	the	heparin	antithrombin	III	binding	sequence,	it	is	likely	that	the	same	sequence	is	essential	for	VACV	infections	as	well	(Figure	5.1A).	Our	findings,	along	
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with	other	studies	determining	rare	sulfation	sequences	along	the	length	of	HS	chains,	raises	the	notion	of	a	so	called	‘sulfation	code’,	which	entails	sulfated	sequences	along	the	length	of	HS	chains	that	permit	selective,	high	avidity,	protein	binding	patterns	(Lindahl	&	Kjellen,	2013).		To	validate	the	‘sulfation	code’	hypothesis,	it	was	important	to	understand	how	individual	modifications	of	HS	chains	impact	on	the	ability	of	HS	to	interact	with	VACV.	Previous	detailed	studies	investigating	HSV	attachment	and	infection	of	cells	
in	vitro	revealed	that	2,3-O-sulfate	and	6-O-sulfate	groups	are	critical	for	heparin	to	interact	with	the	gB	and	gC	glycoproteins	on	the	surface	of	HSV-1	(Feyzi	et	al.,	1997;	Trybala	et	al.,	2000).	Sulfate	groups	on	heparin	are	important	for	inhibition	of	both	MV	and	EV	infectivity,	with	the	removal	of	6-O-sulfate	groups	from	heparin	chains	having	a	detrimental	effect	on	the	ability	of	heparin	to	inhibit	VACV	infections.	However,	when	all	the	inhibition	results	observed	with	the	different	desulfated	heparins	(Figures	5.2	and	5.3)	are	collated,	it	becomes	evident	that	all	3	sulfation	sites	on	heparin	chains	contribute	to	inhibition	of	VACV	infections.	For	example,	despite	removal	of	2-O-sulfate	groups	alone	only	having	a	modest	effect	on	the	ability	of	heparin	to	inhibit	VACV	infections,	when	a	second	sulfate	group	is	removed	from	heparin	(i.e.,	N-desulfation,	N-reacetylation),	the	effects	were	dramatic	with	the	doubly	desulfated	heparin	being	unable	to	inhibit	VACV	infections.	Previous	reports	have	shown	that	the	6-O-sulfate	group	is	the	most	critical	group	on	the	glucosamine	residues	required	for	heparin’s	anti-inflammatory	effects,	which	are	mediated	by	selectin	inhibition	(Wang	et	al.,	2002).	Results	presented	in	Figure	5.2B	also	highlight	the	key	role	of	6-O-sulfate	groups	in	aiding	inhibition	of	VACV	infectivity.	
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Acetylation	of	all	glucosamine	residues	along	the	heparin	chains	did	not	markedly	influence	the	inhibitory	ability	of	heparin	for	VACV	infections,	nor	did	removal	of	the	carboxyl	groups	of	the	iduronic/glucuronic	acid	residues	of	heparin.	This	is	an	important	finding	as	it	defines	the	structural	features	of	heparin/HS	that	are	not	required	for	antiviral	activity.	Such	a	detailed	understanding	of	heparin/HS	chain	structure	is	crucial	for	the	development	of	antivirals	that	are	not	only	potent,	but	also	safe	to	be	administered.	Several	studies	published	previously	have	established	that	HS	is	the	second	largest	group	of	carbohydrate-based	cell	surface	receptors	for	human	viruses	(Olofsson	&	Bergstrom,	2005).	This	has	led	to	the	development	of	HS	mimetics	as	antiviral	compounds	(Pourianfar,	Poh,	Fecondo,	&	Grollo,	2012).	The	findings	reported	in	this	thesis	represent	one	of	the	few	attempts	made	at	understanding	the	specificity	of	virus-HS	interactions,	with	VACV	being	the	model	virus	studied.		As	mentioned	earlier	in	this	Chapter,	heparin	has	been	shown	to	be	an	excellent	anticoagulant,	however,	prolonged	use	of	heparin	in	vivo	results	in	several	undesirable	side	effects	due	to	the	ability	of	heparin	to	interact	with	a	range	of	structurally	diverse	proteins	and	growth	factors	(Bernfield	et	al.,	1999;	Capila	&	Linhardt,	2002;	Esko	&	Selleck,	2002;	Gallagher,	2001;	Perrimon	&	Bernfield,	2000;	Turnbull	et	al.,	2001).	This	led	to	the	development	of	sulfated	oligosaccharides	(HS	mimetics)	using	naturally	available	saccharides	which,	like	heparin,	possess	the	anti-angiogenic	and	anti-inflammatory	properties	of	heparin,	but	lack	many	undesirable	side	effects	(Freeman	et	al.,	2005).	Since	several	previously	published	studies,	and	the	initial	work	described	in	this	thesis,	have	highlighted	the	role	of	cell	surface	HS	as	a	co-receptor	for	VACV	entry,	and	shown	
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that	heparin	is	able	to	inhibit	VACV	infections	in	vitro,	several	sulfated	HS	mimetics	with	known	anti-coagulant,	anti-inflammatory	and/or	anti-angiogenic,	properties	were	screened	to	determine	if	they	can	also	act	as	antivirals	against	VACV	infections.	Sulfated	malto-,	isomalto-,	cello-	and	laminari-saccharides	were	used	in	the	assays	presented	in	the	current	chapter.		In	general,	many	of	the	sulfated	di-	and	oligo-saccharides	tested	could	not	efficiently	inhibit	MV	or	EV	infections	when	compared	to	heparin.	Only	sulfated	maltopentaose	from	the	malto-oligosaccharide	series,	and	sulfated	isomaltopentaose	from	the	isomalto-oligosaccharide	series	had	inhibitory	activity	approaching	that	of	heparin.	It	was	also	shown	that	fondaparinux,	also	a	pentasaccharide,	was	the	most	effective	LMWH	(Figure	5.1A).	Both	these	findings	suggest	that	an	ideal	carbohydrate	based	inhibitor	of	VACV	infectivity	would	be	a	sulfated	pentasaccharide	sequence.	In	terms	of	the	saccharide	backbones	used,	overall	the	cellulose	derived	sulfated	saccharides	were	the	most	effective	VACV	inhibitors	used	in	this	study.	In	fact,	the	data	obtained	indicate	that	the	linkage	of	different	D-glucose-based	sulfated	saccharides	has	a	profound	effect	on	the	ability	of	the	sulfated	saccharides	to	inhibit	VACV	infections,	with	the	order	of	potency	being	β(1g4)	>	α(1g6)	>	α(1g4)	>	β(1g3),	and	sulfated	pentasaccharides	being	usually	the	most	effective.	Such	data	support	the	hypothesis	that	the	position	of	negatively	charged	sulfate	groups	in	3D	space	determines	the	antiviral	activity	of	these	molecules	and,	therefore,	builds	on	the	notion	of	a	‘sulfation	code’.			One	of	the	most	interesting	results	obtained	from	the	VACV	inhibition	assays	using	HS	mimetics,	however,	was	obtained	when	PI-88	was	used	an	inhibitor	of	MV	and	
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EV	infections.	PI-88,	a	highly	sulfated	mixture	of	D-mannose-based	saccharides,	is	structurally	and	functionally	different	from	heparin	and	the	other	HS	mimetics	tested	in	this	study	(Benezra	et	al.,	1994;	Parish	et	al.,	1999).	VACV	infection	assays	performed	using	PI-88	as	a	potential	inhibitor	of	infection	revealed	that	PI-88,	unlike	all	the	LMWHs,	modified	heparins	and	HS	mimetics	tested,	acts	as	a	better	inhibitor	of	MV	infections	than	of	EV	infections	(Figure	5.7).	In	fact,	PI-88	was	able	to	inhibit	MV	infectivity	4-fold	more	efficiently	than	heparin,	a	finding	not	seen	with	any	of	the	LMWHs,	modified	heparins	or	other	HS	mimetic	assayed.	On	the	other	hand,	PI-88	was	16-fold	less	efficient	than	heparin	at	inhibiting	EV	infections.	To	understand	these	results,	it	is	essential	to	understand	the	composition	of	the	PI-88	mixture.	Firstly,	PI-88	is	based	on	the	monosaccharide	D-mannose,	whereas	all	the	other	HS	mimetics	described	in	this	Chapter	are	D-glucose-based	saccharides.	Secondly,	PI-88	is	composed	of	α(1g3)	and	α(1g2)	linked	D-mannose	residues	(Yu	et	al.,	2002),	which	differs	from	the	linkages	of	the	D-glucose-based	HS	mimetics	examined	in	this	Chapter.	Therefore,	the	remarkable	effectiveness	of	PI-88	against	MV	infections	but	not	EV	infections,	could	be	attributed	to	the	α(1g3)	and	α(1g2)	linkage	of	mannose	residues	resulting	in	an	orientation	of	sulfate	groups	that	blocks	selectively	the	interactions	of	MV	particles	with	cell	surface	HS.	A	third	feature	that	distinguishes	PI-88	from	the	other	GAG-based	molecules	used	in	this	study	is	its	structural	heterogeneity.	PI-88	is	mainly	composed	of	pentasaccharide	and	tetrasaccharide	sulfates,	but	the	mixture	also	contains	small	quantities	of	di-,	tri-	and	hexa-phosphomannosulfates	and	a	phosphotetrasaccharylamine	sulfate	(Ferro	et	al.,	2001).	Such	a	heterogeneous	mixture	perhaps	targets	multiple	HS	binding	sites	on	the	surface	of	MV	particles	and,	therefore,	blocks	the	particles	from	interacting	with	cell	surface	HS.	In	fact,	PI-
		 152	
88	has	previously	been	demonstrated	to	have	a	significant	beneficial	effect	on	disease	outcome	in	dengue	virus	and	flaviviral	encephalitis	mouse	models,	such	that	the	mortalilty	rate	in	PI-88	treated	mice	was	reduced	to	39%	compared	to	84%	in	saline	treated	control	mice	(Lee,	Pavy,	Young,	Freeman,	&	Lobigs,	2006).	Furthermore,	results	obtained	from	PI-88	inhibition	of	VACV	infections	also	support	the	hypothesis	that	cell	surface	HS	receptors	for	MV	and	EV	are	structurally	different.			Overall,	the	data	presented	in	this	Chapter	support	the	concept	that	GAG-based	antiviral	drugs	can	be	developed.	Furthermore,	a	detailed	understanding	of	the	structural	features	of	heparin	that	allow	it	to	inhibit	VACV	infections	has	provided	valuable	insights	into	the	groups/modifications	of	cell	surface	HS	chains	that	aid	VACV	infections.	In	addition,	the	sulfated	di-	and	oligo-saccharide-based	HS	mimetics	used	in	this	study	support	the	view	that	the	specificity	of	the	HS-VACV	interaction	differs	markedly	between	the	MV	and	EV	forms	of	VACV.	Finally,	the	major	heparin-/HS-related	bioactivity	targeted	clinically	in	the	past	has	been	antithrombotic	activity,	however,	the	data	presented	in	this	Chapter	suggest	that	other	clinical	uses	of	modified	heparins/HS	mimetics,	notably	as	antivirals,	are	feasible.		 	
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														 		Studies	of	the	interaction	between	EV	and	MV	surface	proteins	and	HS/heparin	
Chapter	6:	
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6.1	Abstract	Since	several	viruses	and	other	pathogens	use	HS	as	initial	attachment	receptors,	identifying	EV	and	MV	surface	proteins	interacting	with	cell	surface	HS	would	be	vital	for	the	development	of	novel	HS	based	antiviral	drugs.	Membrane	proteins	from	purified	EV	and	MV	particles	were	obtained	using	mild	detergent	treatment	and	were	pre-incubated	with	heparin-coupled	beads,	followed	by	detection	via	Western	blotting	using	polyclonal	VACV-specific	antibodies.	Four	potential	heparin-binding	proteins	were	identified	with	molecular	weights	of	150	kDa,	85	kDa,	60	kDa	and	25	kDa,	with	the	85	kDa	protein	being	distinct	from	the	85	kDa	VACV	haemaggluttinin	A56R.	Bioinformatic	searches	performed	to	identify	VACV	proteins	with	HS	binding	domains	identified	the	65	kDa	B4R	protein	and	the	78	kDa	RNA	helicase	DExH-NPH-II	of	VACV	as	possible	candidate	proteins.	Using	1D	nanoLC	ESI	MS/MS	analysis	of	the	150	kDa	protein	detected	by	Western	blotting	identified	it	to	be	a	poxvirus	DNA	directed	RNA	polymerase	with	sequence	similarity	to	VACV	F12,	a	65	kDa	protein	important	in	the	formation	of	EV.	It	was	concluded	that	the	heparin/HS-binding	site	of	many	VACV	EV	proteins	is	not	composed	of	linear	amino	acid	sequences	and	that	there	may	be	multiple	HS	binding	proteins	on	the	surface	of	EV,	all	of	which	contribute	towards	infectivity.	
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6.2	Introduction	and	rationale	To	understand	the	tropism	of	any	viral	infection	it	is	important	to	first	understand	the	interactions	between	the	proteins	on	the	surface	of	viruses	and	their	cell	surface	receptors.	Understanding	and	targeting	such	interactions	could	have	implications	for	antiviral	drug	development.	This	is	the	reason	why	studying	such	interactions	has	lately	gained	considerable	interest	from	the	pharmaceutical	and	scientific	communities.	Developing	strategies	that	simply	block	viruses	from	interacting	with	their	cell	surface	receptors	would	likely	be	less	toxic	and	intrusive	compared	to	currently	used	treatments	like	chemotherapy	(Liu	&	Thorp,	2002).	Furthermore,	there	is	increasing	concern	for	the	selection	of	drug-resistant	strains	of	viruses	due	to	prolonged	use	of	antivirals,	with	immunocompromised	patient	populations	being	at	the	highest	risk	(Strasfeld	&	Chou,	2010).	To	overcome	these	issues,	increasing	efforts	are	being	made	to	develop	compounds	that	block	virus	particles	from	binding	and	entering	target	cells	during	early	stages	of	infection	and,	therefore,	possibly	preventing	infections	caused	by	drug-resistant	virus	strains.	Indeed,	a	series	of	compounds	have	been	identified	that	bind	gp120	glycoproteins	on	the	envelope	of	HIV-1	and	block	the	entry	of	HIV-1	virus	particles	(Si	et	al.,	2004).			The	role	of	HS	as	an	adhesion	receptor	for	several	bacteria,	parasites	and	viruses	has	been	studied	for	more	than	two	decades	(Rostand	&	Esko,	1997;	Wadstrom	&	Ljungh,	1999).	Extensive	research	carried	out	over	the	years	has	established	a	role	for	cell	surface	HS	in	the	infections	of	at	least	19	different	viruses	(Liu	&	Thorp,	2002;	Zhu	et	al.,	2011).	A	large	body	of	data	suggests	that	viruses	interact	with	HS	to	facilitate	their	binding	to	specific	cell	surface	receptors	(Chung	et	al.,	1998;	
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Hsiao	et	al.,	1999;	Lin	et	al.,	2000;	Shieh,	Wudunn,	Montgomery,	Esko,	&	Spear,	1992;	Shukla	et	al.,	1999;	Tyagi,	Rusnati,	Presta,	&	Giacca,	2001).	Furthermore,	the	foot	and	mouth	disease	and	HSV-1	viruses	have	been	shown	to	infect	target	cells	via	interaction	with	cell	surface	HS,	even	in	the	absence	of	known	protein	receptors	on	the	target	cells	(Jackson	et	al.,	1996;	Spear,	Eisenberg,	&	Cohen,	2000).	All	these	findings,	including	the	results	presented	in	this	thesis	thus	far,	collectively	indicate	that	there	is	an	intimate	relationship	between	the	structure	of	HS	polysaccharides	and	their	activity	in	promoting	viral	infections.			So	far,	the	research	focus	of	this	thesis	has	been	to	develop	an	understanding	of	the	key	structural	features	of	cell	surface	HS	required	for	VACV	infections.	Results	presented	in	Chapters	4	and	5	convincingly	show	that	small	molecules,	based	on	the	HS	polysaccharide	structure,	are	able	to	inhibit	VACV	infections,	the	EV	form	of	VACV	being	particularly	susceptible	to	inhibition.	However,	to	fully	understand	the	process	of	heparin/HS	mediated	VACV	inhibition,	it	was	important	to	identify	the	proteins(s)	on	the	surface	of	VACV	responsible	for	such	interactions.	Therefore,	the	specific	aim	of	this	Chapter	was	to	identify	the	protein(s)	in	the	outer	EV	envelope	responsible	for	the	interaction	with	cell	surface	HS.	In	order	to	achieve	this,	EV	particles	were	first	purified	and	the	VACV	membrane	proteins	extracted	using	mild	detergents.		The	proteins	were	visualized	by	Western	blotting	using	polyclonal	VACV	specific	antibodies.	The	extracted	proteins	were	also	subjected	to	mass	spectrometry	(MS)	analysis	for	further	identification.	A	bioinformatics	based	search	was	also	conducted	to	identify	HS	binding	domains	in	proteins	expressed	by	VACV	particles.	
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6.3	Results	
6.3.1	Purification	of	the	EV	and	MV	forms	of	VACV	from	the	IHD-J	strain	and	
extraction	of	membrane	proteins		Much	of	the	research	on	VACV	infections	in	the	past	has	focused	on	the	MV	form	of	VACV,	as	this	form	of	the	virus	is	relatively	easy	to	purify	and	study.	Indeed,	several	studies	have	already	identified	key	proteins	on	the	surface	of	the	MV	form	that	interact	with	cell	surface	HS	(Chung	et	al.,	1998;	Lin	et	al.,	2000)	and	CS	(Hsiao	et	al.,	1999).	However,	the	results	presented	in	previous	Chapters	suggest	that	heparin	and	other	highly	sulfated	molecules	based	on	the	HS	polysaccharide	structure	are	unable	to	have	a	significant	inhibitory	effect	on	MV	infectivity,	compared	with	EV	infectivity,	where	heparin	acts	as	a	much	more	potent	inhibitor.			The	EV	form	of	VACV	has	a	fragile	outer	membrane	around	the	virus	particle	(Figure	3.5),	which	makes	it	difficult	to	purify	intact	EV	particles	for	investigation.	The	EV	form	of	VACV	may	only	represent	a	fraction	of	the	total	VACV	infection,	however,	it	is	extremely	important	biologically	as	this	form	of	VACV	is	responsible	for	long	range	dissemination	of	the	virus	in	cell	cultures	and	in	vivo	(Appleyard.G,	Hapel,	&	Boulter,	1971;	Payne,	1980;	Payne	&	Kristensson,	1985).	Therefore,	it	is	important	to	characterize	the	receptors	on	the	surface	of	the	outer	envelope	of	the	EV	particles	that	are	involved	in	interacting	with	HS	molecules	during	an	infection.	Some	studies	undertaken	previously	have	demonstrated	that	the	A34R	(24-28	kDa)	and	B5R	(42	kDa)	glycoproteins	on	EV	particles	initiate	the	dissolution	process	of	the	outer	membrane	of	EV	particles	upon	contact	with	sulfated	
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Figure	6.1:	Flow	chart	depicting	the	multi-step	process	used	to	obtain	EV	and	
MV	membrane	proteins.	BHK-21	cells	were	infected	with	VACV-IHD-J	at	a	MOI	of	0.1.	The	culture	medium	over	the	infected	monolayers	(containing	EV	particles)	was	gently	aspirated	and	centrifuged	at	230xg	for	10	min	to	remove	any	cell	debris.	The	EV	containing	culture	medium	was	further	centrifuged	at	18,000xg	for	1	hr	to	pellet	EV	particles	and	resuspended	in	Tris-HCl	buffer.	In	parallel,	adherent	cells	(containing	MV	particles)	were	released	by	scraping	the	surface	of	the	flask,	centrifuged	at	1800xg	for	5	min	to	pellet	cells	and	resuspended	in	Tris-HCl	buffer.	Cells	were	transferred	to	a	dounce	homogenizer	where	they	were	homogenized	with	40	strokes	to	release	MV	particles.	Once	homogenized,	the	cells	were	centrifuged	at	300xg	for	5	min	to	remove	any	nuclei	and	other	debris.	The	supernatant	containing	MV	particles	was	further	centrifuged	at	32,000xg	for	1	hr	to	pellet	MV	particles	and	resuspended	in	Tris-HCl.	Both	MV	and	EV	fractions	were	detergent	treated	using	a	cocktail	of	Brij-58,	β-mercaptoethanol	and	complete	protease	inhibitors,	to	release	membrane	proteins.	The	treated	fractions	of	MV	and	EV	particles	were	subsequently	loaded	on	a	caesium	chloride	(CsCl)	gradient	and	centrifuged	at	154,000xg	for	30	min	to	separate	solubilized	outer	membrane	proteins	from	virus	cores.	The	solubilized	membrane	proteins	from	MV	and	EV	were	carefully	removed	using	a	29-gauge	needle	and	syringe	and	transferred	to	respective	10	kDa	cutoff	ultrafiltration	tubes.	The	ultrafiltration	tubes	were	centrifuged	at	3,200xg	for	10	min	to	remove	traces	of	CsCl	from	MV	and	EV	membrane	proteins.	Once	purified,	MV	and	EV	membrane	proteins	were	transferred	to	respective	1.5	mL	tubes.	
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polyanions	(Law	et	al.,	2006).	However,	assays	reported	herein	strongly	indicate	that	soluble	heparin,	or	other	highly	sulfated	HS	structure-based	small	molecules,	inhibit	EV	particles	from	infecting	cells	in	vitro,	possibly	by	inhibiting	virus	particles	from	interacting	with	cell	surface	HS.	It	is	worth	noting	that	results	published	by	Law	et	al.,	were	mainly	obtained	using	plaque	assays	performed	in	the	presence	of	MV	neutralizing	antibodies,	whereas	the	results	presented	in	this	thesis	have	been	obtained	using	a	novel	FACS	based	virus	entry	assay	which	detects	early	events	in	a	VACV	infection.	The	results	presented	in	earlier	Chapters	strongly	indicate	that	heparin,	at	least	very	early	during	infection,	inhibits	EV	infectivity	by	potentially	interfering	with	the	virus/cell-surface	HS	interaction.	It	is	likely	that	later	on	in	the	infection	process	the	viral	glycoproteins	A34R	and	B5R	play	a	role	in	the	dissolution	of	the	outer	EV	envelope	to	initiate	virus	entry	into	cells.	Therefore,	it	was	important	to	determine	protein(s)	on	the	surface	of	the	EV	form	of	VACV	that	bind	heparin	and	could	be	potentially	blocked	in	the	presence	of	soluble	heparin.			As	a	first	step	towards	the	identification	of	protein(s)	on	the	surface	of	EV	that	interact	with	HS,	the	IHD-J	strain	of	VACV	was	cultured	as	described	in	Chapter	2	to	obtain	high	concentrations	of	the	intact	EV	form	of	the	virus.	This	was	followed	by	gentle	detergent	treatment	of	both	EV	and	MV	particles	to	release	proteins	in	the	membranes	of	the	two	forms	of	VACV	as	also	described	in	detail	in	Chapter	2.	The	process	used	for	EV	and	MV	purification,	followed	by	protein	extraction,	is	summarized	in	Figure	6.1.	
	
	
		 161	
6.3.2	SDS-PAGE	and	Western	blotting	of	VACV	membrane	proteins	The	extracted	and	concentrated	EV	and	MV	membrane	proteins	were	visualized	using	Western	blotting.	However,	prior	to	SDS	denaturation,	both	EV	and	MV	membrane	protein	extracts	were	pre-incubated	overnight	with	heparin-Sepharose	6	fast	flow	beads	to	separate	and	enrich	heparin-interacting	membrane	proteins	from	the	rest	of	the	mixture,	as	described	in	section	2.2.6.	The	‘bound’	fraction	represents	membrane	proteins	from	the	MV	and	EV	extracts	that	interact	with	and	bind	to	the	heparin-Sepharose	beads,	whereas	the	‘unbound’	fraction	represents	proteins	in	the	MV	and	EV	extracts	that	did	not	interact	with	the	heparin-Sepharose	beads.	The	‘crude’	fraction	represents	the	total	protein	mixture	extracted	from	both	EV	and	MV	forms	of	VACV.	All	the	three	fractions	were	subjected	to	SDS-PAGE	and	Western	blotting,	with	the	VACV	proteins	being	detected	using	various	antibodies.			The	use	of	polyclonal	anti-VACV	antibodies	revealed	several	VACV	membrane	proteins	that	interacted	with	heparin	coupled	Sepharose	beads	(Figure	6.2A).	Several	proteins	appeared	in	both	the	‘bound’	and	‘unbound’	lanes	of	the	SDS-PAGE	gel	(an	example	highlighted	by	purple	arrows	in	Figure	6.2A).	It	is	likely	that	the	proteins	appearing	in	both	‘bound’	and	‘unbound’	fractions	may,	in	fact,	be	proteins	associated	with	other	heparin	binding	proteins	and,	consequently,	co-purifying	as	a	result	of	incomplete	solubilization	of	VACV	particles.	Another	explanation	for	this	observation	could	be	that	the	proteins	bind	weakly	to	heparin-Sepharose	beads.	Saturation	of	binding	sites	on	heparin-Sepharose	beads	may	also	result	in	some	proteins	appearing	in	‘bound’	and	‘unbound’	fractions,	however,	this	
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possibility	is	unlikely	as	the	binding	capacity	of	heparin-Sepharose	beads	is	extremely	high.			There	were	at	least	4	striking	protein	bands	of	interest	that	appeared	on	the	blots	(highlighted	with	red,	yellow,	blue	and	green	arrows	in	Figure	6.2).	The	150	kDa	band	(red	arrows)	appeared	to	be	present	in	‘bound’	fractions,	but	was	depleted	from	the	‘unbound’	fractions.	The	same	150	kDa	band	was	less	intense	in	the	‘crude’	fractions	compared	to	the	respective	‘bound’	fractions.	Furthermore,	it	is	worth	noting	that	this	band	appeared	to	be	more	intense	in	the	MV	membrane	protein	extracts	compared	to	the	EV	membrane	protein	extracts,	despite	many	other	protein	bands	being	of	similar	intensity	in	the	‘crude’	extracts	from	both	EV	and	MV.	Hence,	it	would	be	safe	to	presume	that	the	overall	concentration	of	proteins	extracted	from	the	MV	and	EV	particles	was	relatively	similar	and,	therefore,	differences	in	the	intensity	of	the	150	kDa	band	in	the	‘crude’	MV	extracts	compared	to	the	‘crude’	EV	extracts	cannot	be	explained	by	there	being	differences	in	protein	concentration.	It	is	worth	highlighting	that	the	relative	volumes	of	material	‘bound’	and	eluted	from	the	beads	compared	to	the	‘unbound’	crude	mixtures	was	kept	the	same	(i.e.,	100	μL),	to	ensure	that	there	were	no	dilution	effects.			The	second	interesting	band	was	an	85	kDa	protein	band	(highlighted	with	yellow	arrows	in	Figure	6.2A).	Similar	to	the	150	kDa	band,	the	85	kDa	band	appeared	to	be	present	in	the	‘bound’	EV	fraction	but	was	depleted	from	the	‘unbound’	fraction,	indicating	that	this	protein	bound	strongly	to	heparin-	Sepharose	beads.	A	band	of	similar	molecular	weight	also	appeared	in	the	MV	extract	but	the	band	was	not	
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fully	depleted	in	the	‘unbound’	MV	fraction.	However,	since	a	polyclonal	antibody	was	used	to	detect	VACV	proteins,	it	is	possible	that	there	were	multiple	85	kDa	MV	proteins	being	detected	by	the	antibody.	Nevertheless,	it	seemed	unlikely	that	this	85	kDa	protein	was,	in	fact,	the	VACV	hemagglutinin	(HA)	(A56R	protein),	a	key	component	of	the	EV	outer	envelope.	Molecular	characterization	of	VACV	HA	revealed	that	the	glycoprotein	is	present	in	two	distinct	forms,	an	85	kDa	form	that	appears	very	early	during	infection	and	continues	to	accumulate	throughout	the	infection,	and	a	smaller	68	kDa	form	which	only	appears	late	during	the	infection	cycle	(Brown,	Turner,	&	Moyer,	1991).	However,	identifying	the	HA	using	a	VACV	HA	(A56R)-specific	mAb	revealed	that	there	was	very	little,	if	any,	HA	in	the	EV	protein	extract	and	heparin-binding	fractions	(Figure	6.2B).	In	contrast,	the	A56R	VACV	HA	appeared	to	be	abundant	in	the	MV	protein	extract	and	fractions	(green	arrows	in	Figure	6.2B).	The	‘crude’	MV	protein	extract	yielded	the	most	intense	band,	whereas	the	‘bound’	fraction	contained	the	least	intense	band,	suggesting	that	VACV	HA	binds	weakly	to	heparin-Sepharose	beads.	Most	of	the	VACV	HA	did	not	bind	to	heparin-Sepharose	beads	and,	therefore,	appeared	as	an	intense	band	in	the	‘unbound’	fraction.	Based	on	the	Western	blotting	results	obtained	using	the	HA-specific	mAb,	it	can	be	concluded	that	the	85	kDa	heparin	binding	EV	protein	detected	using	the	polyclonal	VACV	antiserum	(yellow	arrows	in	Figure	6.2A)	is	not	the	VACV	HA.					A	60	kDa	protein	band	was	also	detected	(purple	arrows	in	Figure	6.2A),	being	more	abundant	in	the	EV	than	the	MV	extract	and	appearing	in	both	the	‘bound’	and	‘unbound’	fractions,	implying	that	the	protein	binds	weakly	to	heparin	or	
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Figure	6.2:	Visualization	of	EV	and	MV	membrane	proteins	using	Western	
blotting.	The	membrane	proteins	extracted	from	the	EV	and	MV	forms	of	VACV	using	gentle	detergent	treatments	(‘crude’	extracts)	were	run	on	SDS-PAGE	along	with	extracted	membrane	proteins	that	bound	(‘bound’	fractions)	or	did	not	bind	(‘unbound’	fractions)	to	heparin-Sepharose	beads,	and	Western	blotted	using	VACV	specific	antibodies.	(A)	Proteins	on	a	nitrocellulose	membrane	detected	using	rabbit	anti-VACV	polyclonal	antibodies.	The	red	arrows	indicate	a	150	kDa	protein	that	is	present	in	crude	EV	and	MV	protein	extracts	and	is	enriched	(darker	band)	in	fractions	binding	to	heparin-Sepharose	beads,	the	150	kDa	band	being	depleted	in	the	‘unbound’	fractions	of	both	EV	and	MV	protein	extracts.	Yellow	arrows	indicate	an	85	kDa	protein	in	EV	extracts	that	binds	to	heparin,	and	is	depleted	in	the	‘unbound’	EV	fraction.	Purple	arrows	indicate	an	~60	kDa	protein	that	appears	in	approximately	similar	amounts	in	both	the	‘bound’	and	‘unbound’	fractions	of	EV	and	MV	proteins.	The	blue	arrows	identify	a	25	kDa	protein	in	the	EV	extract	that	is	also	a	heparin-binding	protein.	Thus,	similar	to	the	150	kDa	band,	the	25	kDa	band	is	depleted	in	the	‘unbound’	EV	protein	fraction.	(B)	An	anti-A56R	mAb	was	used	to	determine	if	the	A56R	protein	(VACV	A56R)	interacts	with	heparin,	only	the	85	kDa	form	of	A56R	being	detected	using	this	mAb.	The	“Control”	lanes	in	both	blots	represent	the	protein	extracted	from	uninfected	cells.	 	
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associates	with	a	heparin-binding	protein.	Also,	there	may	be	multiple	VACV	proteins	in	this	region	of	the	SDS-PAGE	gel.		Both	MV	and	EV	derived	proteins	of	<50	kDa	appeared	as	faint	smears	on	the	blots	and	appeared	in	both	the	heparin-Sepharose	‘bound’	and	‘unbound’	fractions.	However,	from	previously	published	studies,	the	proteins	in	the	smear	would	likely	include	the	42	kDa	trans-membrane	and	35	kDa	secreted	form	of	B5R	(Martinez-Pomares,	Stern,	&	Moyer,	1993),	the	24-28	kDa	A34R	(Duncan	&	Smith,	1992),	the	35	kDa	H3L	(Lin	et	al.,	2000)	and,	possibly,	some	other	proteins	that	are	thought	to	interact	with	heparin.	Of	course,	interpretation	of	these	data	is	difficult	as	many	proteins	may	not	be	directly	heparin	binding	but	forming	muti-molecular	complexes	with	heparin	binding	proteins.	Despite	this	complexity,	a	25	kDa	band	was	observed	in	the	EV	extract	that	bound	to	heparin	(highlighted	with	blue	arrows	in	Figure	6.2A).	Unlike	the	150	kDa	and	85	kDa	bands,	the	25	kDa	band	was	not	as	discrete,	but	was	fully	depleted	in	the	‘unbound’	EV	fraction,	indicating	that	this	protein	may	also	be	another	heparin	binding	protein.	It	is	possible	that	this	25	kDa	protein	is	also	present	in	the	MV	extract,	however,	the	band	is	extremely	faint	and	appears	as	a	smear.		Nevertheless,	since	the	150	kDa	protein	(red	arrows),	the	85	kDa	(yellow	arrows),	the	60	kDa	(purple	arrows)	and	the	25	kDa	protein	(blue	arrows)	from	EV	protein	extracts	all	appear	to	strongly	interact	with	heparin,	these	four	proteins	were	considered	likely	candidates	to	be	on	the	surface	of	the	EV	envelope	and	be	targets	of	heparin	mediated	inhibition	of	infection	in	vitro.	Furthermore,	it	is	possible	that	there	are	more	heparin-binding	proteins	on	the	EV	envelope	that	may	not	have	
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been	detected	on	the	blots	using	the	polyclonal	anti-VACV	antibodies.	Therefore,	to	further	identify	the	EV	protein(s)	that	appeared	to	be	heparin	binding	via	Western	blotting	and	detect	additional	proteins	on	the	surface	of	the	EV	envelope	that	could	potentially	interact	with	heparin	or	cell	surface	HS,	a	bioinformatics	search	approach	was	embarked	upon.	
	
6.3.3	Identification	of	HS	binding	EV	proteins	using	a	bioinformatics	
approach			There	are	two	known	HS	binding	proteins	on	the	outer	membrane	of	the	MV	form	of	VACV,	namely	the	A27L	(14	kDa)	and	the	H3L	(37.5	kDa)	proteins	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	Furthermore,	K2	(42.2	kDa),	a	serine	protease	inhibitor	(SPI)-3	found	on	the	surface	of	EV	virus	particles,	has	been	shown	to	have	heparin	binding	sites	(Brum	et	al.,	2003;	DeHaven	et	al.,	2011).	The	K2	protein	also	forms	a	complex	with	the	A56R	protein	of	VACV.	To	identify	protein(s)	on	the	outer	membrane	of	EV	particles	that	may	interact	with	cell	surface	HS,	a	bioinformatic	approach	was	undertaken	to	search	for	characteristic	HS	binding	domains	within	all	VACV	proteins.	Mr.	Cameron	Jack,	a	bioinformatician	at	the	Genome	Discovery	Unit,	ANU,	initially	characterized	the	amino	acid	sequences	of	known	HS	binding	proteins	by	calculating	the	net	positive	charge	of	their	HS	binding	motifs.	The	two	HS	binding	motif	templates	used	were	XBBXBX	and	XBXXXXBX,	where	X	is	an	uncharged	residue	and	B	is	a	basic	amino	acid.	These	two	motifs	were	added	to	previously	known	HS	binding	motifs	(Hileman,	Fromm,	Weiler,	&	Linhardt,	1998).	The	HS	binding	motif	of	VACV	protein	H3L	has	a	net	charge	of	+3,	A27L	has	a	net	charge	of	+4	and	K2	has	a	net	charge	of	+4.	Since	A56R	exists	as	a	complex	with	K2,	the	net	charge	of	A56R	(+5)	was	also	determined.	
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Based	on	the	net	charge	information,	custom	designed	python	scripts	were	developed	and	used	in	Multiple	Em	for	Motif	Elicitation	(MEME)	(Bailey	&	Elkan,	1994)	to	restrict	search	results	for	protein	sequences	consisting	of	<300	residues	and	>900	residues.	This	was	done	to	narrow	the	search	results	to	proteins	between	80	kDa	and	150	kDa.			An	attempt	to	improve	detection	through	sequence	similarity	was	made	by	using	sequence	“spike-ins”	from	known	HS	binding	VACV	proteins	(K2	(accession	#:	YP_232915.1);	H3L	(accession	#:	YP_232983.1);	A27L	(accession	#:	YP_233032.1)),	and	VACV	HA	(accession	#:	YP_233063.1),	to	deliberately	bias	output	to	include	HS	binding	regions.	As	a	result	nucleoside	triphosphatase	I	(72	kDa	DNA	dependent	ATPase;	accession	#:	YP_232998.1)	appeared	in	the	search	results.	This	search	result	was	of	a	particular	interest,	as	this	does	not	have	any	known	functional	association	with	heparin/HS.	However,	since	the	triphosphatase	must	bind	to	ssDNA	to	exhibit	its	ATPase	activity	and	that	DNA	is	negatively	charged	like	heparin,	it	is	likely	that	the	triphosphatase	has	sequence	similarities	to	heparin	binding	proteins.			Some	of	the	other	search	results	included	three	different	IL-1	receptor	antagonists	(accession	#:	YP_233091.1,	YP_232892.1	and	YP_232906.1).	It	is	known	that	VACV	encodes	IL-1	receptor	antagonists	that	interfere	with	the	host	immune	response	by	blocking	IL-1	(Alcami	&	Smith,	1992).	This	is	an	interesting	finding,	however,	viruses	generally	secrete	IL-1	receptor	antagonists	to	block	IL-1	receptors	and	evade	detection.	Therefore,	it	is	unlikely	that	a	soluble	IL-1	receptor	antagonist	would	inhibit	EV	infectivity	when	in	contact	with	heparin.		
		 169	
Based	on	this	argument	the	above	search	results	were	removed	and	MEME	was	subsequently	re-run,	this	time	with	widened	parameters	to	include	shorter	protein	sequences	from	100	residues	upwards	(to	900	residues	maximum),	leaving	in	place	true	positives	and	removing	known	false	positives.	The	output	appeared	biased	towards	these	newly	introduced	low	molecular	weight	proteins	but	did	not	return	any	expected	motifs.		Restricting	the	protein	search	list	to	higher	molecular	weight	VACV	proteins	(implying	less	post-translational	modifications)	was	more	productive.	Proteins	consisting	of	<450	amino	acid	residues	in	length	were	removed	from	the	search	list.	These	modified	scripts,	when	run	again	on	MEME,	identified	the	65	kDa	VACV	ankyrin/F-box	B4R	protein	(accession	#:	Y233068.1)	as	containing	a	possible	HS-binding	motif	(residues:	KHRWHNA)	with	a	net	positive	charge	of	+4,	placing	it	firmly	in	the	range	of	likely	candidate	sites.	Another	protein	that	was	identified	based	on	this	modified	search	was	the	77.6	kDa	RNA	helicase	DExH-NPH-II	domain	(accession	#:	YP_232959.1)	with	a	net	positive	charge	of	+4	(residues:	KHKQHNA).		Since	MEME	uses	the	residue	frequencies	of	the	supplied	sequences	as	the	control	for	calculating	relative	entropy	scores	(Bailey	&	Elkan,	1994)	for	short	sequence	lists,	there	is	always	potential	for	random	positives.	For	instance,	a	protein	hit	containing	one	or	more	‘discovered	motifs’	may	in	fact	be	a	protein	with	well-characterized	functions	and	therefore	may	not	be	the	protein	of	interest.	However,	it	is	well	known	that	viruses	continue	to	evolve	to	produce	viral	proteins	which	can	perform	multiple	functions	(Hasiow-Jaroszewska,	Fares,	&	Elena,	2014).	Therefore,	the	‘positive’	hits	obtained	from	such	a	BLAST	search	cannot	be	
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disregarded	as	false	positive	hits	just	because	the	identified	proteins	have	another	well-characterized	function.	The	bioinformatic	search	for	HS-binding	EV	membrane	proteins	was	informative,	nevertheless,	the	150	kDa	protein	(red	arrows	in	Figure	6.2A)	and	the	85	kDa	protein	(yellow	arrows	in	Figure	6.2A)	observed	in	Western	blotting	analysis	of	EV	membrane	proteins	could	not	be	identified	using	this	approach.		
6.3.4	The	use	of	1D	nanoLC	ESI	MS/MS	to	identify	EV	proteins	that	interact	
with	heparin/HS	The	bioinformatics	search	performed	as	part	of	the	identification	process	of	heparin/HS	interacting	EV	membrane	protein(s),	identified	several	protein	hits	with	possible	heparin	binding	domains.	However,	the	150	kDa	protein	(red	arrows	in	Figure	6.2A)	observed	on	Western	blots	developed	using	a	polyclonal	anti-VACV	antiserum,	could	not	clearly	be	identified	using	a	bioinformatic	approach.	Therefore,	the	~150	kDa	protein	band	was	excised	from	a	freshly	run	SDS-PAGE	gel	and	sent	to	the	Australian	Proteome	Analysis	Facility	(APAF)	where	a	team	led	by	Dr.	Xiaomin	Song	performed	1D	nano-scale	liquid	chromatography	electrospray	ionization	tandem	mass	spectrometry	(1D	nanoLC	ESI	MS/MS)	on	the	protein	sample.	Unfortunately,	due	to	time	restrictions,	the	85	kDa	band	(yellow	arrows	in	Figure	6.2A)	and	the	25	kDa	band	(blue	arrows	in	Figure	6.2A)	could	not	analyzed	using	1D	nanoLC	ESI	MS/MS	prior	to	thesis	submission.			The	ESI	MS/MS	technique	of	identifying	peptides	in	protease	digested	complex	mixtures	of	proteins	is	very	well	established.	Coupling	of	liquid	chromatography	to	electrospray	ionization	mass	spectrometry	allows	for	highly	efficient	identification	
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of	peptides	and	increased	sample	throughput	(Yang	et	al.,	2007).	The	proteins	containing	peptide	hits	obtained	from	this	analysis	of	the	~150	kDa	protein	band	are	presented	in	Table	6.1.	An	encouraging	aspect	of	the	APAF	output	was	that	all	of	the	high	scoring	hits	detected	were	poxvirus-specific.	This	indicates	that	the	VACV	extracts	were	of	high	purity	and	were	not	contaminated	with	proteins	derived	from	the	cell	line,	which	the	two	VACV	forms	were	cultured	in.			Similar	to	the	bioinformatic	searches,	proteins	with	well-characterized	functions	appeared	to	have	significant	sequence	similarity	to	the	150	kDa	unidentified	protein.	A	simple	BLAST	search	of	the	147	kDa	DNA	directed	RNA	polymerase	(third	hit	in	Table	6.1)	to	identify	other	proteins	with	sequence	similarity	to	the	RNA	polymerase	yielded	interesting	findings.	The	VACV	F12	polypeptide	appeared	to	have	97%	sequence	similarity	to	the	polymerase,	with	the	expect	value	(E)	being	8	x	10-3.	A	very	low	E	value	represents	a	very	highly	significant	match.	VACV	F12	is	a	65	kDa	protein	that	is	involved	in	export	of	newly	formed	virions	from	the	virus	factories	to	the	cell	periphery	via	microtubules	using	kinesin-1	(Zhang,	Wilcock,	&	Smith,	2000).	Also,	it	should	be	noted	that	a	~60	kDa	band,	which	could	be	the	F12	protein,	was	identified	by	Western	blotting	in	approximately	similar	amounts	in	the	‘bound’	and	‘unbound’	heparin-Sepharose	fractions	for	both	EV	and	MV	extracts	(Figure	6.2A)	although,	if	so,	F12	appears	to	have	a	low	affinity	for	heparin.	
	The	mass	spectrometry	search	also	identified	two	VACV	core	proteins	P4a	(60	kDa)	and	P4b	(62	kDa),	as	possible	heparin-binding	proteins.	Both	proteins	localize	to	viral	factories	and	are	responsible	for	organization	of	the	viral	core	and	
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Table	6.1:	List	of	protein	hits	from	1D	nanoLC	ESI	MS/MS	analysis	of	the	150	
kDa	unidentified	protein.	
	
Proteins	identified	 Accession	#:	 Score†	 Sequences	matched*	
DNA	directed	RNA	polymerase	132	kDa	peptide	(Cowpox	virus)	 NP_619941.1	 1436	 26	DNA	directed	RNA	polymerase	147	kDa	peptide	(Variola	virus)	 ABG44469.1	 254	 7	DNA	directed	RNA	polymerase	147	kDa	peptide	(Vaccinia	virus)	 AAB96506.1	 223	 7	
Major	core	protein	4b	(Vaccinia	virus)	 AAA48118.1	 103	 2	
Major	core	protein	4a	(Vaccinia	virus)	 AAA48129.1	 72	 1	
	
†Ion	score	is	-10*Log(p),	where	P	is	the	probability	that	the	observed	match	is	a	random	event.	Individual	ion	scores	>	27	indicate	identity	or	extensive	homology	(p<0.05).	Protein	scores	are	derived	from	ions	scores	as	a	non-probabilistic	basis	for	ranking	protein	hits.		 *Number	of	peptide	sequences	identified.	
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DNA	encapsulation	(Heljasvaara	et	al.,	2001;	Resch,	Hixson,	Moore,	Lipton,	&	Moss,	2007).	As	described	earlier,	it	is	likely	that	these	core	proteins	that	interact	with	DNA	were	co-purified	with	the	membrane	proteins.		Furthermore,	since	many	heparin-binding	proteins	interact	with	negatively	charged	DNA,	it	is	likely	that	this	is	the	reason	why	DNA	interacting	proteins	appear	in	the	search	to	identify	heparin-binding	proteins.				
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6.4	Discussion	There	is	substantial	evidence	suggesting	that	viruses	can	interact	with	and	recognize	a	wide	spectrum	of	cell	surface	molecules	including	glycoproteins,	glycolipids	and	proteoglycans.	Results	presented	in	this	thesis,	along	with	previously	published	studies,	indicate	that	cell	surface	HS	plays	an	important	role	in	VACV	infections	(Chung	et	al.,	1998;	Hsiao	et	al.,	1999;	Lin	et	al.,	2000).	There	are	at	least	two	proteins	on	the	surface	of	MV	that	have	previously	been	shown	to	interact	with	heparin/HS	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	However,	since	it	has	already	been	established	in	previous	Chapters	that	the	EV	form	of	VACV	is	much	more	highly	dependent	on	cell	surface	HS	for	infectivity	than	the	MV	form,	it	was	important	to	identify	protein(s)	on	the	surface	of	EV	that	interact	with	heparin/HS.		Membrane	proteins	from	both	MV	and	EV	particles	were	extracted	by	following	a	multi-step	extraction	procedure	(Figure	6.1).	Once	isolated,	the	proteins	were	incubated	with	heparin-coupled	beads	to	separate	heparin	interacting	VACV	proteins	from	the	rest	of	the	protein	mixture.	Detection	of	VACV	proteins	by	Western	blotting	using	a	polyclonal	VACV	antiserum,	which	should	react	with	most	VACV	proteins,	revealed	at	least	four	different	heparin-binding	proteins	of	150	kDa,	85	kDa,	60	kDa	and	25	kDa	(Figure	6.2A),	the	85	kDa	and	25	kDa	proteins	appearing	to	be	EV	specific.			MS	analysis	of	the	150	kDa	band	identified	the	147	kDa	DNA	directed	RNA	polymerase	from	3	different	poxvirus	species,	all	with	a	very	high	expect	score.	Viruses	do	pack	a	high	number	of	multifunctional	proteins,	however,	it	is	highly	
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unlikely	that	a	RNA	polymerase	is	present	on	the	outer	EV	envelope.	It	is	possible	that	the	heparin-binding	site	of	the	147	kDa	RNA	polymerase	could	be	the	site	where	RNA	binds	to	the	polymerase	as	RNA,	like	heparin,	is	also	negatively	charged.	Furthermore,	several	DNA/RNA	interacting	proteins	have	been	shown	to	be	heparin-binding	as	well	(Gadgil	&	Jarrett,	1999).	Nevertheless,	a	BLAST	search	performed	on	the	RNA	polymerase	from	VACV	to	identify	other	proteins	similar	in	sequence	to	that	of	the	polymerase	discovered	a	65	kDa	VACV	F12	protein.	An	extremely	low	expect	value	of	8	x	10-3	suggests	a	strong	sequence	similarity	between	the	polymerase	and	the	F12	protein.	VACV	F12	has	previously	been	shown	to	participate	in	the	export	of	newly	formed	MV	particles	from	the	virus	factories	to	the	cell	periphery.	A	mutant	virus	lacking	F12	produces	smaller	plaques	(Zhang	et	al.,	2000)	and	F12	has	been	shown	to	interact	with	and	form	a	complex	with	VACV	E2	and	A36,	both	of	which	contribute	towards	the	transportation	of	virions	to	the	cell	surface	(Morgan	et	al.,	2010).			A	bioinformatics	search	approach	was	also	used	to	identify	possible	VACV	heparin-binding	proteins,	however,	neither	the	147	kDa	DNA	directed	RNA	polymerase,	nor	the	65	kDa	F12	protein	could	be	detected	by	the	bioinformatics	approach.	Both	the	bioinformatics	approach	and	SDS-PAGE	separation	followed	by	MS/MS	are	excellent	tools	that	are	widely	used	in	the	field	of	proteomics,	however,	interpreting	interactions	of	proteins	with	other	molecules	in	3D	space	based	on	the	results	from	these	two	techniques	may	not	be	as	informative.	It	is	plausible	that	the	147	kDa	DNA	directed	RNA	polymerase	and	the	65	kDa	F12	protein	are	heparin	binding	in	their	tertiary	conformation,	however,	the	primary	amino	acid	sequence	of	both	proteins	may	not	have	obvious	HS	binding	motifs,	which	would	
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explain	why	both	molecules	were	not	identified	in	the	bioinformatic	searches.	Furthermore,	a	weakly	heparin	binding	protein	of	similar	molecular	weight	to	F12	was	detected	by	Western	blotting	(Figure	6.2A).	Therefore,	in	order	to	determine	if	F12	is	indeed	a	heparin	binding	protein,	Western	blotting	analysis	using	a	F12-specific	mAb	followed	by	MS	analysis,	would	be	required.			The	85	kDa	protein	of	interest	resulting	from	the	Western	blotting	experiments	(Figure	6.2A)	was	initially	believed	to	be	the	VACV	HA,	also	known	as	VACV	A56R.	The	use	of	a	VACV	HA-specific	mAb	revealed,	however,	that	the	85	kDa	heparin-binding	protein	(Figure	6.2A)	was,	in	fact,	not	the	85	kDa	HA	(Figure	6.2B).	Indeed,	there	was	little	HA	in	the	EV	protein	extract	and	heparin-Sepharose	fractions	compared	to	the	MV	extract	and	fractions	where	the	HA	was	abundant.	Furthermore,	the	MV	derived	VACV	HA	detected	by	a	HA-specific	mAb	was	observed	to	interact	very	weakly	with	heparin-coupled	beads	as	most	of	the	85	kDa	HA	appeared	in	the	‘unbound’	fraction.			The	bioinformatics	searches	did	identify	three	VACV	proteins	with	potentially	strong	heparin/HS	binding	sequences,	the	strongest	hits	being	the	VACV	IL-1	receptor	antagonist.	Many	viruses	have	been	shown	to	have	elegant	methods	to	avoid	detection	by	the	immune	system	by	mimicking	cytokines	and	chemokine	receptors,	a	mechanism	that	has	been	extensively	studied	(Alcami,	2003).	Indeed,	structural	studies	performed	in	the	past	have	shown	that	IL-1	has	a	heparin	binding	sites,	such	that	heparin/HS	molecules	are	able	to	regulate	the	synthesis	of	IL-1	(Chowers	et	al.,	2001).	However,	interaction	between	the	VACV	the	IL-1	receptor	antagonist	and	HS	is	unlikely	to	have	a	role	in	EV	infectivity	as	the	
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receptor	antagonist	is	released	from	infected	cells	and	does	not	associate	with	the	virus	particle	itself.			The	second	protein	identified	by	the	bioinformatic	searches	with	a	possible	HS-binding	motif	was	the	65	kDa	VACV	ankyrin/F-box	protein,	B4R.	There	is	little	known	about	the	VACV	B4R	protein	in	the	literature.	Some	recent	studies	have	demonstrated	that	mutant	viruses	lacking	B4R	form	both	MV	and	EV	forms	of	VACV	just	like	the	wild	type	VACV,	however,	plaque	sizes	are	reduced	considerably	with	a	decreased	ability	of	the	virus	to	spread	(Burles	et	al.,	2014).	Furthermore,	there	is	an	unknown	~60	kDa	protein	detected	by	Western	blotting	that	weakly	binds	to	heparin-Sepharose,	which	could	be	a	candidate	B4R	protein	(Figure	6.2A).	Therefore,	it	is	possible	that	B4R	could	be	playing	a	role	in	the	interaction	of	heparin/HS	with	EV,	however,	the	unavailability	of	a	B4R	specific	mAb	meant	that	this	hypothesis	could	not	be	directly	tested.		The	third	protein	identified	by	the	bioinformatic	searches	with	a	possible	HS-binding	motif	within	the	77.6	kDa	RNA	helicase	DExH-NPH-II	domain.	The	helicase	superfamily	is	a	class	of	enzymes	involved	in	almost	every	aspect	of	RNA	metabolism	(Taylor,	Solem,	Kawaoka,	&	Pyle,	2010).	The	VACV	NPH-II	has	been	shown	to	be	essential	for	mRNA	transcription	by	enzymes	encapsulated	in	the	virions	(Jankowsky,	Gross,	Shuman,	&	Pyle,	2001;	Schwer,	2001).	Furthermore,	the	helicases	have	also	been	speculated	to	affect	RNA-protein	interactions	and	therefore	may	participate	in	the	structural	reorganization	of	ribonucleoprotein	assemblies	(Jankowsky	et	al.,	2001;	Schwer,	2001).	The	bioinformatic	searches	described	in	this	thesis	revealed	a	potential	heparin-binding	domain,	with	a	net	
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positive	charge	of	+4,	within	the	VACV	DExH	RNA	helicase,	suggesting	a	new	role	for	the	helicase.	However,	the	helicase	is	unlikely	to	be	expressed	on	the	outer	EV	membrane,	possibly	associating	with	the	EV	envelope	from	the	inside.	Furthermore,	it	is	possible	that	this	apparent	heparin-binding	site	could	also	bind	negatively	charged	RNA/DNA.	It	is	also	possible	that	the	77.6	kDa	DNA	helicase	is,	in	fact,	the	~85	kDa	band	that	appears	in	Western	blotting	using	polyclonal	antibodies	(Figure	6.1A).			The	bioinformatic	searches	provided	several	hits	with	possible	heparin-binding	regions,	however,	none	of	the	identified	protein	hits	have	been	previously	reported	to	be	part	of	the	EV	envelope.	Nevertheless,	the	most	likely	candidate	protein	identified	from	the	bioinformatic	searches	with	a	possible	heparin-binding	domain,	and	also	likely	to	be	EV	membrane	associated,	was	the	65	kDa	protein	B4R.	None	of	the	protein	hits	identified	by	the	bioinformatic	searches	had	molecular	weights	of	150	kDa,	and	25	kDa	as	identified	by	Western	blotting.	It	is	possible,	however,	that	the	four	heparin-binding	proteins	identified	by	Western	blotting	could	have	undergone	extensive	post-translational	modifications,	which	would	result	in	the	protein	bands	appearing	at	unexpected	positions	on	the	Western	blots.	Therefore,	MS	analysis	of	the	85	kDa,	60	kDa	and	25	kDa	protein	bands	(Figure	6.2A)	is	required	to	conclusively	identify	the	three	(or	more)	heparin	binding	proteins,	with	the	possible	use	of	F12,	DNA	helicase	and	B4R-specific	mAbs	to	determine	whether	or	not	VACV	F12,	DNA	helicase	and	B4R	are	heparin/HS	binding	proteins.		
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Finally,	there	is	increasing	evidence	suggesting	that	there	are	multiple	HS	binding	sites	on	the	surface	of	viruses	like	human	papillomavirus	type	16.	Studies	have	shown	that	the	primary	HS	interacting	site	of	the	capsid	protein,	following	interactions	with	HS	undergoes	a	conformational	change,	allowing	secondary	HS	binding	sites	to	be	exposed,	which	then	interact	with	HS	(Richards,	Bienkowska-Haba,	Dasgupta,	Chen,	&	Sapp,	2013).	Based	on	the	results	reported	in	this	thesis,	it	could	be	hypothesized	that	there	are	multiple	HS	binding	proteins	on	the	surface	of	the	EV	form	of	VACV,	all	of	which	contribute	towards	the	inhibition	of	EV	infectivity	by	heparin.	It	is	likely	that	VACV,	like	human	papillomavirus	type	16,	also	has	a	multi-step	HS	interaction	profile.	Further	identification	of	the	heparin-binding	EV	proteins	detected	by	Western	blotting	is	likely	to	help	in	the	delineation	of	many	of	the	HS	interacting	proteins	on	the	surface	of	the	EV	envelope.		
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													 		Demonstration	of	a	role	for	heparanase	in	VACV	spread	post	intranasal	and	intramuscular	inoculation	
Chapter	7:	
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7.1	Abstract	VACV,	like	several	other	viruses,	interacts	with	cell	surface	HS	prior	to	interacting	with	specific	cellular	receptors	to	infect	cells.	The	EV	form	of	VACV,	when	in	contact	with	HS,	sheds	its	outer	envelope	to	release	the	enclosed	MV	form	of	VACV,	which	is	then	able	to	interact	with	VACV	specific	cellular	receptors.	Heparanase	is	the	only	known	mammalian	endoglycosidase	that	can	target	and	degrade	HS.	Data	presented	in	this	Chapter	shows	that	following	intranasal	(i.n.)	or	intramuscular	(i.m.)	inoculation	of	VACV,	the	onset	of	disease	was	delayed	in	heparanase	deficient	(HPSE	-/-)	mice,	compared	to	wild	type	(WT)	mice.	The	onset	of	disease	was	measured	by	weight	loss	analysis	along	with	virus	titres	in	organs	harvested	from	infected	mice	at	different	time	points.	Comparable	virus	titres	were	observed	at	the	primary	site	of	inoculation	in	both	WT	and	HPSE	-/-	mice	by	48	hr	post	inoculation	regardless	of	the	inoculation	route,	despite	there	being	a	24-48	hr	delay	in	the	spread	of	the	infection	to	ovarian	tissue	in	HPSE	-/-	mice	receiving	VACV	by	both	the	i.n.	and	i.m.	routes,	and	also	in	the	splenic	spread	of	VACV	inoculated	via	the	i.m.	route.	These	data	suggest	that	similar	to	HSV-1,	VACV	may	also	rely	on	heparanase-mediated	degradation	of	HS	to	migrate	to	distant	sites	and	establish	an	infection	at	the	new	sites.	This	conclusion	is	contrary	to	the	prevailing	immunological	dogma,	which	predicts	that	heparanase	deficiency	would	aid	VACV	replication	and	spread	by	preventing	the	entry	of	leukocytes	with	antiviral	activity	into	sites	of	infection.		
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7.2	Introduction	and	rationale	Pathogens,	including	viruses,	bacteria	and	parasites,	adopt	various	strategies	to	overcome	host	defense	responses	in	order	to	invade	host	cells	and	establish	an	infection.	Several	published	studies	have	shown	that	certain	viruses	use	cell	surface	GAGs	as	an	interface	to	interact	with	and	infect	the	host	(Kamhi,	Joo,	Dordick,	&	Linhardt,	2013).	Results	presented	in	this	thesis	suggest	a	dependency	of	one	such	virus,	VACV,	on	cell	surface	HS	for	infections	in	vitro,	in	particular	the	EV	form	of	VACV.	The	MV	form	of	VACV	also	uses	cell	surface	HS	for	infection,	however,	unlike	EV,	MV	is	able	to	establish	an	infection	in	the	absence	of	HS.			Heparanase,	an	endo-	β-glucuronidase,	is	the	only	known	mammalian	endoglycosidase	that	can	degrade	HS	in	the	ECM	and	BM	(Hulett	et	al.,	1999;	Vlodavsky	et	al.,	2000;	Vlodavsky	et	al.,	1999).	During	inflammation,	in	order	to	traverse	the	subendothelial	BM,	leukocytes	deploy	various	proteases	and	the	HS	degrading	enzyme,	heparanase,	to	solubilize	components	of	basement	membranes	(Parish,	2006).	This	heparanase	mediated-degradation	of	HS	liberates	factors	such	as	cytokines,	chemokines,	HS-binding	growth	factors	and	enzymes,	that	bind	to	HS	with	a	high	affinity,	for	physiological	processes	like	angiogenesis	and	wound	healing	(Hulett	et	al.,	1999;	Parish	et	al.,	2001;	Szymczak	et	al.,	2010;	Vlodavsky	et	al.,	2000;	Vlodavsky	et	al.,	1999).	Since	heparanase	is	an	important	regulator	of	HS	function	in	vivo,	it	was	of	interest	to	understand	VACV	spread	in	vivo	in	a	mouse	model	that	was	deficient	in	heparanase	production.			Of	particular	interest	was	whether	heparanase	facilitates	the	spread	of	HS-binding	viruses,	such	as	VACV,	as	these	viruses	would	be	expected	to	be	trapped	in	the	
		 184	
ECM,	bound	to	HS.	Thus,	heparanase	would	function	as	a	VACV	releasing	enzyme,	analogous	to	neuraminidase	liberating	influenza	virus	by	removing	cell	surface	sialic	acid	residues	recognized	by	the	virus	hemagglutinin	(Gamblin	&	Skehel,	2010).	Of	course,	this	effect	of	heparanase	on	virus	spread	would	be	counterbalanced	by	heparanase	aiding	the	entry	of	leukocytes	into	sites	of	infection.	Nevertheless,	early	on	in	a	VACV	infection	heparanase	deficiency	may	inhibit	virus	spread	rather	than	prevent	virus	control	by	the	immune	system,	a	proposition	that	was	investigated	in	this	Chapter.		 	
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7.3	Results		
7.3.1	Spread	of	WR	strain	of	VACV	following	intranasal	inoculation	of	WT	and	
HPSE-/-	C57BL/6	mice	Since	heparanase	is	an	important	regulator	of	HS	degradation	in	vivo	and	HS	plays	an	important	role	in	VACV	infections,	it	was	of	interest	to	determine	the	effect	of	heparanase	deficiency	on	the	replication	and	spread	of	VACV	following	inoculation	at	restrictive	sites	such	as	i.n.	and	i.m.	Thus,	WT	and	HPSE	-/-	C57BL/6	mice	were	initially	inoculated	i.n.	with	105	PFU	of	the	WR	strain	of	VACV,	as	described	in	the	section	2.3.1.	It	should	be	noted	that	the	MV-rich	WR	strain	of	VACV	was	used	for	these	experiments	rather	than	the	EV-rich	strain	as	at	the	time	these	experiments	were	performed,	it	was	not	realized	that	the	EV	form	of	VACV	is	much	more	dependent	on	HS	for	its	infectivity	than	the	MV	form.	The	animals	were	monitored	over	a	5-day	period	by	maintaining	a	health	score	for	each	animal.	Body	weights	were	recorded	at	24	hr	intervals	post	inoculation.	From	day	2	post	inoculation,	4	animals	were	ethically	euthanized	every	24	hr,	with	lungs,	spleens	and	ovaries	harvested	from	all	the	animals.	Figure	7.1	shows	weight	loss	of	animals	over	the	5-day	period	as	a	percentage	compared	to	weight	of	the	respective	animals	at	the	time	of	inoculation,	for	both	WT	and	HPSE	-/-	mice.	As	seen	in	Figure	7.1,	WT	mice	continued	to	lose	weight	from	day	2	post	inoculation	with	the	average	weight	loss	being	approximately	10%	by	day	3,	whereas	the	weight	loss	in	HPSE	-/-	mice	was	significantly	less	compared	to	the	WT	mice	up	to	day	3	post	inoculation,	with	the	average	weight	loss	being	approximately	4%.	However,	by	days	4	and	5	post	infection,	HPSE	-/-	mice	had	lost	a	considerable	amount	of	weight,	with	the	weight	loss	trend	of	HPSE	-/-	mice	becoming	similar	to	WT	mice	thereafter	(Figure	7.1).			
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Figure	7.1:	Weight	loss	analysis	post	intranasal	inoculation	with	VACV	WR	in	
WT	and	HPSE	-/-	C57BL/6	mice	over	a	course	of	5	days.	A	total	of	20	WT	and	20	HPSE	-/-	mice	were	inoculated	with	VACV	WR	i.n.	at	105	PFU	on	day	0.	At	24	hr	intervals	post	inoculation,	4	mice	from	each	WT	and	HPSE	-/-	group	were	first	weighed	and	then	sacrificed	to	harvest	organs	for	virus	titrations.	The	%	weight	loss	was	calculated	based	on	the	weight	of	each	respective	mouse	at	the	time	of	inoculation	on	day	0.	Data	presented	as	mean	±	SEM	(n=4)	and	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	an	unpaired	Student’s	t-test.					 	
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Weight	loss	is	considered	a	clinical	sign	of	disease	spread	(Bouvier	&	Lowen,	2010;	Hayasaka,	Ennis,	&	Terajima,	2007),	a	uniform	weight	loss	in	WT	mice	post	VACV	inoculation	being	indicative	of	a	steady	spread	of	VACV	within	WT	mice.	However,	based	on	weight	loss,	HPSE	-/-	mice	appeared	to	resist	VACV	spread	until	day	3	post	inoculation	(Figure	7.1).			The	weight	loss	analysis	suggested	that	there	was	a	delay	in	the	spread	of	VACV	in	
vivo	in	HPSE	-/-	mice	compared	to	WT	animals.	VACV	spread	was	evaluated	in	vivo	in	lungs,	spleens	and	ovaries	harvested	from	euthanised	animals.	The	organs	were	individually	weighed	and	processed	to	determine	VACV	titres	in	the	respective	organs	as	described	in	section	2.4.2.	Lungs	served	as	a	positive	control	for	the	primary	site	of	VACV	replication.	Plaque	assays	performed	using	lungs	harvested	at	day	2	post	inoculation	from	both	WT	and	HPSE	-/-	mice	indicated	that	VACV	was	able	to	establish	an	infection	equally	well	in	both	groups	of	animals	(Figure	7.2).	Ovaries	served	as	the	distant	organ	to	evaluate	VACV	spread	kinetics	in	mice	as	VACV	is	known	to	exhibit	a	strong	tropism	for	ovarian	tissue	(Zhao,	Adams,	&	Croft,	2011).	Spleen	virus	titres	were	also	determined	for	all	the	infected	animals.			As	seen	in	Figure	7.3,	spleen	virus	titres	were	observed	by	day	2	post	inoculation	in	both	WT	and	HPSE	-/-	animals	and	were	maintained	over	days	2-5	with	virus		titres	in	the	spleens	from	HPSE	-/-	mice	tending	to	be	lower	than	in	WT	mice	on	days	2-4,	although	this	difference	was	not	statistically	significant.	Furthermore,	VACV	appeared	to	accumulate	in	the	ovarian	tissue	of	WT	mice	from	day	2	onwards	(Figure	7.3).	However,	the	ovary	virus	titres	decreased	dramatically	in			
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Figure	7.2:	Measurement	of	lung	VACV	titres	in	WT	and	HPSE	-/-	C57BL/6	mice	
at	day	2	post	intranasal	inoculation	of	the	WR	strain	of	VACV.	WT	and	HPSE	-/-mice	were	weighed	on	day	2	post	i.n.	inoculation,	followed	by	harvesting	and	weighing	their	lungs	prior	to	measuring	lung	VACV	titres.	Lungs	from	all	the	mice	were	homogenized	using	a	micro-homogenizer	and	used	as	virus	stocks	to	infect	confluent	143B	osteosarcoma	monolayers	in	6-well	plates.	Culture	medium	was	removed	from	monolayers	and	cells	stained	to	identify	plaques	48	hr	post	infection.	The	PFU/g	for	all	the	lungs	harvested	was	calculated	and	the	data	are	presented	as	mean	PFU/g	at	the	respective	time	points,	along	with	±	SEM	(n=4),	for	each	group	of	mice.	Data	presented	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	the	Wilcoxon	Rank-Sum	test.		 	
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WT	mice,	by	day	4	only	one	of	four	mice	having	detectable	VACV	in	their	ovaries	and	there	being	no	detectable	virus	on	day	5	(Figure	7.3).	On	the	other	hand,	only	one	of	four	HPSE	-/-	mice	had	detectable	VACV	in	their	ovarian	tissue	at	day	2	post	inoculation	and	by	day	3	post	inoculation,	still	only	two	out	of	four	HPSE	-/-	animals	had	detectable	VACV.	However,	by	day	4	post	inoculation	there	was	~100-fold	increase	in	ovarian	VACV	titres	over	day	3,	with	the	titres	starting	to	decline	by	day	5.	Comparing	the	trends	of	VACV	spread	in	the	ovaries	of	WT	and	HPSE	-/-	mice	strongly	highlights	a	delay	in	spread	of	VACV	to	distant	organs	in	mice	deficient	in	heparanase.	In	fact,	ovary	virus	titre	trends	directly	correlate	with	weight	loss	trends	in	the	two	groups	of	animals,	with	the	delay	in	VACV	spread	in	HPSE	-/-	mice	resulting	in	a	delay	in	the	onset	of	sickness	as	seen	by	a	delay	in	weight	loss	and	a	delay	in	spread	of	VACV	to	distant	organs	like	ovaries.	As	mentioned	above,	spleen	titres	were	not	significantly	different	in	the	two	animal	groups,	with	Figure	7.3	clearly	depicting	splenocytes	being	infected	by	day	2	in	both	WT	and	HPSE	-/-	mice,	which	could	be	due	to	the	ability	of	VACV	to	rapidly	reach	the	spleen	once	it	has	entered	the	circulation.		
7.3.2	Spread	of	WR	strain	of	VACV	following	intramuscular	inoculation	of	WT	
and	HPSE	-/-	C57BL/6	mice		To	understand	the	role	of	heparanase	mediated	HS	degradation	in	VACV	spread,	a	second	restrictive	infection	strategy	was	used	where	animals	were	inoculated	with	VACV	via	the	i.m.	route.	Quadricep	muscles	of	WT	and	HPSE	-/-	mice	were	inoculated	with	105	PFU	of	VACV	WR	as	described	in	section	2.3.1.	Mice	were	monitored	over	a	5-day	period	and	weighed	every	24	hr	as	done	previously	after	i.n.	inoculation.	From	day	3	post	inoculation,	4	animals/day	were	ethically		
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Figure	7.3:	Measurement	of	VACV	WR	strain	spread	in	WT	and	HPSE	-/-	
C57BL/6	mice	over	5	days	post	intranasal	inoculation.	WT	and	HPSE	-/-	mice	were	weighed	on	days	2,	3,	4	and	5	post	i.n.	inoculation,	followed	by	harvesting	and	weighing	their	ovaries	and	spleens	prior	to	measuring	ovary	and	spleen	VACV	titres.	To	assess	VACV	titres,	all	the	harvested	organs	were	homogenized	using	a	micro-homogenizer	and	used	as	virus	stocks	to	infect	confluent	143B	osteosarcoma	monolayers	in	6-well	plates.	Culture	medium	was	removed	from	monolayers	and	cells	stained	to	identify	plaques	48	hr	post	infection.	The	PFU/g	for	every	organ,	harvested	at	different	time	points,	was	calculated	and	the	data	are	presented	as	mean	PFU/g	for	every	organ	at	the	respective	time	points,	along	with	±	SEM	(n=4),	for	each	group	of	mice.	Data	presented	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	the	Wilcoxon	Rank-Sum	test.					
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euthanised	and	quadricep	muscles,	spleens	and	ovaries	harvested	for	viral	titre	measurements.	The	change	in	whole	animal	weight	is	depicted	in	Figure	7.4	as	a	percentage	of	the	weight	of	the	respective	animals	at	the	time	of	inoculation.	Unlike	i.n.	inoculation	however,	the	i.m.	route	of	inoculation	did	not	result	in	a	significant	difference	in	weight	loss	between	the	WT	and	HPSE	-/-	animals,	in	fact	there	was	little	weight	loss	in	all	the	infected	animals.	A	direct	comparison	between	weight	loss	in	WT	and	HPSE	-/-	mice	following	i.m.	inoculation,	therefore,	could	not	be	used	to	predict	the	development	of	a	VACV	infection	or	sickness.	To	ensure	VACV	delivery	to	the	quadricep	muscles	was	successful,	inoculated	mice	from	both	WT	and	HPSE	-/-	groups	were	euthanised	on	day	2	post	inoculation,	as	performed	previously	for	the	i.n.	inoculation,	and	the	quadriceps	were	harvested	for	assessment	of	virus	titres.	High	organ	virus	titres	in	both	right	and	left	quadriceps	from	both	WT	and	HPSE	-/-	mice	indicated	successful	inoculation	and	comparable	virus	replication	in	WT	and	HPSE	-/-	mice	(Figure	7.5).	Spleens	and	ovaries	harvested	from	the	WT	and	HPSE	-/-	mice	were	processed	to	determine	virus	titres	and	thereby	evaluate	the	VACV	infection	profile	in	the	two	groups	of	mice.	Ovaries	and	spleen	served	as	the	distant	organs	of	interest	as	described	earlier	in	section	7.3.1	for	the	i.n.	inoculation	route.		Since	quadriceps,	compared	to	the	lungs,	are	a	much	more	restrictive	site	for	virus	replication	and	for	virus	spread	to	distant	sites,	it	was	anticipated	that	organs	harvested	on	days	3,	4	and	5	following	i.m.	inoculation	of	VACV	would	show	a	delayed	time	course	of	virus	spread	than	that	seen	on	days	2,	3	and	4	following	i.n.	inoculation.	As	seen	in	Figure	7.6,	spleen	virus	titres	were	observed	by	day	3	post	inoculation	in	WT	animals	and	persisted	over	the	next	two	days.	Furthermore,	in		
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Figure	7.4:	Weight	loss	analysis	post	intramuscular	inoculation	with	VACV	
WR	in	WT	and	HPSE	-/-	C57BL/6	mice	over	a	course	of	5	days.	A	total	of	20	WT	and	20	HPSE	-/-	mice	were	inoculated	with	VACV	WR	i.m.	at	105	PFU	on	day	0.	At	24	hr	intervals	post	inoculation,	4	mice	from	each	WT	and	HPSE	-/-	group	were	first	weighed	and	then	sacrificed	to	harvest	organs	for	virus	titrations.	The	%	weight	loss	was	calculated	based	on	the	weight	of	each	respective	mouse	at	the	time	of	inoculation	on	day	0.	Data	presented	as	mean	±	SEM	(n=4)	and	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	an	unpaired	Student’s	t-test.				 	
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Figure	7.5:	Measurement	of	VACV	titres	in	the	quadricep	muscles	of	WT	and	
HPSE	-/-	C57BL/6	mice	at	day	2	post	intramuscular	inoculation	of	the	WR	
strain	of	VACV.	WT	and	HPSE	-/-	mice	were	weighed	on	day	2	post	i.m.	inoculation,	followed	by	harvesting	and	weighing	their	quadricep	muscles	prior	to	measuring	VACV	titres.	Left	and	right	quadricep	muscles	from	all	the	mice	were	individually	homogenized	using	a	micro-homogenizer	and	used	as	virus	stocks	to	infect	confluent	143B	osteosarcoma	monolayers	in	6-well	plates.	Culture	medium	was	removed	from	monolayers	and	cells	stained	to	identify	plaques	48	hr	post	infection.	The	PFU/g	for	all	the	muscles	harvested	was	calculated	and	the	data	are	presented	as	mean	PFU/g	at	the	respective	time	points,	along	with	±	SEM	(n=4),	for	each	group	of	mice.	The	data	presented	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	the	Wilcoxon	Rank-Sum	test.		 	
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WT	mice	substantial	ovary	virus	titres	also	appeared	by	day	3	post	inoculation,	but	were	reduced	to	below	the	detection	limit	by	day	5.	Contrary	to	WT	mice,	VACV	was	undectectable	in	the	spleens	of	HPSE	-/-	mice	until	day	5	post	inoculation.	The	titres	of	VACV	in	the	ovaries	of	HPSE	-/-	mice	followed	a	similar	trend	to	the	spleen,	only	appearing	at	day	5	(Figure	7.6).			These	results	indicate	that	there	was	a	clear	delay	in	the	spread	of	VACV	to	distant	organs	in	mice	deficient	in	heparanase.	Unlike	with	the	i.n.	route	of	virus	delivery,	the	weight	loss	trends	and	titres	of	virus	within	distant	organs	did	not	correlate	when	the	delivery	route	of	VACV	was	changed	to	i.m.	This	could	be	due	to	muscle	being	a	highly	restrictive	site	for	VACV	replication	and	trafficking.	Nevertheless,	the	overall	results	obtained	with	the	i.m.	route	of	inoculation	are	consistent	with	the	i.n.	inoculation	route	findings,	suggesting	that	lack	of	heparanase	hampers	the	ability	of	VACV	to	spread	to	distant	organs	from	the	primary	site	of	infection.			
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Figure	7.6:	Measurement	of	VACV	WR	strain	spread	in	WT	and	HPSE	-/-
C57BL/6	mice	over	5	days	post	intramuscular	inoculation.	WT	and	HPSE	-/-	mice	were	weighed	on	days	3,	4	and	5	post	i.m.	inoculation,	followed	by	harvesting	and	weighing	their	ovaries	and	spleens	prior	to	measuring	ovary	and	spleen	VACV	titres.	To	assess	VACV	titres,	all	the	harvested	organs	were	homogenized	using	a	micro-homogenizer	and	used	as	virus	stocks	to	infect	confluent	143B	osteosarcoma	monolayers	in	6-well	plates.	Culture	medium	was	removed	from	monolayers	and	cells	stained	to	identify	plaques	48	hr	post	infection.	The	PFU/g	for	every	organ,	harvested	at	different	time	points,	was	calculated	and	the	data	are	presented	as	mean	PFU/g	for	every	organ	at	the	respective	time	points,	along	with	±	SEM	(n=4),	for	each	groups	of	mice.	The	data	presented	are	representative	of	at	least	two	independent	experiments,	with	statistical	analysis	performed	using	the	Wilcoxon	Rank-Sum	test.	
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7.4	Discussion	It	is	clear	from	the	current	study	that	cell	surface	HS	plays	an	important	role	in	VACV	infectivity	and	soluble	GAG	molecules	can	inhibit	VACV	infections	in	vitro.	However,	the	role	of	HS	in	the	spread	of	VACV	in	vivo	needs	to	be	addressed.	Therefore,	prior	to	progressing	with	the	development	of	GAG	based	small	molecules	that	can	act	as	antivirals,	it	was	first	important	to	understand	the	role	of	HS	in	VACV	spread	in	vivo.	Of	particular	interest	was	whether	the	HS	degrading	enzyme,	heparanase,	aids	the	spread	of	HS-binding	viruses	like	VACV,	analogous	to	neuraminidase	aiding	the	spread	of	sialic	acid	binding	influenza	virus.		Two	different	mouse	strains	were	used	to	understand	VACV	spread,	namely	heparanase	deficient	HPSE	-/-	and	WT	C57BL/6	mice.	Heparanase	is	the	only	known	mammalian	endoglycosidase	that	is	able	to	cleave	HS	chains	to	release	small	saccharide	products	(Levy-Adam	et	al.,	2010;	Parish	et	al.,	2001).	In	order	to	understand	the	role	of	HS	and	heparanase	in	VACV	movement	from	one	site	to	another	in	vivo,	it	was	important	to	design	an	assay	that	would	require	VACV	to	establish	a	local	infection	before	spreading	to	distant	organs,	thus	the	i.n.	and	i.m.	routes	of	VACV	inoculation	were	used.	Initial	studies	using	the	i.n.	route	of	inoculation	revealed	a	24	hr	delay	in	VACV-induced	weight	loss	in	the	HPSE	-/-	mice	compared	to	the	WT	mice,	suggesting	a	delay	in	the	onset	of	disease	(Figure	7.1).	Furthermore,	a	24-48	hr	delay	was	also	observed	in	the	ability	of	VACV	to	reach	ovarian	tissue	in	HPSE	-/-	mice	compared	to	WT	mice	(Figure	7.3),	with	VACV	titres	being	detected	in	the	ovaries	of	WT	mice	at	day	2	post	infection,	but	declining	over	the	next	two	days	and	reaching	undetectable	levels	by	day	5.		
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In	contrast,	ovary	titres	of	VACV	were	observed	to	be	low	on	days	2-3	in	HPSE	-/-	mice,	but	the	ovaries	of	all	mice	having	high	viral	titres	on	days	4	and	5	post	infection.	Furthermore,	lungs	from	both	HPSE	-/-	and	WT	mice	were	infected	equally	well	on	day	2	post	infection	(Figure	7.2),	indicating	that	the	differences	seen	in	VACV	spread	were	not	due	to	any	differences	in	VACV	replication	at	the	inoculation	sites	of	the	two	mouse	strains.	Thus,	the	ovary	virus	titres	clearly	indicate	that	the	lack	of	heparanase	in	HPSE	-/-	mice	reduces	the	ability	of	VACV	particles	to	spread	from	the	primary	site	of	infection.		Although	the	i.n.	route	of	infection	gave	informative	results	regarding	a	role	for	heparanase	in	VACV	spread,	the	nasal	vestibule	does	contain	small	hairs	and	a	mucus	layer	covering	the	entire	respiratory	area	of	the	nasal	cavity.	It	is	possible	that	the	mucociliary	clearance	of	VACV	particles	could	carry	the	particles	to	the	back	of	the	throat	and	down	the	oesophagus	and	further	down	the	digestive	tract	(Illum,	2003).	This	could	be	the	reason	why	low	PFU	counts	were	seen	in	the	lungs	of	the	infected	mice	(Figure	7.2).	Therefore,	to	confirm	the	results	obtained	from	the	i.n.	route	of	delivery	of	VACV,	the	i.m.	route	of	delivery	was	examined	next.			As	seen	with	the	i.n.	route	of	delivery	by	day	2	post	inoculation	VACV	was	able	to	replicate	to	similar	levels	at	the	primary	site	of	inoculation	in	both	the	HPSE	-/-	and	WT	mice	(Figure	7.5).	However,	unlike	the	i.n.	route	of	delivery,	infected	HPSE	-/-	and	WT	mice	did	not	lose	a	significant	amount	of	weight	over	the	5	day	observation	period	(Figure	7.4).	Therefore,	weight	loss	post	i.m.	inoculation	could	not	be	used	as	an	indicator	of	sickness	resulting	from	VACV	infections.	Nevertheless,	the	effects	of	heparanase	deficiency	on	VACV	spread	were	more	
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marked	following	i.m.	inoculation.	Thus,	inhibition	of	virus	spread	to	the	spleen	was	clearly	evident	on	days	3	and	4	following	i.m.	inoculation	of	the	HPSE	-/-	mice,	whereas	such	a	difference	was	not	seen	in	i.n.	inoculated	mice.	On	the	other	hand,	the	effects	of	heparanase	deficiency	on	virus	spread	to	the	ovaries	gave	similar	results	for	both	routes	of	inoculation,	in	both	cases	there	being	a	24-48	hr	delay	in	the	spread	of	VACV	to	the	ovaries	in	the	HPSE	-/-	mice.		Thus	the	key	finding	from	both	the	i.n.	and	i.m.	routes	of	VACV	delivery	is	that	heparanase	deficiency	substantially	delays	VACV	spread	from	the	inoculation	site,	which	implies	a	direct	role	for	heparanase	in	enabling	the	escape	of	VACV	particles	from	sites	of	primary	infection.	It	is	well	documented	that	HS	in	the	ECM	binds	to	a	number	of	cytokines,	chemokines	and	enzymes	with	high	affinity,	which	are	made	available	for	physiological	processes	such	as	angiogenesis	and	wound	healing	by	the	enzymatic	action	of	heparanase	(Hulett	et	al.,	1999;	Parish	et	al.,	2001;	Szymczak	et	al.,	2010).	Therefore,	to	put	the	findings	obtained	from	the	current	study	in	perspective,	it	is	likely	that	similar	to	chemokines	and	cytokines,	newly	synthesized	EV	and	MV	particles	exiting	primary	infected	cells	become	trapped	in	cell	surface	and	ECM	HS.	Furthermore,	since	it	is	well	established	that	heparanase	mediated	degradation	of	HS	in	the	ECM	and	BM	is	a	prerequisite	for	leukocytes	to	invade	tissues	(Parish	et	al.,	2001;	Vlodavsky	et	al.,	2000;	Vlodavsky	et	al.,	1999),	leukocyte-derived	heparanase	could	possibly	allow	newly	synthesized	progeny	EV	particles	to	escape	from	the	primary	site	of	infection	and	establish	an	infection	at	a	distant	site.	Another	possibility	is	that	platelets	are	the	source	of	heparanase	(Freeman	&	Parish,	1998)	as	they	are	likely	to	enter	and	be	activated	to	release	heparanase	at	sites	of	infection,	particularly	with	cytopathic	viruses	like	VACV.	
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There	is	ample	evidence	suggesting	that	several	viruses,	bacteria	and	parasites	use	evolutionary	conserved	glycosaminoglycans,	such	as	HS,	as	adhesion	receptors	possibly	due	to	their	high	abundance	(Rostand	&	Esko,	1997;	Wadstrom	&	Ljungh,	1999).	However,	a	disadvantage	of	using	HS	as	an	adhesion	ligand	is	that	its	abundance	acts	as	a	barrier	to	virus	spread.	Having	host-derived	heparanase	to	degrade	HS	is	one	way	in	which	pathogens	can	overcome	this	disadvantage.	Therefore,	it	is	likely	that	similar	to	VACV,	other	HS	binding	pathogens	may	also	rely	on	heparanase-mediated	degradation	of	ECM	HS	as	a	mechanism	to	aid	spread	to	distant	sites.	In	fact,	a	recent	study	of	herpes	simplex	virus-1	(HSV-1)	infection	of	the	cornea	clearly	demonstrated	that	host-derived	heparanase	digests	cell	surface	HS,	thereby	facilitating	HSV-1	release	in	vivo	(Hadigal	et	al.,	2015).	In	this	study,	knocking	down	heparanase	expression	in	mouse	corneas	using	shRNA	against	murine	heparanase,	followed	by	infection	with	HSV-1,	decreased	virus	egress	and	tissue	damage	at	the	site	of	infection,	whereas	overexpression	of	heparanase	significantly	increased	HSV-1	spread	and	tissue	damage	(Hadigal	et	al.,	2015).	Interestingly,	these	findings	with	VACV	and	HSV-1	are	contrary	to	the	immunological	dogma	that	would	predict	that	heparanase	deficiency	would	enhance	virus	spread	by	preventing	the	heparanase	dependent	entry	of	leukocytes	with	antiviral	activity	into	sites	of	infection.		Collectively,	the	findings	presented	in	this	Chapter	suggest	that	like	influenza	virus,	VACV	relies	on	a	glycosidase	for	virus	spread.	However,	influenza	virus	encodes	within	its	genome	the	neuraminidase	required	for	virus	escape,	whereas	VACV	relies	on	host-derived	heparanase	to	aid	its	exit	from	the	primary	site	of	infection	and	to	spread	to	other	organs.	Targeting	this	heparanase-HS	interplay	exploited	by	
		 202	
VACV,	could	allow	the	development	of	novel	therapies	for	treating	HS-dependent	viral	infections.		 	
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8.1	Introduction	The	expansion	of	traditional	areas	of	habitation,	along	with	mass	long-distance	travel,	has	opened	up	the	possibility	of	rapid	widespread	dissemination	of	new	and	re-emerging	pathogens	once	considered	eradicated	and	is	regarded	as	a	major	concern	for	the	medical	and	public	health	systems	worldwide	(Littler	&	Oberg,	2005;	Morens	et	al.,	2004).	Moreover,	the	threat	of	eradicated	viruses	like	smallpox	being	used	as	potential	weapons	of	bioterrorism	has	attracted	a	lot	of	interest	in	the	scientific	community	and	has	stimulated	the	fast-track	development	of	novel	antiviral	treatments	(Hughes	et	al.,	2010).	With	this	increasing	disease	burden	on	the	public	health	system,	increasing	efforts	are	being	made	by	the	scientific	community	to	understand	viral	pathogenesis	and	develop	new	strategies	to	treat	these	infections	(Finlay	et	al.,	2004).		Research	targeted	at	understanding	the	molecular	pathways	controlling	virus	life	cycles	is	the	engine	that	drives	the	development	of	therapies	against	viral	infections	(Liang	&	Ghany,	2013).	Furthermore,	use	of	‘combination	therapies’	using	disease-modifying	treatments	acting	on	hosts,	coupled	with	inhibitors	of	virus	replication,	have	shown	great	potential	in	the	treatment	of	viral	infections	(Littler	&	Oberg,	2005).	An	example	of	combination	therapy	is	the	treatment	of	hepatitis	C	virus	(HCV)	using	inhibitors	of	HCV	proteases,	along	with	treatment	for	fibrosis,	which	could	have	a	major	impact	on	liver	disease	(Elbaz,	El-Kassas,	&	Esmat,	2015;	Littler	&	Oberg,	2005).	Another	example	is	the	treatment	of	HSV	where	the	use	of	aciclovir,	an	inhibitor	of	HSV	replication,	combined	with	an	anti-inflammatory	agent,	has	resulted	in	a	significant	decrease	in	HSV-1	infections	
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(Hull,	Levin,	Tyring,	&	Spruance,	2014;	Littler	&	Oberg,	2005;	Opstelten,	Neven,	&	Eekhof,	2008).			
8.2	VACV	interacts	with	cell	surface	HS	The	research	focus	of	this	thesis	was	the	development	of	an	understanding	of	the	molecular	mechanisms	used	by	VACV	to	enter	and	infect	cells,	particularly	the	role	of	HS,	an	understanding	that	would	be	valuable	for	the	design	of	antivirals	that	could	potentially	inhibit	VACV	infections.	VACV	is	a	member	of	the	Orthopoxvirus	(OPV)	genus	of	the	Poxviridae	family.	VACV	was	the	vaccine	strain	used	to	eradicate	smallpox,	however,	it	wasn’t	until	1939	that	scientists	realized	that	the	strain	of	poxviruses	being	used	to	vaccinate	against	smallpox	was,	in	fact,	VACV	and	not	the	cowpox	virus	(CPXV)	originally	used	by	Edward	Jenner	in	1796	(Roberts	&	Smith,	2008).	Today,	VACV	is	commonly	used	as	the	prototype	virus	to	study	poxviruses.			VACV,	like	many	other	viruses,	interacts	with	cell	surface	HS	prior	to	interacting	with	specific	cell	surface	receptors	that	mediate	its	entry	into	cells	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	ELISA	results	presented	in	Chapter	3	of	this	thesis	clearly	suggest	that	the	MV	form	of	VACV	binds	to	immobilised	HShi,	with	only	soluble	heparin	being	a	potent	inhibitor	of	this	binding,	suggesting	that	the	MV	form	of	VACV	preferentially	interacts	with	GAG	molecules	with	extremely	high	sulfate	content	(Figures	3.1	and	3.2).	The	MV	form	of	VACV	also	has	a	known	CS	binding	protein	on	its	outer	membrane	(Hsiao	et	al.,	1999),	however,	the	unavailability	of	BSA	conjugated	CS	meant	similar	ELISA	studies	could	not	be	performed	to	determine	the	strength	of	interaction	between	MV	particles	and	immobilised	CS.	
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Nevertheless,	an	alternative	ELISA	assay	was	designed	to	determine	if	soluble	CS	could	inhibit	MV	particles	from	binding	to	immobilised	HShi	in	ELISA	wells.	Only	very	high	concentrations	of	CS	could	partially	inhibit	MV	binding,	suggesting	that	soluble	CS	could	indirectly	interfere	with	the	interaction	between	immobilised	HShi	and	proteins	on	the	MV	outer	membrane	(Figure	3.4).	Furthermore,	there	is	ample	published	evidence	indicating	that	soluble	CS	has	little	effect	on	MV	infectivity	(Carter	et	al.,	2005),	therefore,	it	would	be	safe	to	conclude	that	the	GAG	molecule	that	plays	a	major	role	in	VACV	infectivity	is	cell	surface	HS	(and	soluble	heparin,	a	highly	sulfated	version	of	HS).		Previously	published	studies	have	shown	that	there	are	at	least	two	HS-binding	proteins	on	the	outer	membrane	of	MV	particles,	however,	due	to	the	fragile	nature	of	the	outer	EV	envelope,	similar	studies	using	the	EV	form	of	VACV	have	not	been	undertaken	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	Nevertheless,	plaque	assay	results	presented	in	Figure	3.5	clearly	demonstrate	that	heparin/HS	play	a	crucial	role	in	the	way	VACV	forms	plaques	on	cell	monolayers	in	vitro.	Not	only	does	the	presence	of	heparin	in	the	culture	medium	reduce	the	plaque	numbers	of	the	WR	and	IHD-J	strains	of	VACV	by	5-	to	10-fold,	but	it	also	influences	the	plaque	morphology	(Figure	3.5).	Thus,	there	was	an	incremental	increase	in	the	diameter	of	WR	strain	plaques	(MV	rich	strain	of	VACV)	in	the	presence	of	heparin.	However,	the	effect	of	heparin	on	IHD-J	strain	plaques	(EV	rich	strain	of	VACV)	was	more	dramatic,	with	the	disappearance	of	the	trademark	‘comets’	associated	with	EV	plaques	and	a	similar	incremental	increase	in	plaque	diameter	as	seen	with	the	WR	strain.		
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Previously	published	studies	have	shown	that	the	VACV	A56	protein,	also	known	as	the	VACV	haemagglutinin	(HA),	binds	to	and	forms	a	complex	with	a	serine	protease	inhibitor	(K2)	(DeHaven	et	al.,	2011;	Moss,	2006).	Infected	cells	express	A56/K2	complexes	on	their	plasma	membranes,	which	interact	with	the	entry/fusion	complex	(EFC)	on	the	membrane	of	new	MV	particles	and	inhibit	the	ability	of	the	EFC	to	mediate	MV	entry	into	cells	(DeHaven	et	al.,	2011;	Turner	&	Moyer,	2008).	The	EFC	is	composed	of	at	least	eight	proteins,	namely,	A16,	A21,	A28,	G3,	G9,	H2,	J5	and	L5	(Wagenaar	&	Moss,	2009).	The	interaction	of	the	A56/K2	complex	with	the	EFC	on	the	surface	of	MV	particles	is	a	mechanism	in	place	to	avoid	superinfection	of	infected	cell,	resulting	in	MV	particles	only	being	able	to	infect	cells	that	do	not	have	the	A56/K2	complex	expressed	on	their	surface	(Turner	&	Moyer,	2008).	Antibodies	against	the	A56	or	K2	proteins	have	been	shown	to	decrease	the	interaction	of	the	A56/K2	complex	with	EFC	on	MV	and,	therefore,	increase	the	amount	of	superinfection	(DeHaven	et	al.,	2011).	Furtheremore,	the	A56/K2	complex	has	been	shown	to	inhibit	syncytia	formation	(Moss,	2006)	and	infected	cells	are	able	to	fuse	with	uninfected	cells	at	neutral	pH	when	mutant	viruses	lacking	A56	or	K2	are	used	to	infect	cells	(Turner	&	Moyer,	2008).	There	is	also	evidence	that	suggests	that	K2	contains	a	heparin-binding	site	similar	to	that	of	antithrombin	III	(Brum	et	al.,	2003;	Turner	&	Moyer,	2006).	Furthermore,	Western	blotting	results	presented	in	Figure	6.2B	clearly	indicate	that	the	A56	protein	binds	to	heparin-Sepharose	beads.	Therefore,	to	put	the	plaque	assay	results	presented	in	Figure	3.5	in	perspective,	a	possible	reason	for	the	increased	plaque	diameter	is	that	the	A56/K2	complexes	expressed	on	the	plasma	membrane	of	infected	cells	could	be	blocked	by	heparin,	similar	to	the	effects	seen	when	an	antibody	against	A56	or	K2	is	used,	which	then	permits	
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syncytia	formation.	This	would	mean	that	plaque	size	would	grow	at	a	faster	rate	in	the	presence	of	heparin.	Apart	from	interacting	with	the	A56/K2	complex,	heparin	also	directly	inhibits	EV	and	MV	forms	of	VACV	from	interacting	with	cell	surface	HS,	which	would	explain	the	5-	10-fold	reduction	in	plaque	numbers	observed.			Unlike	MV	particles,	which	are	generally	released	from	dying	cells,	EV	particles	are	actively	ejected	from	infected	cells	(Figure	1.4),	a	process	that	results	in	the	infection	of	distal	cells	and	the	formation	of	the	trademark	‘comet’	shaped	plaques.	However,	in	the	presence	of	heparin,	the	comets	formed	by	the	IHD-J	strain	of	VACV	almost	completely	disappeared	(Figure	3.5A	and	B).	It	is	likely	that	heparin	inhibits	freshly	released	EV	particles	from	infecting	neighbouring	cells	as	heparin	is	a	potent	inhibitor	of	EV	infections	in	vitro	as	measured	by	the	infections	using	GFP	expressing	EV	form	of	VACV	(Chapters	4	and	5)	and	by	the	IHD-J	strain	(EV	rich)	plaque	formation	(Figure	3.5).	Furthermore,	newly	formed	MV	particles	in	an	infected	cell	can	directly	be	pushed	into	neighbouring	cells	and	escape	interaction	with	heparin	(Marsh	&	Helenius,	2006).	Therefore,	it	is	likely	that	in	the	presence	of	heparin,	the	predominant	mode	of	spread	of	the	IHD-J	strain	of	VACV	is	via	the	punching	mechanism	used	by	MV	particles.	This	would	also	explain	why	the	IHD-J	strain	of	VACV	forms	round	plaques	in	the	presence	of	heparin.			
8.3	EV	and	MV	forms	of	VACV	interact	differently	with	cell	surface	HS		The	plaque	assay	results	presented	in	Figure	3.5	clearly	show	that	heparin	affects	the	EV	rich	strain	of	VACV	(IHD-J)	differently	to	the	MV	rich	strain	(WR).	
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Therefore,	it	was	important	to	evaluate	the	role	of	heparin/HS	in	infections	caused	by	the	EV	and	MV	forms	of	VACV.			The	outer	most	envelope	of	the	EV	form	of	VACV	is	extremely	fragile	(Ichihashi,	1996).	This	makes	purification	of	the	EV	form	extremely	challenging	because	an	EV	particle	with	a	damaged	outer	membrane	behaves	like	an	MV	particle	(see	Figure	3.5F	showing	broken	outer	EV	envelope).	Therefore,	to	understand	the	interaction	between	EV	particles	and	cell	surface	HS,	it	was	first	essential	to	design	protocols	to	obtain	relatively	concentrated	stocks	of	EV.	Since	the	IHD-J	strain	of	VACV	is	constitutively	rich	in	the	amount	of	EV	particles	it	sheds	compared	to	the	WR	strain	of	VACV,	the	IHD-J	strain	was	used	to	obtain	EV	stocks	for	the	assays	performed	in	this	thesis.	The	WR	strain	of	VACV	was	used	to	obtain	MV	stocks.			In	order	to	understand	the	interaction	between	cell	surface	HS	and	VACV	during	an	infection,	GFP	expressing	recombinants	of	both	the	WR	and	IHD-J	strains	of	VACV	were	created.	The	kinetics	of	EV-GFP	and	MV-GFP	infection	were	monitored	by	measuring	GFP	expression	in	cells	at	different	time-points	post	infection.	Co-incubation	of	heparin	with	either	EV-GFP	or	MV-GFP	during	the	infection	of	cell	monolayers	revealed	that	heparin	was	a	much	more	potent	inhibitor	of	EV	infections	than	MV	infections	(Figures	4.3	and	4.7).	Since	the	EV	and	MV	forms	of	VACV	used	in	these	infection	assays	were	purified	from	two	different	strains	of	VACV,	it	was	important	to	rule	out	the	possibility	that	strain	differences	were	the	cause	of	the	differences	seen	in	EV	and	MV	infectivity.	It	was	found,	however,	that	the	EV	particles	isolated	from	the	WR	strain	of	VACV	could	be	inhibited	by	heparin	to	a	similar	extent	as	EV	particles	isolated	from	the	IHD-J	strain	(Figure	4.7).	
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Similarly,	MV	particles	isolated	from	the	IHD-J	strain	of	VACV	showed	comparable	inhibition	by	heparin	to	MV	particles	isolated	from	the	WR	strain	of	VACV	(Figure	4.7).	These	observations	clearly	suggest	that	EV	particles,	regardless	of	their	source,	are	more	susceptible	to	inhibition	by	heparin	than	MV	particles.	The	tightly	overlapping	inhibition	curves	observed	in	these	experiments	also	highlight	the	reproducibility	of	the	inhibition	assay	used.		
8.4	Role	of	heparanase	in	VACV	spread	Heparanase	is	the	only	known	mammalian	endoglycosidase	that	is	able	to	cleave	HS	in	ECM	and	BMs,	therefore,	it	was	of	interest	to	understand	the	effect	of	heparanase-mediated	digestion	of	HS	on	EV	and	MV	infectivity	in	vitro.	Digestion	of	cell	surface	HS	using	platelet	derived	HPSE	or	commercially	available	
Flavobacterium	HPNSEs,	significantly	reduced	EV	and	MV	infectivity,	however,	the	reduction	in	infectivity	was	more	severe	for	the	EV	particles	than	the	MV	particles	(Figure	4.5).	Since	HPSE	and	HPNSE	digestion	of	cell	surface	HS	is	incomplete,	the	digestions	probably	leaving	HS	stubs	on	cell	monolayers,	this	could	explain	why	a	complete	inhibition	of	the	EV	and	MV	infections	was	not	observed.	Nevertheless,	it	was	evident	that	EV	infections	are	more	dependent	on	the	presence	of	cell	surface	HS	than	MV	infections.	Furthermore,	infection	assays	performed	with	a	cell	line	genetically	deficient	in	the	production	of	HS	confirmed	the	previous	finding	that	EV	infections	are	significantly	affected	by	the	unavailability	of	cell	surface	HS	(Figure	4.6),	whereas	the	MV	form	is	much	less	dependent	on	HS	to	infect	cells.	Since	the	EV	form	of	VACV	is	responsible	for	long-range	dissemination	in	vivo	(Ichihashi,	1996)	and	the	knowledge	that	heparanase	is	the	only	known	mammalian	endoglycosidase	that	mediates	extracellular	HS	degradation	in	vivo	
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(Levy-Adam	et	al.,	2010;	Parish	et	al.,	2001),	it	was	of	interest	to	determine	the	ability	of	VACV	to	spread	in	mice	deficient	in	heparanase	expression.			To	perform	in	vivo	spreading	assays,	it	was	essential	to	consider	the	route	of	inoculation	of	VACV.	Traditionally	used	routes	for	infection	assays,	such	as	intraperitoneal	or	intravenous	inoculation,	allow	the	systemic	spread	of	VACV	particles,	which	is	essential	to	study	immune	responses	against	VACV	infections.	However,	since	the	research	question	in	this	thesis	was	to	understand	VACV	spread	to	different	organs,	it	was	important	to	deliver	VACV	at	restrictive	sites	in	order	to	cause	VACV	particles	to	first	establish	an	infection	at	the	primary	site	of	inoculation,	before	spreading	to	distant	organs.	Both	i.m.	and	i.n.	routes	of	delivery	where	thus	used	to	perform	the	in	vivo	assays.			Results	presented	in	Chapter	7	clearly	suggest	that	there	is	a	definite	delay	in	disease	onset	in	HPSE-/-	mice	inoculated	with	the	WR	strain	of	VACV	by	both	the	i.n.	and	i.m.	routes,	compared	to	WT	C57BL/6	control	mice.	Plaque	assays	performed	on	organs	harvested	from	both	the	HPSE-/-	and	WT	mice	infected	with	the	WR	strain	of	VACV	clearly	demonstrated	that	VACV	was	able	to	establish	an	infection	at	the	primary	site	of	inoculation	with	comparable	efficiency	in	both	animal	groups,	however,	VACV	dissemination	to	ovaries,	a	distal	organ,	was	delayed	in	the	HPSE-/-	mice	compared	to	the	WT	mice.	Since	the	EV	form	of	VACV	is	mainly	responsible	for	the	long-range	dissemination	of	the	virus,	it	is	likely	that	the	lack	of	heparanase	in	the	HPSE-/-	mice	had	its	greatest	effect	on	the	dissemination	of	progeny	EV	particles.	The	in	vitro	results	presented	in	Chapter	4	showing	that	EV	particles,	but	not	MV	particles,	much	less	efficiently	infect	
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heparanase	treated	cell	monolayers,	is	consistent	with	the	spread	of	the	EV	form	of	VACV	being	highly	heparanase	dependent.	In	fact,	it	could	be	argued	that	the	existence	of	two	forms	of	VACV,	namely	the	EV	and	MV	forms,	with	substantially	different	affinities	for	HS,	provides	the	virus	with	a	diversity	of	spreading	mechanisms	that	could	be	advantageous.			There	is	a	large	body	of	evidence	indicating	that	several	viruses,	bacteria	and	parasites	use	evolutionary	conserved	glycosaminoglycans,	including	HS,	as	adhesion	receptors	during	their	infection	of	cells	(Rostand	&	Esko,	1997;	Wadstrom	&	Ljungh,	1999).	However,	based	on	the	data	presented	in	this	thesis,	it	is	highly	likely	that	such	pathogens	are	dependent	on	heparanase,	usually	host	derived,	for	their	dissemination	from	their	initial	site	of	infection.	In	fact,	a	recent	publication	reported	that	the	spread	of	HSV-1	is	heparanase	dependent	(Hadigal	et	al.,	2015).	Of	considerable	interest	is	whether	viruses,	such	as	HSV-1,	produce	progeny	virus	particles	with	variability	in	their	affinity	for	HS	as	is	the	case	with	VACV.	It	should	be	noted,	however,	that	heparanase	deficiency	delays	but	does	not	totally	prevent	virus	spread.	The	heterogeneity	in	HS	binding	affinity	of	viruses	could	partially	explain	this	observation.	An	additional	possibility	is	that	proteases	that	degrade	ECM	and	BMs	could	also	aid	the	spread	of	HS	binding	viruses	(Levy-Adam	et	al.,	2010).		
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8.5	Chemically	modified	heparins	and	HS	mimetics	can	inhibit	VACV	
infections	Having	established	that	cell	surface	HS	is	important	for	the	infection	of	cells	by	both	the	EV	and	MV	forms	of	VACV,	but	particularly	the	EV	form,	combined	with	the	ability	of	soluble	heparin	to	interfere	with	EV	and	MV	infections,	it	was	important	to	delineate	the	structural	features	of	heparin/HS	that	influence	the	infectivity	of	the	EV	and	MV	forms	of	VACV.		Initial	inhibition	assays	performed	using	Fondaparinux,	along	with	other	commercially	available	LMWHs,	suggested	that	these	compounds	are	just	as	potent	as	heparin	in	their	ability	to	inhibit	EV	and	MV	infections	(Figure	5.1).	Since	Fondaparinux	and	other	LMWHs	contain	the	antithrombin	III	binding	pentasaccharide	of	heparin,	which	allows	them	to	be	antithrombotic,	it	is	likely	that	the	EV	and	MV	particles	also	interact	with	the	same	pentasaccharide	sequence.	Similar	to	heparin,	EV	infections	are	more	susceptible	to	inhibition	by	Fondaparinux	and	other	LMWHs,	compared	to	MV	infections.	However,	based	on	these	results,	it	is	likely	that	antithrombotic	drugs	may	be	able	to	act	as	antivirals	by	interfering	with	the	interaction	of	EV	and	MV	particles	of	VACV	with	cell	surface	HS.	These	results,	along	with	previously	published	results,	raise	the	notion	of	a	so	called	‘sulfation	code’,	which	entails	sulfated	sequences	along	the	length	of	HS	chains	that	permits	high	avidity	binding	to	certain	proteins	or	VACV,	as	seen	in	the	current	study	(Lindahl	&	Kjellen,	2013).		Previously	published	studies	showing	inhibition	assays	performed	using	HSV,	which	also	interacts	with	cell	surface	HS	prior	to	infecting	cells,	revealed	that	2,3-
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O-sulfate	and	6-O-sulfate	groups	are	critical	for	heparin	to	interact	with	the	gB	and	gC	glycoproteins	on	the	surface	of	HSV-1	(Feyzi	et	al.,	1997;	Trybala	et	al.,	2000).	Results	presented	in	Chapter	4	indicate	that	highly	sulfated	HS	(HShi)	inhibits	VACV	infections	much	more	efficiently	than	under-sulfated	HS	(HSlow).	Previously	published	HSV	infection	studies,	together	with	the	finding	reported	in	this	thesis	that	key	sulfate	groups	on	free	heparin/HS	chains	can	inhibit	VACV	infections,	suggest	that	cell	surface	HS	can	act	as	an	important	co-receptor	for	VACV	infections.	However,	to	validate	the	‘sulfation	code’	hypothesis,	a	series	of	inhibition	assays	were	performed	to	extensively	analyze	key	structural	features	of	heparin/HS	to	which	VACV	particles	bind.	Structural	analyses	using	chemically	modified	heparins	revealed	that	the	2-O-sulfate	groups	of	the	iduronic/glucuronic	acid	residues	are	not	important	for	the	ability	of	heparin	to	inhibit	EV	and	MV	infections.	However,	6-O-sulfate	and	N-sulfate	groups	of	the	D-glucosamine	residues	are	crucial	for	the	ability	of	heparin	to	inhibit	VACV	infections	(Figure	5.2).		Furthermore,	neither	N-acetylation	of	glucosamine	residues,	nor	the	removal	of	carboxyl	groups	from	the	iduronic/glucuronic	acid	residues,	had	any	effect	on	the	ability	of	heparin	to	inhibit	EV	and	MV	infections	(Figure	5.3).	These	results,	therefore,	validate	the	‘sulfation	code’	hypothesis	in	the	context	of	VACV	infections.			In	addition	to	using	chemically	modified	heparins,	sulfated	di-	and	oligo-saccharides	that	differ	in	their	sulfation	patterns,	monosaccharide	constituents	and	linkages	were	examined	in	Chapter	5	for	their	anti-VACV	activity,	these	molecules	being	termed	HS	mimetics.	Data	obtained	from	these	studies	indicate	that	the	linkage	of	different	D-glucose-based	sulfated	saccharides	plays	a	crucial	role	in	the	ability	of	the	molecules	to	inhibit	VACV	infections,	with	the	order	of	
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potency	being	β(1g4)	>	α(1g6)	>	α(1g4)	>	β(1g3),	with	sulfated	pentasaccharides	being	usually	the	most	effective.	These	results	add	a	layer	of	complexity	suggesting	that	the	position	of	negatively	charged	sulfated	groups	in	3D	space	determines	the	antiviral	activity	of	these	molecules	and,	therefore,	builds	on	the	notion	of	a	‘sulfation	code’.		
8.6	Anti-cancer	drug	PI-88	(Muparfostat)	can	inhibit	VACV	infections	The	anti-cancer	drug	PI-88	inhibits	heparanase-mediated	degradation	of	HS,	thereby	inhibiting	tumour	metastasis	and	reducing	tumour	growth	by	inhibiting	angiogenesis	(Khachigian	&	Parish,	2004).	PI-88	is	currently	in	a	Phase	III	trial	as	a	monotherapy	in	post-resection	hepatocellular	carcinoma	patients.	Since	PI-88	is	a	mixture	of	highly	sulfated	oligosaccharides,	it	was	of	interest	to	determine	if	PI-88	can	act	as	an	inhibitor	of	VACV	infections.	Indeed	PI-88	could	inhibit	both	EV	and	MV	infections,	however,	it	was	surprising	to	note	that	of	all	the	inhibitors	tested	in	the	assays	presented	in	this	thesis,	PI-88	was	the	only	molecule	that	was	a	more	potent	inhibitor	of	MV	infections	than	of	EV	infections.	PI-88	does	differ	from	other	HS	mimetics	as	PI-88	is	based	on	the	monosaccharide	D-mannose,	whereas	the	other	HS	mimetics	described	in	Chapter	5	as	inhibitors	of	VACV	are	D-glucose-based	saccharides.	Furthermore,	PI-88	is	composed	of	α(1g3)	and	α(1g2)	linked	D-mannose	residues	(Yu	et	al.,	2002),	which	also	differs	from	the	linkages	of	the	D-glucose-based	HS	mimetics	examined.	These	data	are	again	consistent	with	the	notion	that	the	ability	of	HS-based	saccharide	molecules	to	inhibit	VACV	infectivity	is	dependent	on	the	position	of	the	negatively	charged	groups	of	the	inhibitor	in	3D	space.			
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PI-88	has	also	been	shown	to	have	a	significant	effect	on	the	disease	outcome	in	dengue	virus	and	flaviviral	encephalitis	mouse	models	(Lee	et	al.,	2006).	Therefore,	based	on	the	results	presented	in	this	thesis,	mixtures	of	heparin-/HS-based	molecules,	an	excellent	example	being	a	mixture	of	PI-88	and	Fondaparinux	that	are	drugs	already	used	clinically,	would	likely	be	effective	antiviral	agents	against	VACV	as	each	saccharide	molecule	targets	different	VACV	forms.			
8.7	EV	surface	proteins	that	interact	with	HS/heparin	The	MV	form	of	VACV	has	two	known	HS-binding	proteins	on	its	outer	membrane	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	Studies	published	by	Law	et	al.,	2006,	suggest	that	the	EV	outer	membrane	proteins	A34R	(24-28	kDa)	and	B5R	(42	kDa)	interact	with	cell	surface	HS,	which	results	in	lysis	of	the	outer	EV	envelope	to	release	the	enclosed	MV	particles	(Law	et	al.,	2006).	However,	results	presented	in	this	thesis	clearly	suggest	that	soluble	heparin,	LMWHs,	certain	chemically	modified	heparins	and	HS-based	oligosaccharides,	are	able	to	inhibit	EV-mediated	infectivity	with	higher	affinity	than	the	MV-mediated	infectivity.	Therefore,	it	was	important	to	determine	whether	any	other	protein(s)	on	the	surface	of	EV	interact	with	heparin/HS.			Bioinformatic	searches	were	performed	to	identify,	based	on	sequence	homology	using	known	HS-binding	protein,	the	outer	EV	membrane	proteins	that	would	interact	with	cell	surface	HS.	The	EV	membrane	proteins	were	also	solublised,	co-incubated	with	heparin-coupled	beads,	and	identified	via	Western	blotting	using	VACV-specific	antibodies.	A	150	kDa	protein	band	observed	on	blots	was	excised	and	sent	to	APAF	for	identification	by	mass	spectrometry	(MS)	analysis.	The	MS	
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analysis	identified	the	150	kDa	band	as	the	147	kDa	DNA	directed	RNA	polymerase	with	a	sequence	similarity	to	65	kDa	VACV	F12,	a	protein	involved	in	the	export	of	newly	formed	MV	particles.		Interestingly,	Western	blotting	also	identified	a	~60	kDa	heparin	binding	protein,	however,	due	to	time	constrains,	the	~60	kDa	band	could	not	be	sent	for	MS	analysis.	Nevertheless,	the	VACV	F12	protein	could	be	a	candidate	for	the	unknown	~60	kDa	protein	identified	via	Western	blotting.	Furthermore,	the	bioinformatics	searches	identified	a	65	kDa	VACV	B4R	protein	that	is	an	important	protein	responsible	for	effective	plaque	formation.	Therefore,	VACV	B4R	could	also	be	a	candidate	protein	for	the	unknown	~60	kDa	protein.		Western	blotting	also	identified	an	85	kDa	heparin-binding	protein,	which	was	a	different	protein	to	VACV	HA	(A56R).	Bioinformatic	searches	identified	a	77.6	kDa	RNA	helicase	that	had	a	possible	heparin-binding	motif.		Therefore,	it	is	possible	that	the	77.6	kDa	RNA	helicase	is	the	~85	kDa	unknown	protein	(Figure	6.2A).	Similar	to	B4R,	an	RNA	helicase-specific	mAb	would	be	required	to	conclusively	identify	the	~85	kDa	protein.	Furthermore,	MS	analysis	could	be	performed	to	identify	the	unknown	protein.	Lastly,	a	25	kDa	heparin-binding	protein	was	also	observed	in	blots,	however,	the	identity	of	this	protein	is	unknown	although	it	could	be	the	previously	described	24-28	kDa	A34R	protein	on	the	EV	surface	that	binds	heparin	(Law	et	al.,	2006).	MS	analysis	would	be	required	to	conclusively	identify	all	the	unknown	proteins.		Assays	performed	using	heparin/HS	mimetics	clearly	support	the	notion	of	the	‘sulfation	code’	in	3D	space.	Therefore,	it	is	likely	that	there	are	protein(s)	on	the	surface	of	the	EV	envelope,	other	than	A34R	and	B5R,	that	based	on	bioinformatics	
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analysis	are	not	obvious	HS-binding	proteins	but	when	folded	in	their	tertiary	orientation	are	able	to	interact	with	HS.	As	an	example,	human	papillomavirus	type	16	has	multiple	HS-binding	proteins	on	its	capsid,	with	the	interaction	between	primary	HS-binding	sites	and	HS	inducing	a	conformational	change	that	exposes	secondary	HS-binding	sites,	which	are	then	able	to	interact	with	cell	surface	HS	(Richards	et	al.,	2013).		
8.8	Conclusion	and	future	directions	To	summarize,	it	is	clear	that	VACV,	like	several	other	viruses,	interacts	with	cell	surface	HS	to	infect	cells.	However,	as	described	in	a	recently	published	study	on	HSV-1,	it	is	likely	that	VACV	also	relies	on	heparanase-mediated	degradation	of	HS	in	order	to	spread	to	distal	sites	in	vivo.	Nevertheless,	HS-based	molecules	could	potentially	be	used	to	inhibit	VACV	infections.	In	fact,	extensive	studies	of	different	HS	mimetics	outlined	in	this	thesis	suggest	that	synthetic	HS-based	molecules	could	be	synthesized	that	target	both	EV	and	MV	forms	of	VACV.	Furthermore,	many	of	the	HS	mimetics	with	antiviral	activity	may	also	act,	like	PI-88,	as	heparanase	inhibitors	and	consequently	inhibit	virus	spread.		A	number	of	important	unanswered	questions	arise	from	the	data	presented	in	this	thesis.	First,	what	are	the	key	heparin/HS	binding	molecules	on	the	surface	of	the	MV	and	EV	forms	of	VACV.	Western	blotting	studies	have	identified	several	VACV	proteins,	based	on	molecular	weight,	that	bind	heparin/HS.	MS	studies	need	to	be	undertaken	to	identify	these	molecules,	similar	to	the	approach	used	to	identify	the	150	kDa	VACV	protein	binding	to	heparin-Sepharose	beads	in	Chapter	6.	Whether	the	newly	identified	heparin/HS	binding	proteins	simply	aid	adhesion	
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of	VACV	to	cells,	activate	EV	envelope	disintegration	or	prevent	superinfection	of	cells	by	VACV	also	needs	to	be	investigated.	Second,	although	heparanase	has	been	clearly	shown	to	aid	VACV	spread,	the	source	of	the	host-derived	heparanase	is	unknown.	An	obvious	source	is	host	leukocytes	entering	sites	of	infection,	particularly	neutrophils	and	macrophages.	Platelets	are	another	source	of	heparanase	as	the	platelets	carry	large	amounts	of	preformed	heparanase	that	is	rapidly	released	following	platelet	activation	(Freeman	&	Parish,	1998),	a	likely	scenario	for	cytopathic	viruses	such	as	VACV.	Thrombocytopenic	mice,	such	as	the	
c-mpl	knockout	mice	(Murone,	Carpenter,	&	de	Sauvage,	1998),	or	platelet	depleting	mAbs	could	be	used	to	establish	whether	VACV	spread	is	platelet	dependent.	If	this	is	the	case,	use	of	mice	in	which	platelet	heparanase	is	conditionally	knocked	out	would	conclusively	demonstrate	that	platelet-derived	heparanase	aids	VACV	spread.	Conversely,	if	platelets	are	not	involved,	the	conditional	knocking	out	of	heparanase	in	myeloid	cells	could	be	used	to	establish	the	leukocyte	origin	of	heparanase.			Finally,	it	will	be	of	considerable	interest	whether	other	pathogens	that	use	HS	as	a	co-receptor	for	infecting	cells	behave	in	a	similar	manner	as	VACV.	In	particular,	do	they	use	host	heparanase	to	aid	pathogen	spread	and	do	they	produce	pathogen	variants	with	different	HS	binding	properties?	Such	questions,	when	answered,	may	reveal	new	approaches	to	controlling	the	spread	of	numerous	pathogens.	
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